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ABSTRACT
WHITNEY SHAREE GIBBS. The Role of the 5-hydroxytrptamine 1F Receptor in
Mitochondrial Biogenesis and Acute Kidney Injury. (Under the direction of RICK G
SCHNELLMANN)

Mitochondrial dysfunction exacerbates cellular injury, impairs energy-dependent repair,
and leads to kidney damage and failure following acute kidney injury (AKI). Mitochondrial
dysfunction and impaired mitochondrial biogenesis correlate with decreased in
peroxisome proliferator-activated receptor coactivator 1-α (PGC-1α), the reported master
regulator of mitochondrial biogenesis, and its downstream targets following I/R-induced
AKI. Furthermore, recovery of renal function and tubular injury is accelerated following
pharmacological induction of mitochondrial biogenesis following I/R-induced AKI. These
results suggest that recovery of mitochondrial number and function may be an effective
therapeutic strategy in restoring renal function following AKI.
We recently made the novel observation that agonists of 5-HT1F receptor induce
mitochondrial biogenesis in vitro and in vivo. Specifically, following I/R-induced AKI, the
5-HT1F receptor selective agonist LY344864 enhanced the recovery of mitochondrial DNA
(mtDNA) copy number and renal function, as indicated by decreased blood urea nitrogen
(BUN). These findings demonstrate that 5-HT1F receptor stimulation promotes recovery
from AKI and activates mitochondrial biogenesis pathways.
The goal of the first aim was to determine the signaling pathways involved in mediating
renal proximal tubule 5-HT1F receptor-induced mitochondrial biogenesis. Using
pharmacological approaches, we identified Gβγ heterodimer-dependent activation of
Akt/eNOS/cGMP/PKG/PGC-1α and inhibition of c-raf/ERK/FOXO3a pathways as the
mechanism responsible for 5-HT1F receptor-induced mitochondrial biogenesis. We also
identified Akt as the link between these stimulatory and inhibitory pathways, and that the
stimulatory pathway is required for mitochondrial biogenesis. Elucidation of this pathway
xv

may facilitate the development of novel therapeutic approaches to enhance mitochondrial
biogenesis for the treatment of diseases characterized by mitochondrial dysfunction.
We then examined the role of the 5-HT1F receptor in renal mitochondrial homeostasis and
biogenesis under physiological conditions. To complete this aim, we utilized young (10
weeks) and aged (26 weeks) 5-HT1F receptor knockout (KO) mice. In young 5-HT1F
receptor KO mice, we observed increased expression of mtDNA copy number as well as
of genes involved in renal mitochondrial biogenesis, oxidative phosphorylation, fission and
autophagy compared to wild-type (WT) controls. Aged 5-HT1F receptor KO mice also
exhibit increases in renal PGC-1α mRNA expression and mtDNA copy number.
Interestingly, we detected a tissue-specific difference in renal cortical mitochondrial
homeostasis compared to that of the heart. Specifically, cardiac left ventricular
mitochondrial homeostasis markers were initially decreased in the absence of the 5-HT1F
receptor KO mice compared to WT mice. However, as the mice aged, these markers
returned to WT control levels and this rescue was associated with increased PGC-1α
mRNA expression. To determine the potential mechanism responsible for tissue-specific
differences in mitochondrial homeostasis markers and the compensatory effect displayed
in the renal cortex of the 5-HT1F receptor KO mice, we assessed the gene expression of
other 5-HT1 and 5-HT2 receptors. Interestingly, in the heart and kidney of 5-HT1F receptor
KO mice, there is a tissue-dependent difference in the gene expression of 5-HT2A and 5HT2B receptors, both of which have been linked to mitochondria. Further work may lead to
the identification of compensatory mechanisms that are activated in the absence of the 5HT1F receptor.
Our final study tested the role of the 5-HT1F receptor in renal mitochondrial biogenesis in
AKI and in the recovery of mitochondrial and renal function following I/R-induced AKI. The
absence of the 5-HT1F receptor increased tubular injury as measured by KIM-1 and
neutrophil gelatinase-associated lipocalin (NGAL) at 24 hr following I/R-induced AKI.
xvi

Additionally, the 5-HT1F receptor KO mice exhibited reduced renal recovery at 144 hr
following I/R-induced AKI as measured by serum creatinine and BUN levels. Impaired
renal function and tubular injury recovery was also associated with a persistent
suppression in mitochondrial biogenesis as evidenced by reduced

PGC-1α and

respiratory chain protein expression at 144 hr following renal I/R injury. Injured 5-HT1F
receptor KO mice also displayed sustained depletion in ATP generation and elevated
oxidative protein damage at 144 hr. In summary, this study reveals that the 5-HT1F
receptor 1) regulates mitochondrial biogenesis and homeostasis under physiological
conditions in a tissue-dependent manner, 2) is renal protective in the setting of I/R-induced
AKI and 3) promotes the recovery of mitochondrial homeostasis and renal function
following I/R injury.

xvii

CHAPTER ONE:
Review of acute kidney injury, ischemia/reperfusion, mitochondrial biology and
serotonin receptor biology and function

ACUTE KIDNEY INJURY
Definition of Acute Kidney Injury
Acute kidney injury (AKI) is defined broadly as a rapid loss of renal function over hours
or days leading to structural damage and disruption in clearance of waste products,
electrolyte and fluid balance, and/or urine concentration and output (1). The diagnosis of
AKI is traditionally based on a rise in serum creatinine (SCr), indicating altered
glomerular filtration rate (GFR) and a fall in urine output. Since outcomes and treatment
strategies are directly correlated with severity of diagnostic endpoints, classification
systems of AKI were developed to provide consensus and evidence-based guidelines to
stratify AKI cases with the primary goal of timely recognition of AKI and outcome
prediction of AKI. Specifically, the RIFLE criteria (Risk, Injury, Failure, Loss of function,
and End-Stage kidney disease) developed by the Acute Dialysis Quality Initiative (ADQI)
workgroup, is perhaps the most comprehensive clinical classification of AKI as it relies
on easy clinical applicability, sensitivity and specificity, while accounting for baseline SCr
variations and ‘acute-on-chronic’ phenomenon of AKI (2). A similar classification system,
referred to as AKIN (Acute Kidney Injury Network), has also been developed for the
appropriate stratification of AKI patients (3). An outline of criteria for both RIFLE and
AKIN classification systems is provided below (Figure 1.1). These systems combine SCr
and urine output to stage patients by injury severity to better predict disease outcomes
and mortality (4, 5).

1

Figure 1.1: RIFLE and AKIN classifications for the staging of AKI. Cr: creatine, ARF:
acute renal failure, GFR: glomerular filtration rate, RRT: renal replacement therapy, UO:
urine output. Adapted from (6).

2

Impact of AKI on Global Population
Epidemiology. AKI is now well-established as a common and often under-recognized
disorder, which is associated with increased long-term risk of poor outcomes, including
death and greater utilization of health resources (7). Observational studies indicate that
the incidence of AKI is increasing and patients struggle with the long-term sequelae of
AKI (8). In a community based assessment following approximately four million
individuals in the United States, the incidence of non dialysis-requiring AKI and dialysis
requiring AKI was estimated at 384 and 24 per 10,000 persons-years, respectively (9).
The occurrences of AKI is most common among elderly, male and hospitalized patients.
A systemic review conducted in developed nations, which included 49 million patients,
found that AKI occurred in one in five adults and one in three children hospitalized with
acute illness (10). Among critically ill patients in the intensive care unit (ICU), the
incidence of AKI rates are as high as 70% (11).
Morbidity and Mortality. Increasing severity of AKI correlates with increased mortality in
various clinical settings, such as cardiac surgery (12), major trauma (13), and critical
illness (14). AKI-associated mortality occurs at an alarming rate of approximately 24% in
adults and 14% in children (10). In-patient mortality is highest among ICU patients
requiring renal replacement therapy (RRT), with incidence of mortality approaching 60%.
Although mortality is concurrently declining due to better diagnosis and supportive
strategies, patients who survive an acute episode of AKI have an increased risk of
morbidity associated with the disease, leading to poor outcomes and long-term mortality.
In a retrospect assessment following US veterans who were discharged following acutecare hospitalization, long-term mortality was approximately two times greater of those
with AKI compared to those who did not have AKI (15). Among AKI survivors,
intermediate and long-term mortality has a strong association with the development of
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chronic kidney disease (CKD) and further progression of end-stage renal disease
(ESRD) (16), leading to poor quality of life and significant global financial burden. Taken
together, given the significant long-term morbidity following AKI, there is an estimated 34
million hospitalizations per year, with $10 billion in healthcare expenses annually in the
US (17).The figure below illustrates the relationship between SCr and AKI-associated
mortality and healthcare costs (Figure 1.2, 3).

4

Figure 1.2: Association between severity of AKI and mortality. Orange bars
represent incidence percentage as a result of absolute change in SCr levels, blue line
graph reflects odds ratio (OR) of mortality in respect to absolute change in SCr levels
(a). Green bars represent incidence percentage as a result of changes in SCr levels
relative to baseline, blue line graph reflects OR of mortality in respect to adjusted SCr
levels (b). Adapted from (18).

Figure 1.3: Association between severity of AKI and healthcare cost. Green bars
represent unadjusted data, blue bars are adjusted for age and gender and grey bars are
adjusted for age, gender, diagnosis related-group (DRG) weight and ICD-9-CM codes
for cardiovascular, respiratory, malignant, and infectious diseases; n= 1564, 885, 246
and 105 for SCr changes of 0.3 to 0.4, 0.5 to 0.9, 1.0 to 1.9 and ≥ 2.0 mg/dl,
respectively. Adapted from (17).
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Causes of AKI

AKI is often classified into three categories based on the causes of AKI: prerenal
(caused by decreased renal perfusion), intrinsic renal (caused by a process within the
kindeys) and postrenal (caused by inadequate drainage of urine distal to the kidneys)
(19).
Prerenal AKI. Prerenal AKI is estimated to account for approximately 70% of communityacquired AKI and 40% of hospital-acquired AKI (20, 21). Prerenal AKI is a result of
decrease renal blood flow (RBF) and subsequent renal hypoperfusion in the absence of
renal parenchyma damage (22). Most common causes of prerenal AKI include cardiac
surgery, septic shock and congestive heart failure (21, 23). Prerenal AKI can also occur
in the setting of hypovolemia resulting from hemorrhage, vomiting, poor fluid intake and
diuresis. Several medications can also cause prerenal AKI, notably, angiotensinconverting

enzyme

inhibitors,

non-steroidal

anti-inflammatory

drugs

(NSAIDs),

vasoconstrictors and diuretics (19). It is important to note that prolong or profound
prerenal AKI can result in ischemic damage to the kidney and thus inducing renal tubular
epithelial cell structural and functional alterations. The extent of these alterations is
dependent upon severity and duration of prerenal and ischemic injury.
Intrinsic AKI. Intrinsic AKI is estimated to account for approximately 35-40% of all
patients with AKI (24). Intrinsic AKI is classified anatomically by the region of the kidney
parenchyma that is damaged; these four structures are the tubules, glomeruli, interstitum
and intrarenal vessels. Tubular injury as a result of acute tubular necrosis (ATN) is the
most common among hospitalized AKI patients. The development of ATN typically
follows exposure to a nephrotoxic compound such as aminoglycoside antibiotics and
chemotherapeutic drugs, or an ischemic event, with the latter being the most common.
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Ischemia as a result of profound obstruction of blood flow leads to direct injury to
tubules, thus prerenal AKI and intrinsic AKI represent a continuum of damage due to a
common insult (19).
A less common cause of intrinsic AKI, acute interstitial nephritis (AIN) is most often
caused by an allergic reaction to a drug, such as certain classes of antibiotics, penicillins
and cephalosporin and NSAIDs. Additionally, patients with autoimmune diseases and
systemic infections, such as systemic lupus erythematosus and HIV, have increased
susceptibility for the development of AIN (25). Allergic reactions to medications and
altered

immune

systems

have

been

reported

to

induce

immune-mediated

tubulointerstitial injury, resulting in diminished tubular function. It is important to note that
patients of autoimmune diseases are at risk for glomerulonephritis, inflammation and
damage to the glomerular membrane.
Postrenal AKI. Postrenal AKI is relatively uncommon accounting for 20% of communityacquired AKI and <5% of hospital- acquired AKI (26). Postrenal AKI is caused by an
acute obstruction of the urinary flow causing waste build up in the kidneys and a
subsequent increase in tubular pressure and reduction in GFR. Postrenal AKI occurs
more often in elderly male patients with prostatic hypertrophy or prostate cancer (27).
Additional causes of postrenal AKI include gynecologic cancers, such as cervical cancer,
ureteral stones and precipitation of various substances such as acyclovir (28).
The multifactorial nature of AKI contributes to the complexity of this condition and the
unsuccessful

attempts

to

develop

therapeutic

treatments.

Understanding

the

overwhelming number of pathological contributors and mechanisms of AKI will help lead
to the development of drug therapies in the hope of in decreasing the morbidity and
mortality associated with AKI.
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Since the studies presented herein will address ischemia reperfusion-induced AKI, this
review will focus intrinsic AKI with particular emphasis on the role of the proximal tubular
epithelial cells.
Pathogenesis of Ischemia/Reperfusion-induced AKI
Ischemia/ reperfusion (I/R)-induced AKI is associated with an unacceptable high
incidence and mortality due to the incredible number of patients that are at risk for
ischemic AKI, including patients of trauma, major surgery, congestive heart failure, and
sepsis. Renal I/R injury is characterized by a sudden blockade of oxygen and nutrient
delivery to the kidneys (29). The complex interactions between epithelial, endothelia
and inflammatory cells, as well as dysfunctional mitochondria and reactive oxygen
species (ROS) substantially contribute to the extension phase of I/R- induced AKI
(Figure 1.5).
Endothelial Injury. Endothelial cells are important regulators of vascular tone, blood flow,
vascular permeability, leukocyte function, and smooth muscle responsiveness (30). An
important feature of renal I/R injury is prominent damage to the endothelium. In turn,
vasoconstriction is significantly enhanced as a result of decreased nitric oxide production
and enhanced production of vasoactive cytokines, including TNF-α, IL-1β and
endothelin, generated as a consequence of increased leukocyte- endothelial adhesion
and leukocyte activation following ischemic injury (31-34). In addition, upregulation of
chemokines and adhesion molecules in the endothelium results in the infiltration of
inflammatory cells like neutrophils, lymphocytes and macrophages from the blood
vessels into the interstitum of the kidney (35, 36). These inflammatory cells can produce
vasoconstrictors, such as prostaglandins, that have the reputation to worsen blood flow
and vascular injury. Recent attention has focused on the impact of endothelial
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mitochondria in the role of vasoconstriction and capillary permeability due to altered
calcium and ATP homeostasis (37, 38).
Epithelial Injury. Tubular epithelial cell dysfunction and death of one or several tubular
segments following I/R renal injury is common in the development of ATN. Specifically,
renal proximal tubule cells (RPTC), the most populous cell type in the kidney regulating
reabsorption of substances such as glucose and amino acids and the control of acidbase balance by the excretion of bicarbonate and synthesis of ammonia, are particularly
sensitive to ischemic injury (39, 40). Under physiological conditions, RPTC attach to the
basement membrane and maintain high polarity with both the apical and basolateral
membrane. Na+/K+-ATPase on the basolateral membrane utilizes ATP to establish the
sodium gradient that drives subsequent secondary and tertiary transport processes
across both the apical and basolateral membranes (38). After renal I/R injury, transport
processes necessary for the reabsorption and secretion of molecules are disrupted due
to loss of polarity, marked reduction in cellular ATP content, mislocalization of the
Na+/K+-ATPase and decline in its activity (41, 42). In addition, mitochondrial dysfunction
and cytoskeletal disruptions are also critical pathogenic factors in renal I/R injury (43).
With increasing severity, these cellular impairments leads to RPTC apoptosis and
necrosis. As a result, detachment of both necrotic and viable cells that have lost
basolateral expression of integrin receptors slough into the tubular lumen and form
tubular casts, potentiating injury and decline in GFR (41, 44, 45).
Several reports indicate that surviving RPTC restore physiological functions and nephron
integrity. The surviving cells dedifferentiate, migrate along the basement membrane,
proliferate to restore cell number and then differentiate (19, 44, 46). Figure 1.5 illustrates
normal repair of the RPTC following renal I/R injury. While the precise mechanisms of
renal repair and recovery remain largely unknown, recent attention has focused on the
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role of mitochondria in mediating restoration of tubule function. Proximal tubule epithelial
cells are rich in mitochondria relying heavily on oxidative phosphorylation for ATP
generation, so, RPTC are especially vulnerable to mitochondrial dysfunction (47).
Recent evidence indicates that promoting the repair of mitochondrial structure and
function is a promising strategy to facilitate recovery of the damaged kidney. Targeting
RPTC mitochondria will be the major focus of this review.
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Figure 1.4: The Pathogenesis of Ischemic AKI. Major pathways of ischemic AKI
include the complex interaction between endothelial and epithelial cells. These
processes are regulated by the activation of inflammatory response, vasoconstriction,
alteration in adhesion molecules expression, apoptosis, necrosis and cytoskeleton
disruption. Ultimately, reduction in glomerular filtration rate (GFR), fractional excretion of
sodium (FENa) and defect in urine concentration. WBC: white blood cells, TGF-β:
transforming growth factor β. Adapted from (48).
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Figure 1.5: Normal Repair in Ischemic AKI. Following ischemic renal injury, renal
epithelial cells lose their polarity and brush border with proteins translocated from the
basolateral membrane to the apical membrane. In the case of severe ischemia, cell
death occurs via necrosis and/or apoptosis. Necrotic debris and detached viable cells
are released into the lumen, potentiating renal dysfunction. Viable cells undergo division
to replace lost cells, and subsequent differentiation to restore nephron structure and
function. Adapted from (41).
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Biomarkers of AKI
As discussed above, the earlier an intervention can be instituted for patients with AKI,
the more favorable the outcome. As a result, there has been a tremendous investment to
identify novel plasma and serum proteins that may characterize the course of renal
injury. SCr, as well as blood urea nitrogen (BUN) have been historically used in the
clinical setting because both endpoints are easy and inexpensive to measure (49).
However, SCr and BUN are not ideal biomarkers as they are both influenced by multiple
non-renal factors such as age, nutrition status, muscle mass and metabolism and
medications (50). In addition, clinical data revealed that large changes in GFR results in
small changes in SCr in the first 24-48 hr following AKI. Thus, delayed intervention and
underestimation of the degree of injury has also been attributed to the deficiency of SCr
as an AKI marker (51). Given the limitations of SCr and BUN as markers of renal
function, novel urinary and serum proteins have rigorously been investigated over the
past decade. Given the significant number of biomarkers recently elucidated such as
interleukin-18 (IL-18), cystatin C and glutathione S-transferase (Figure 1.7), this review
will focus on two noninvasive markers, neutrophil gelatinase-associated lipocalin (NGAL)
and kidney injury molecule-1 (KIM-1). Both markers are highly upregulated in renal
tubules and present in the urine and blood of animals and patients with AKI (51, 52)
Neutrophil Gelatinase-Associated Lipocalin. NGAL is a 25-kD protein expressed and
secreted by immune cells, hepatocytes and renal tubular cells following various insults
(53). Experimental data demonstrates that NGAL protein expression is rapidly and
persistently increased, upwards of 10-fold, in the renal proximal tubule 24 hr following
I/R injury in mice. Interestingly, urinary NGAL was detected in mice 3 hr following renal
I/R injury, while SCr levels were only elevated after 24 hr following I/R injury (54).
Experimental evidence also revealed excretion of NGAL with no change in SCr levels in
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a mouse model of mild renal ischemia, indicating that expression of NGAL is correlative
with severity and duration of renal ischemia (54). Clinical data also supports NGAL as a
powerful early, sensitive marker of AKI, preceding increase in SCr by 1-3 days in
pediatric patients. In addition, significantly higher levels of NGAL were associated with
the development of AKI in adult patients following cardiac surgery (51, 55, 56). In
summary, NGAL has been indicated as a reliable predictive biomarker in acute and
chronic settings of AKI.
Kidney Injury Molecule-1. KIM-1 is a type I transmembrane glycoprotein with an
immunoglobulin-line domain and mucin-rich extracellular region conserved across
rodents, primates and humans (57). Following ischemic and toxic renal injury, the
extracellular domain of KIM-1 is detached and extracted into urine, consequently, a
quantitative marker of AKI (51). It is important to note that KIM-1 robust expression is
largely restricted to proximal tubule epithelial cells, so, it is also a specific indicator of
proximal tubule injury (52, 58). In a mouse model of I/R-induced AKI, both KIM-1 mRNA
and protein expression increased with decline of renal function (59). In addition,
laboratory evidence revealed that KIM-1 increases apoptosis by facilitating phagocytosis
and clearance of apoptotic debris, in turn, dampening the proinflammatory response
(60). Rodent studies have also been translated into clinical studies demonstrating 5-fold
increase in urinary KIM-1 within 24 hr of renal tubular injury, with no change in serum
SCr and BUN until 72 hr following tubular insult (58). Studies have also indicated that
KIM-1 excretion is more specific for I/R renal injury compared to other AKI biomarkers
(listed in Fig. 1.7), indicating the increased sensitivity of proximal tubules following
ischemic renal injury (58). Due to its organ specificity, sensitivity to minor changes in
renal function and injury-dependent expression, KIM-1 is considered an ideal maker of
AKI and is an approved by the FDA for pre-clinical drug development for AKI.
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Figure 1.6: Biomarkers of AKI. GFR: glomerular filtration rate, IL: interleukin, KIM-1:
kidney injury molecule-1, NGAL: neutrophil gelatinase-assocaited liocalin, γ-glutamyl
transpeptidase, AP: alkaline phosphatise, NAG: n-acetyl-glucosaminidase. Adapted from
(61).
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Clinical Management and Treatment of AKI
There is at present, no effective treatment for AKI, therapeutic strategies are largely
limited to control of hypertension and hyperglycemia, volume replacement and renal
replacement therapy.
As discussed in previous sections, reduced blow flow to the kidney is a major contributor
to the onset and progression of AKI. Thus, vasodilators have been under investigation
as a potential therapeutic option to improve renal perfusion. Fenoldopam, a selective
dopamine receptor 1 agonist, has been effective in increasing renal blood flow to the
renal cortex and medullary regions, particularly effective in patients with hypertension
(62). Small doses of dopamine also selectively increases the dilation of renal
vasculature, enhancing renal perfusion and urine output (63). More studies are need to
explore the true therapeutic efficacy of fenoldopam and dopamine; however, compelling
clinical evidence supports the notion that vasodilators alone are not sufficient to improve
renal function in AKI patients.
Another supportive strategy for AKI patients where hemodynamic changes and volume
depletion contributes to the development and progression of AKI, fluid resuscitation with
colloid or crystalloid solutions is commonly used to replenish body fluid (64). Control and
optimization of fluid replacement is key to health management to avoid fluid overload,
which is a mediator of adverse outcomes in AKI patients. In the unfortunate case of fluid
overload, patients are typically prescribed diuretics as an adjunctive therapy (65). Fluid
replacement serves as method to minimize complications associated with AKI and not
the treatment of AKI.
There is strong experimental and clinical data to support the benefits of loop diuretics
such as furosemide for the management of AKI. Loop diuretics are proposed
renoprotective agents with the rationale being that diuretics decrease cellular transport
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of solute and ions, reducing cellular energy demand and hence potentially preserving
cell viability (66). In addition, loop diuretics are also associated with reduced tubular cast
obstruction, improving urine flow. However, there is some clinical concern that loop
diuretics may also be harmful in some scenarios such as in patients with myocardial
dysfunction, a common cause of AKI (67). While diuretics have a number of
physiological benefits, data from multiple randomized meta-analyses assessing
furosemide and mannitol, an osmotic diuretic in the setting of AKI, are inconclusive in
determining the true therapeutic efficacy of diuretics (67, 68).
With no lifesaving therapies, renal replacement therapy, commonly known as dialysis,
has become routine in the management of critically ill patients and patients that are
unresponsive to other interventions (69). As such, dialysis is the only FDA-approved
intervention. Meta-analyses data indicates that early initiation of dialysis is associated
with better outcomes; however, clinical tests (measurement of SCr and BUN) for the
diagnosis and staging of AKI are not ideal for early diagnosis. Thus, there is an
incredible need for the identification of therapeutic targets for the effective treatment of
AKI. This review will specifically focus on the mitochondrion as a viable therapeutic
target in the setting of AKI.
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MITOCHONDRIAL BIOLOGY
Mitochondrial Structure
Mitochondria are structurally distinct from other organelles as they are composed of two
membranes comprised of phospholipid bilayers: outer mitochondrial membrane (OMM)
and inner mitochondrial membrane (IMM). The OMM is selectively permeable containing
channel proteins known as porins for transporting molecules across the membrane. The
IMM folds inward to form the cristae and is the location of the oxidative phosphorylation
machinery, complexes I-IV of the electron transport chain (ETC) and ATP Synthase β
(70). In addition to the functional role of the double membranes, they also give rise to the
intermembrane space and the mitochondrial matrix. The intermembrane space
maintains the protein gradient established by ETC activity and; the mitochondrial matrix
contains metabolic enzymes that regulate the citric acid cycle, fatty acid oxidation and
protein synthesis (71). In addition, the mitochondrial matrix houses circular and double
stranded mitochondrial DNA (mtDNA), which mtDNA encodes for 37 genes necessary
for the architecture and function of mitochondria, including 22 transfer RNAs (tRNAs), 2
ribosomal RNAs (rRNAs) and 13 transport chain proteins (72). It is important to note that
due to the limited coding capacity of mtDNA, cross talk between nuclear and
mitochondrial genomes is essential to the maintenance of mitochondrial function and
homeostasis as over 1,500 of the proteins in the mitochondria are nuclear-encoded and
subsequently imported into the mitochondria through protein translocation machinery on
the OMM and IMM (73).
Mitochondrial Function
Mitochondria play an integral multifaceted role within the cell, with the most prominent
function being the generation of ATP by oxidative phosphorylation. In addition to energy
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production, mitochondria are also the main sites of calcium sequestration, fatty acid
oxidation, reactive oxygen species (ROS) generation and detoxification, heme and
steroid synthesis, cholesterol metabolism and apoptotic cell death (74-79).

These

complex cellular processes are dependent upon functioning mitochondria, highlighting
the importance of mitochondria homeostasis in disease and aging populations.
Mitochondrial Homeostasis
Mitochondrial homeostasis, the proper balance of mitochondrial content and metabolism,
is a tightly controlled process mediated by the interplay between mitochondrial
biogenesis (MB), fusion and fission and mitochondrial clearance (mitophagy) (80, 81).
Mitochondria are highly dynamic organelles that are not generated de novo, therefore,
fusion and fission play critical roles in the preservation of mitochondrial number and
morphology necessary to meet cellular energy demands, especially in the face of injury.
Fusion results in long continuous mitochondrial networks through the mixing of healthy
mitochondrial components and DNA with those of damaged mitochondria. Fusion is
regulated by mitofusin 1 and 2(Mfn1/Mfn2), both located on the OMM and optic atrophy
1 (OPA1) located on the IMM (82). Mfn2 mediates mitochondria-endoplasmic reticulum
interactions by aiding in calcium exchange between the two organelles and has been
implicated as an essential regulator for proper mitochondrial transport, localization and
calcium flux (83). Mfn1 and Mfn2 deficiency in mice results in improper development of
the placenta and consequently, midgestational lethality, owing largely to increased
mitochondrial fragmentation (84). Additionally, both Mfn2 and OPA1 are associated with
neurodegernative diseases, including Charcot-Marie-Tooth (CMT) and autosomal
dominant optic atrophy (DOA) (85-87).
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Fission refers to the budding of mitochondria into punctate or sphere shaped units
through the interaction of OMM proteins cytosolic GTPase dynamin-related protein 1
(Drp1) and mitochondrial fission 1 (Fis1) (82). During mitochondrial fission, Drp1 is
translocated to the mitochondria where it interacts with Fis1, leading to the
oligomerization of Drp1 and the facilitation of mitochondrial cleavage. A number of posttranslational modifications, modulate the functional properties of Drp1, including
phosphorylation, SUMOylation, ubiquitination and S-nitrosylation (88), modulates the
functional properties of Drp1. Abnormal Drp1 function has been associated with
enhanced intracellular ROS, altered calcium flux and apoptosis (89, 90). Like Mfn-null
mice, Drp1 knockout mice die early during embryonic development due to improper
synapse formation and suppressed neurite growth (91).
Fission also contributes to quality control by enabling the selective removal of damaged
mitochondria. Mitophagy is a tightly controlled process by which injured or dysfunctional
mitochondria are isolated from the active pool and undergo lysosomal degradation (92).
Mitophagy is generally upregulated with aging and injury. There are a number of
signaling pathways that facilitate mitophagy, such as those mediated by FUN14 domaincontaining protein 1 (FUNDC1), an integral OMM receptor or OMM proteins, BCL2
interacting protein 3/NIX (BNIP3/NIX), which are both induced under hypoxic conditions.
(93). It should be also be noted that BNIP3 has proapototic functions (94), highlighting
the interconnectivity of two clearance mechanisms to maintain proper mitochondrial
function and homeostasis. The most notable mitophagy pathway is mediated by PTENinduced putative kinase 1 (PINK1) on the OMM and the cytosolic E3 ubiquitin ligase
Parkin (81, 93). When PINK1 accumulates on the OMM, the translocation of Parkin to
the mitochondria is triggered. PINK-1-mediated phosphorylation of Parkin activates its
ubiquitin ligase activity. Parkin then induces the ubiquitination of OMM proteins, such as
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autophagasomes through the recruitment of p62 and LC3-binding domain (95). While
abnormal Parkin is most notable for its role in Parkinson’s disease (96). Both PINK1 and
Parkin1 deficiency have been linked to mitochondrial defects (97, 98). Because of its
importance in maintaining proper mitochondrial homeostasis, it is unsurprising that
mitophagy has proven to be cytoprotective under cellular stress conditions, such as in
the case of I/R injury.
Mitochondrial Biogenesis
As mentioned above MB is broadly defined as the process by which cells generate, new
functional mitochondria (99). The purpose of MB is to not only maintain physiological
state, but also increase mitochondrial mass and copy number, and thereby increasing
ATP, in response to pathological stressors, exercise, caloric restriction and low body
temperatures (100). MB relies on the aforementioned regulators of mitochondrial fusion
and fission in order to increase the active pool of mitochondria. MB occurs following the
transcription and translation of both nuclear-and mitochondrial-derived proteins, which
are then incorporated into newly establish mitochondrial networks.

(81). Figure 1.7

illustrates the mitochondrial life cycle: biogenesis, fission/fusion and mitophagy.
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Figure 1.7: Mitochondrial Life Cycle. Mitochondrial homeostasis is a multifactorial
process governed by MB, fission/fusion and mitophagy. PGC-1α activates nuclear
respiratory factor 1 (Nrf1) and nuclear respiratory factor 2 (Nrf2) to coordinate the
expression of nuclear genes required for MB. PGC-1α also activate mitochondrial
transcription factor A (TFAM) and mitochondrial transcription factor B (TFBM), which
regulate the transcription of genes encoded by mtDNA. Mitochondria undergo cycles of
fusion, which is mediated by mitofusin (Mfn) 1, Mfn2 and optic atrophy protein (Opa1).
Fission is mediated by dynamin-related protein 1 (Drp1) and fission 1 (Fis1). Fission also
promotes the isolation of damaged mitochondria for selective mitochondrial degradation,
a process called mitophagy. Mitophagy involves the mitochondrial depolarization,
accumulation of putative kinase protein kinase 1 (Pink1) on the mitochondrial
membrane, recruitment of Parkin, which targets the mitochondria to the autophagasome
through the ubiquitination of mitochondrial proteins. Assembly of the phagasome
involves beclin-1, p62 and conjugation of microtubule-associated protein 1 light chain 3
(LC3II). Adapted from (101).
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Transcriptional Regulation of MB
The transcriptional regulation of MB is largely governed by the peroxisomal proliferatoractivated receptor γ coactivator 1 (PGC-1) family of transcriptional co-activators,
including PGC-1α, PGC-1β and PGC-1 related coactivator (PRC), which are all selective
regulators of MB and respiratory function (102-104). PGC-1 members are characterized
by an N-terminal activation domain with a leucine-rich LXXLL motif that medicates their
interaction with various nuclear transcription factors (105). The PGC-1 co-activators do
not directly bind DNA, but instead serve as docking platforms that recruit additional
protein complexes responsible for the coordination of both the nuclear and mitochondrial
genomes (104).
PGC-1α is termed the “master regulator” of MB and is highly expressed in tissues with
highmetabolic demand including the skeletal muscle, heart, brown adipose tissue (BAT),
brain and kidney (102, 106-108). Activation of PGC-1α not only activates the expression
of genes involved in MB, but also activates the expression of antioxidant enzymes such
as catalase, superoxide dismutase (MnSOD) and glutathione peroxidase, indicative of
the extensive role of PGC-1α extends in the regulation of mitochondrial health (109).
PGC-1α was initially described as a coactivator for peroxisomal proliferator-activated
receptor γ (PPARγ) in a yeast two-hybrid screen and subsequently as a PPARγinteracting protein in brown adipose tissue (BAT) to regulate adaptive thermogenesis
(108). PGC-1α has recently emerged as a co-activator of several nuclear transcription
factors including PPARs (PPARα, PPARδ, PPARγ), nuclear respiratory factors (NRF-1
and NRF-2), forkhead box protein O3 (FOXO3a), as well as nuclear hormone receptors
estrogen related receptors (ERRα, ERRβ and ERRγ) (110, 111).
Nuclear Respiratory Factors (NRF-1 and NRF-2). NRF-1 was originally discovered as a
transcriptional regulator of cytochrome c and has since been associated with the
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expression of a variety of genes required for subunits of respiratory complexes I-V (112).
Similarly, gene expression of machinery involved in heme biosynthesis, protein import
and assembly (TOM20, TOMO70 and COX17), mitochondrial translation (ribosomal
proteins, tRNA synthetases) and mitochondrial transcription (mitochondrial transcription
factor A, TFAM) are also NRF-1 dependent. NRF-2 was initially characterized by its
direct interaction with the cytochrome c oxidase subunit IV (COXIV) promoter (113, 114).
Recent experimental evidence revealed that NRF-2 also exerts its effects through
modulating the expression of genes involved in oxidative phosphorylation, mitochondrial
transcription factors (TFAM, mitochondrial transcription factor B isoforms) and receptor
complexes involved in protein import (TOM20 and TOM70) (113).Homozygous
knockouts of NRF-1 are embryonic-lethal. Specifically, NRF-1 null blastocysts exhibit
mtDNA depletion and disrupted mitochondrial membrane potential, highlighting the
importance of NRFs in the development of proper mitochondrial function and biogenesis
(115). Despite the overlapping functions of NRF-1 and NRF-2, experimental evidence
demonstrates that NRF-2 cannot rescue the embryonic-lethal phenotype in NRF-1
knockout mice, indicating that NRF-1 and NRF-2 have differential expression during
developmental stages and modulate specific transcriptional programs (116). In
summary, overwhelming evidence indicates that NRFs play a vital role in mitochondrial
function and homeostasis.
Peroxoisome Proliferator-Activated Receptors (PPARα, PPARγ and PPARδ). PPARs are
nuclear ligand-activated transcription factors that are key in modulating expression of
genes involved in lipid and fatty acid metabolism. The PPAR family is comprised of three
isoforms PPARα, PPARγ and PPARδ which have distinct tissue distributions and
functions. PPARα is primarily expressed in the liver, kidney and heart and promotes the
utilization and catabolism of fatty acids by upregulating genes involved in fatty acid
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transport and mitochondrial fatty acid β-oxidation (117). PPARδ is expressed mainly in
the brain, adipose tissue and skin where it also promotes uptake and oxidation of fatty
acids (118, 119). Because β-oxidation produces substrates for the citric acid cycle and
ETC, PPARα and PPARδ are also implicated regulating energy homeostasis and
mitochondrial function. PPARγ is highly expressed in white and brown adipose tissue
and endothelial cells, with a function of adipocyte proliferation and differentiation, as well
as fatty acid synthesis and lipid transport. All PPARs homodimerize with retinoid Xreceptor-α and subsequently binds to the promoter regions of target genes such as
uncoupling protein 1 (UCP1) and UCP2 (120, 121). UCPs are IMM transporters
responsible for dissipating the electrochemical gradient generated by the respiratory
chain, and therefore, play a major role in oxidative phosphorylation and adaptive
thermogenesis. In terms of promoting MB, PPARs, specifically PPARδ and PPARγ,
serve as powerful inducers of PGC-1α gene transcription, acting through a PPARresponsive element (PPRE) in the distal promoter and successfully induce MB in
adipose tissue and skeletal muscle (122). In summary, PPARs are essential in an array
of mitochondrial functions from lipid oxidation to MB, demonstrating their importance in
mitochondrial homeostasis.
Estrogen-Related Receptors (ERRα, ERRβ and ERRγ). Estrogen-related receptors
(ERRs) are orphan nuclear receptors that target a vast number of genes involved fat and
glucose metabolism, as well as and MB and function (123). ERRα is the most prominent
ERR isoform and is abundantly expressed in highly oxidative tissues. ERRα promotes βoxidation, citric acid cycle progression, oxidative phosphorylation and ATP synthesis
through its control of the medium chain acyl-coenzyme A dehydrogenase (MCAD),
fumarate, cytochrome c and subunits of ATP synthase, respectively (124). Through its
involvement in fatty acid oxidation and by serving as a binding partner to PGC-1α, ERRα
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regulates both oxidative phosphorylation and MB. In fact, experimental inhibition of
ERRα disrupts PGC-1α-mediated transcriptional programs, indicating that ERRα is
necessary for the induction of MB (125). It is noteworthy to mention that there are cell
type-specific differences in the manner by which ERRα regulates mitochondrial function
and biogenesis. For example, ERRα may operate in concert with other transcriptional
coactivators (NRF2 and PPARα) or may operate independently (126). To further
substantiate the importance of ERRs in orchestrating MB and function, ERR-null mice
exhibit reduced expression of genes involved in oxidative phosphorylation and altered
ETC complex activity in a variety of tissue types including the heart, skeletal muscle and
adipose tissue (127-129). These experimental findings support the notion that ERRs are
key transcriptional modulators in regulating mitochondrial oxidative phosphorylation and
biogenesis.
Mitochondrial Transcription and Replication in MB
As mentioned above, mitochondria are unique in that they contain their own genome
encoding for 13 components of the ETC and RNA components required for
mitochondrial translation. PGC-1α helps orchestrate mitochondrial transcription and
replication by modulating the expression of key players from the nuclear and
mitochondrial genomes, such as the mitochondrial DNA polymerase and helicase. This
section will briefly discuss the machinery responsible for the transcription and replication
of mtDNA for MB.
mtDNA Transcription. The mitochondrial genome is transcribed by RNA polymerase
(POLRMT), TFAM and one of two mitochondrial transcription factor B isoforms (TFB1M).
Transcription of mtDNA is initiated when POLRMT binds to either of three promoters,
heavy strand (HSP) 1 and 2 or light strand (LSP), followed by TFAM recruitment. It has
been reported that TFAM may structurally alter and relax by relaxing the mtDNA
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exposing the promoter region to facilitate binding of POLRMT and other transcription
complexes such as TFBM-POLRMT (130, 131). POLRMT activity yields full-length
mtDNA that are subsequently cleaved into mRNAs, tRNAs and rRNAs.
mtDNA Replication. mtDNA replication, DNA helicase (Twinkle), DNA polymerase γ
(POLγ), single-stranded binding protein (mtSSB), RNAse H1, DNA ligase III and
mitochondrial topoisomerase 1 (TOP1MT), the machinery necessary for mtDNA
replication, are all nuclear-encoded and responsible for unwinding, DNA synthesis and
repair of mtDNA. mtDNA replication is also intimately linked to transcription through
POLRMT and TFAM synthesis of RNA primers used by POLγ for the initiation of
replication. It is noteworthy to mention that POLγ is the only mtDNA polymerase and its
catalytic domain contains DNA polymerase activity, but also exonuclease and 5’dRP
lyase activity, promoting its participation in mtDNA damage censoring and repair (132).
Physiological Regulation of PGC-1α in MB
An extensive amount of attention has focused on understanding the molecular
mechanisms responsible for the regulation of PGC-1α expression and activity. A vast
range of physiological cues and signals have been elucidated, however, these pathways
are both tissue-and environmental-dependent. Major signaling events, including posttranslational modifications of PGC-1α are discussed below.
cAMP-CREB .A large body of evidence has emerged characterizing the cyclic AMP
(cAMP) response element-binding protein (CREB). CREB is a well-studied positive
regulator of PGC-1α, which act on the conserved CRE in the PGC-1α promoter. In
hepatocytes, PGC-1α expression is induced downstream of glucagon signaling, which
leads to increased cAMP, protein kinase A (PKA) and CREB in response to dietary
alterations (133). Cold temperatures and exercise activates the β2 adrenergic receptor
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leading to enhanced cAMP-PKA-CREB signaling and the subsequent in PGC-1α
expression (103). In addition, increased cellular calcium induces CREB activation and
ultimately PGC-1α expression via calcium/calmodulin-dependent protein kinase IV
(CaMKIV) (134, 135).Calcium also mediates PGC-1α expression, independent of CREB,
through the interaction of calcineurin A with the myogenic transcription factors myocyte
enhancer factor 2C (MEF2C).
p38. Another mechanism regulating PGC-1α expression involves p38 mitogen-activated
protein kinase (p38 MAPK), which is activated during muscle contraction and exercise
(136, 137). p38 MAPK-dependent activation of PGC-1α can occur through both MEF2
and activating transcription factor 2 (ATF2). ATF2 is a transcriptional activator of PGC1α, that when phosphorylated by p38 MAPK, binds to CRE within the PGC-1α promoter.
p38 MAPK-dependent activation of ATF2 often occurs in BAT during cold exposure,
indicating the role of ATF2 in adaptive thermogenesis (103).
AMPK. AMP-activated protein kinase (AMPK) is a well-studied inducer of PGC-1α and
MB. AMPK is a cellular energy sensor and is activated when AMP/ATP ratio is high,
ultimately triggering a vast range of pathways to increase cellular levels of ATP. During
exercise, ATP levels decrease, in turn, activating AMPK in the muscle (138). A number
of reports have revealed that activated AMPK induces MB through the induction of PGC1α in skeletal muscle. While further studies are needed to elucidate the mechanisms by
which AMPK activation increases PGC-1α transcript levels, AMPK has been studied as
a pharmacological target for the activation of MB (138).
Nitric Oxide. Activation of nitric oxide synthase (NOS) in BAT and endothelial cells via
the generation of cyclic GMP (cGMP) has also been suggested as a potent induce of
PGC-1α expression (139). There are three isoforms of NOS (endothelial: eNOS,
inducible: iNOS and neuronal: nNOS), and recent evidence has implicated eNOS has a
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regulator of MB by increasing PGC-1α, NRF-1 and TFAM mRNA expression, as well as
mtDNA content in human cells (139). In particular, eNOS increases cGMP levels through
guanylate cyclase, leading to induction of gene transcripts involved in MB though an
unknown mechanism.
Receptor-interacting protein 140. Experimental evidence characterizes receptorinteracting protein 140 (RIP140) as a corepressor of PGC-1α by interacting with ERRs
and PPARs to antagonize gene expression of PGC-1α and its downstream targets.
RIP140-deficient mice exhibit increased mitochondrial gene expression and oxidative
capacity; in fact, these transgenic mice are protected against diet-induced obesity due to
the increased energy expenditure (140, 141). RIP140 is known to be a regulator of
oxidative metabolism in both skeletal muscle and adipocytes (142, 143)
Extracellular signal-regulated kinase. The MEK/ERK signaling cascade has also been
implicated as a negative regulator of PGC-1α and MB, particularly under pathological
conditions. ERK1/2 reduces PGC-1α and its downstream targets in a number of disease
models. In animal models of Parkinson’s disease (PD), TFAM phosphorylation as a
result of ERK1/2 activation decreased mtDNA transcription (144). In a mouse model of
Alzheimer’s disease (AD), ERK1/2 activation impaired mitochondrial function, as
evidenced by altered mitochondrial fission and fusion and reduced mitochondrial
membrane potential (145). Of particular interest, following administration of the oxidant
tert-butyl hydroperoxide (TBHP) to RPTC, ERK1/2 phosphorylation correlated with
reduced complex I activity and ATP production (146). Furthermore, ERK1/2 activation
preceded the decrease in renal PGC-1α mRNA and loss of renal function in a mouse
model of I/R-induced AKI (147). Pharmacological inhibition of ERK1/2 phosphorylation
has been implicated as protective in a number of animal disease models, indicating the
importance of ERK1/2 signaling in mitochondrial homeostasis and cell survival.
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Post-translational Modifications of PGC-1α. PGC-1α is also regulated through a host of
post-translational modifications, including methylation, acetylation, small ubiquitin-like
modifier (SUMO)-ylation, phosphorylation and ubiquitination. Deacetylation by silent
mating type information regulation 2 homologue (SIRT1) and methylation by protein
arginine methyltransferase 1 (PRMT1) increases PGC-1α activity, whereas acetylation
by general control nonderepressible 5 (GCN5) and SUMOylation by SUMO1 negatively
impacts the function of PGC-1α (148-151). Phosphorylation of PGC-1α can either
increase or decrease its activity depending on the phosphorylating kinase. For example,
p38 MAPK and AMPK phosphorylation increases PGC-1α activity, while AKT and
GSK3β phosphorylation inhibits its activity (152, 153). Ubiquitination of PGC-1α via an
E3 ubiquitin ligase, Skp1/Cullin/F-box-cell division control 4 (SCFCdc4), targets PGC-1α
for proteasomal degradation (154). These modifications allow for the fine-tuning of PGC1α activity in a context-dependent manner.
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Figure 1.8: Regulation of PGC-1α and MB. A summary of the pathways involved in the
promotion and mediation of MB through modulating PGC-1 transcription, posttranscriptional status, or both as described above. Because of the complexity of the
pathways involved, many intermediates and feedback interactions are not included.
Inhibitory factors, such as receptor-interacting protein 140 (RIP140), general control
nonderepressible 5 (GCN5) and Akt are not shown. Red boxes indicate essential targets
required for MB. AMPKP: AMP-activated protein kinase, CAC: citric acid cycle, CamK:
calcium-calmodulin-dependent protein kinase, CO: carbon monozide, eNOS: endothelial
nitric oxide synthase, FAO: fatty acid oxidation, GABP: GA-binding protein α, GSK-3β:
glycogen synthase kinase-3β, HO-1: heme oygenase 1, NO: nitric oxide, OXPHOS:
oxidative phosphorylation, PKA: protein kinase A, PRC: PGC-1 related coactivator,
TZDs: thiazolinediones, UCP: uncoupling protein. Adapted from (111)
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MITOCHONDRIAL DYSFUNTION AND BIOGENESIS IN AKI
Renal Proximal Tubule Bioenergetics
Active transport of solutes in proximal tubules require high turnover of ATP derived
almost exclusively through mitochondrial oxidative phosphorylation. In fact, at least 70%
of mitochondrial oxygen consumption is utilized by the renal proximal tubule to drive the
ATP-dependent sodium pump and establish the chemical gradients necessary for
reabsorption (155). The proximal tubule primarily oxidizes fatty acids, amino acids and
pyruvate to fuel oxidative phosphorylation to meet this constant metabolic demand (155).
It is important to emphasize that the proximal tubule does not rely on glycolytic
metabolism, thus, the major regulatory enzymes of glycolysis have very low activity in
the renal cortex (156). As the proximal tubule is the most metabolically active epithelia in
the kidney, it is unsurprising that AKI, whether nephrotoxic, septic or ischemic in origin,
involves pathological changes in the mitochondria, in turn, contributing extensively to
renal dysfunction and damage (157, 158)
Evidence of Mitochondrial Dysfunction in I/R-induced AKI
Mitochondria have been a major focus for understanding the pathophysiology of I/Rinduced AKI. There is overwhelming evidence indicating mitochondrial dysfunction as an
initiator of renal dysfunction and damage in both cellular and animal models. I/R-induced
mitochondrial alterations include reduction in ATP-generating capacity, alterations in
mitochondrial dynamics, enhanced ROS production and apoptosis.
Decline in ATP Content. AKI is commonly characterized as a state of tubular ATP
depletion, which has been linked to impaired oxidative phosphorylation and loss of
mitochondrial membrane potential (158-162). Mice subjected to I/R-induced AKI exhibit
protein reduction in oxidative phosphorylation subunits such as cytochrome c oxidase I
(COXI), NADH dehydrogenase [ubiquinone] 1 beta subcomplex 8 (NDUFB8) and ATP
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Synthase β, subunits of complexed I, IV and V, respectively. In addition, alterations in
complex I activity and loss of mitochondrial membrane potential was observed in
isolated proximal tubular cells following hypoxia-reoxygeneation (160, 163). It should be
noted that reduction in energy production following I/R-induced AKI prevents not only the
transportation of solutes, but also energy-dependent repair processes and initiates
additional pathological events, including loss of renal brush border, calcium
accumulation, apoptosis and mitochondrial fragmentation (159, 164-166). Taken
together these findings highlight the important role of mitochondrial dysfunction in the
pathophysiology of is I/R-induced AKI.
Reactive Oxygen Species Generation. ROS formation in the kidney plays a significant
role in ischemia/perfusion, cisplatin, mercury and glycerol models of AKI (167-171).
Electron leakage in the mitochondrial respiratory chain and activation of leukocytes are
largely responsible for the generation of ROS following ischemia (172, 173). While
mitochondria are a major source of ROS generation, mitochondria are also a primary
target for ROS-mediated damage. ROS reacts with proteins, lipids and nucleic acids
contributing to sublethal cellular injury and apoptosis (174). In particular, mtDNA is
extremely susceptible to oxidative damage due to its proximity to ROS generated by
complex

I

and

III

of

the

electron

transport

chain,

mitochondria-localized

dehydrogenases, oxidases and enzymes involved in β-oxidation (78, 175). Renal I/R
injury also impairs ROS scavenging processes as demonstrated mitochondrial
superoxide dismutase 2 (SOD2) reduction. In turn, overexpression and/or induction of
SOD2 has resulted in renoprotective effects through attenuation of oxidative stress and
renal dysfunction in animal models of I/R-induced AKI (176). Additionally, positively
charged antioxidant agents that selectively accumulate in the mitochondrial matrix, such
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as SkQ1 and SkQR1 provided renoprotection under I/R conditions, indicating the
significant impact of ROS on tubular function in the setting of AKI (177).
Apoptosis. Mitochondria are also key regulators of apoptotic signaling in response to
renal ischemic and nephrotoxic insults. Mitochondria regulate caspase activation and
cell death through a process called mitochondrial outer membrane permeabilization
(MOMP) (178). MOMP is highly regulated by the pro-apoptotic Bcl-2 family members,
such as Bax, which inserts into the outer membrane of the mitochondria, increasing
mitochondrial permeability to proteins, allowing for cytochrome c release (179).
Cytochrome c then interacts with the caspase adaptor molecule apaf-1, in turn, recruiting
pro-caspase-9 and the subsequent activation of caspase 9 (179). Activated caspase 9 is
responsible for the cleavage and activation of the executioner caspases-3 and -7 and
the subsequent proteolytic cleavage of cellular components, ultimately leading to cell
death (179, 180). It is noteworthy to mention that the two additional pro-apoptotic
members of the Bcl-2 family, Bid and Bad, also translocate to the mitochondria in
response to I/R renal injury and subsequently activates proteolytic caspases similar to
Bax (181). Plotnikov et al demonstrated that the translocation of Bax to the mitochondria
increased by 50% after renal I/R in rats and this was directly associated with a 40%
reduction in cytochrome c content in the mitochondria (182). Treatment with diosmetin,
an anti-inflammatory and anti-apoptotic flavonoid, protected against tubular damage,
renal dysfunction and cell death following I/R-induced AKI (183). These studies, among
several others, provide strong evidence that enhanced apoptotic cell death is a major
determinant in the pathophysiology of AKI.
Altered Mitochondrial Dynamics. Mitochondrial size and integrity are important aspects
when considering the role of mitochondrial in the setting of AKI. As mentioned earlier,
mitochondrial are dynamic organelles that are continuously fusing and dividing in
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response to cellular needs. An increasing level of attention has been given to
mitochondrial fragmentation, or fission, and how it contributes to mitochondrial damage
and subsequent cell death. Under stress conditions, such as I/R injury, Drp1
translocates from the cytosol to the OMM, where it oligomerizes to drive OMM
constriction and cleavage (184, 185). The activation and recruitment of Drp1 to the
mitochondria is mediated by a number of post-translational modifications as well as its
interaction with Fis1 (186). It is also important to discuss the functional link between loss
of mitochondrial membrane potential, mitochondrial fission and apoptosis. A number of
studies have documented changes in mitochondrial morphology as a result of ATP
depletion and MOMP (187, 188). Addtionally, mitochondrial fragmentation is thought to
occur during the cell death pathway (188). Experimental inhibition of Drp1 prior to the
initiation of apoptosis not only inhibited mitochondrial fission but also delayed caspase
activation and cell death (188, 189). In particular, Brooks et al reported enhanced
mitochondrial fission in renal tubules in response to I/R injury(158). Additional studies
revealed the administration of Mdivi-1, a pharmacological inhibitor of Drp-1, reduced
mitochondrial fragmentation, having conferred beneficial effects in experimental models
of AKI by blocking cell death (158). In summary, the role of mitochondrial is multifactorial
and multiphasic in the setting of AKI; therefor, minimizing these deleterious
mitochondrial events has the potential to reduce injury and improve cellular energetics,
integrity and function.
Altered MB in I/R-induced AKI
Intensive exploration has focused on understanding the underlying mechanism leading
to mitochondrial dysfunction following AKI. In particular, our laboratory has focused on
the disruption of MB as a key mediator of mitochondrial dysfunction. As discussed
earlier, MB, through the actions of PGC-1α, is responsible for regulating the
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transcriptional and translational programs required for the proper maintenance of
mitochondrial content and function under physiological and pathological conditions. The
study of PGC-1α and MB is particularly important when assessing tubular mitochondrial
homoeostasis as renal PGC-1α is primarily localized in the proximal tubule in order to
meet the high cellular energy demand (190). We demonstrated early reduction in PGC1α and PGC-1β mRNA expression followed by sustained depletion of respiratory chain
proteins NDUFB8, ATP Synthase β and COX1 in the renal cortex, which is mostly
comprised of proximal tubules, of mice following I/R-induced AKI (191)(Fig. 1.9). In
addition, these animals also exhibited increased Drp1 protein expression and
procaspase 3 cleavage, indicating increased mitochondrial fragmentation and apoptosis
(191). In a subsequent study, depletion of renal cortical mtDNA content was also noted
in a mouse model of I/R-induced AKI (192). It is important to note that suppression of
PGC-1α and MB has also been witnessed in other models of AKI. For instance,
reduction of PGC-1α expression and its downstream targets was observed in a mouse
folic-acid model of AKI and this was correlated with persistent suppression of renal
cortical mtDNA copy number (193). In addition, Smith et al. demonstrated reduced renal
cortical PGC-1α mRNA and protein levels, along with decreased respiratory chain
protein expression, correlated with tubular injury as evidenced by KIM-1 and renal
dysfunction as evidenced by BUN in a endotoxin model of AKI (194). Taken together,
these findings indicate that PGC-1α and MB serve as
mitochondrial content and function in the setting of AKI.
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potential targets to rescue

Figure 1.9: Disrupted MB in I/R-induced AKI. Renal cortical gene expression of
nuclear-encoded respiratory components, NADH dehydrogenase [ubiquinone] 1 beta
subcomplex subunit 8 (NDUFB8) and ATP Synthase β (ATPβ) were assessed in sham
and I/R- injured mice at 24, 72 and 144 hr following injury (A). Protein expression of
renal cortical NDUFB8, ATPβand COX1 was also assessed in the same animals (B).
Sustained depletion of genes and proteins required for respiratory chain function was
observed in mice subjected to renal I/R injury. Immunoblot and immunohistochemical
analysis (C, D) of cytochrome c oxidase IV (COXIV) was also assessed, following the
same pattern as other respiratory proteins.
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Pharmacological Induction of MB
The most convincing data that illustrates the true potential of MB as a viable target
following AKI is depicted in studies utilizing pharmacological induction of MB and
subsequent restoration in mitochondrial homeostasis and renal function. A proof-ofprinciple experiment was perform by our laboratory in rabbit primary RPTC that were
exposed to H2O2 followed by the overexpression of PGC-1α (195). PGC-1α
overexpression restored respiratory chain protein expression, cellular respiration and
ATP content, as well as facilitated the recovery of sodium transport in oxidant treated
RPTC (195). Collectively, this study provided evidence that the induction of MB is
capable of reversing mitochondrial dysfunction, which may be driving the recovery of
normal proximal tubule cellular function following acute oxidant injury.
Our

laboratory

previously

demonstrated

that

isoflavones,

cGMP-specific

phosphodiesterase (PDE) inhibitor and 5-HT2 pan agonist 1-(2,5-dimethyoxy-4iodophenyl)-2-aminopropane (DOI) promoted the increase of nuclear-encoded and
mitochondrial-encoded proteins involved in MB in RPTC in vitro (196, 197). Additionally,
pharmacological activators of SIRT1 deacetylated PGC-1α, thereby, increasing the
active pool of PGC-1α, and attenuating renal and mitochondrial dysfunction in a rat
model of I/R-induced AKI (198). Lastly, treatment with formoterol and sildenafil
(phosphodiesterase, PDE5 inhibitor) beginning 24 hr following bilateral renal I/R injury or
folic acid-induced AKI, respectively, accelerated mitochondrial and renal function
recovery in mice (193, 199). Taken together, these studies strongly support the notion
that the induction of MB serves as a viable treatment for the restoration of mitochondrial
homeostasis for the consequent recovery of tubular and renal function following AKI.
Despite the overwhelming amount of preclinical evidence, relatively few drugs have
been identified for the induction of MB. Thus, there is a tremendous need for the
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identification of novel therapeutic targets that not only stimulates MB but also extend
beyond partial restoration of cellular function. Figure 1.10 summarized pharmacological
approaches for the stimulation of MB.
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Figure 1.10: Pharmacological Activation of MB. MB is a complex process controlled
by the transcriptional regulator peroxisome proliferator-activated receptor gamma
coactivator-1 alpha (PGC-1α). PGC-1α expression and activity is regulated by a variety
of pathways including receptor tyrosine kinases, G-protein coupled receptors (GPCR),
naturetic peptide receptors, cyclic guanosine monophosphate (cGMP) , as well as sirtuin
(SIRT)1-mediated deacetylation. In response to various stimuli, mitochondrial undergo
the process of mitochondrial fusion via mtofusin (Mfn) 1, Mfn 2, optic atrophy 1 (Opa1) or
fission via a host of proteins such as dynamin-related protein 1 (Drp1).Damaged
mitochondria are cleared by the selective degradation in lysosomes. EGF: epidermal
growth factor, VEGF: vascular endothelial growth factor, RTKs: receptor tyrosine
kinases, β2AR: β2-adrenergic receptor, 5HTR: serotonin receptor, GC-A/B: guanylyl
cyclase A/B, eNOS: endothelial nitric oxide synthase, NO: nitric oxide, sGC: soluble
guanylate cyclase, cAMP: cyclic adenosine monophosphate, AMPK: AMP-activated
kinase, PPAR: peroxisome proliferator activated receptor, ERR: estrogen related
receptor, NRF1: nuclear respiratory factor 1, Ac: acetyl, TCA: tricarboxylic acid cycle,
OXPHOS: oxidative phosphorylation, TOM: translocase of the outer membrane, TIM:
translocase of the inner membrane, mtDNA: mitochondrial DNA. Adapted from (200).
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SEROTONIN AND SEROTONIN RECEPTORS
Serotonin and its Function
5-hydroxytryptamine (serotonin, 5-HT) is a monoamine neurotransmitter synthesized
from its precursor amino acid L-tryptophan through a biochemical pathway comprised of
three enzymes: tryptophan hydroxylase (TPH), aromatic acid decarboxylase (DDC) and
pyridoxal phosphate (201). The metabolism of 5-HT is mediated by the OMM enzyme
monoamine oxidase (MAO) and aldehyde dehydrogenase and the metabolites are then
excreted by the kidney (202).
While serotonin is best known for its role in the central nervous system (CNS), the
majority of 5-HT is primarily found in the periphery with approximately 90% of total body
5-HT released into the gastrointestinal tract or stored in blood platelets (203). Serotonin
mediates a vast array of physiological processes including behavior and mood, pain
control, hemostasis and platelet function, cardiovascular function and valvular closure,
breathing and respiratory drive and gastrointestinal motility.
Central Nervous System. Serotonin modulates a number of behavioral processes though
specific serotonin receptors (discussed below). Mainly, serotonin regulates anxiety-like
behavior, reward processing, locomotion, appetite and energy balance (204-206). 5-HT
also mediates the release of other neurotransmitters such as glutamate and dopamine.
In addition, pharmacological inhibition of serotonin reuptake has proven to be viable
approach in the management of depression by increasing serotonin pools in the brain
(207-209).
Another important role of serotonin in both the CNS and peripheral nervous system
(PNS) is its modulation in pain perception and nociceptive processing (210). 5-HT is
released within inflamed tissue to mediate the signal transduction of nociceptive
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information to the brainstem, cortical and limbic regions, in turn, modulating the
psychological perception of pain (210). The 5-HT receptor have been successfully
drugged for the treatment of pain, specifically, triptans which were developed for the
treatment of migraine symptoms.
Blood Platelets. Blood platelets have a significant storage of serotonin as they lack the
machinery to synthesize serotonin de novo. Serotonin is taken up from the plasma by
blood platelets to promote platelet aggregation and vasoconstriction in the surrounding
tissues to facilitate hemostasis. Interestingly, serotonin also has the capacity to activate
vasodilation, which is commonly observed following the stimulation of a specific class of
5-HT receptors (discussed below) (211).
Cardiac Tissue. Several studies have documented the role of serotonin in regulating
cardiac

function.

Serotonin

modulates

the

release

and

activity

of

several

vasoconstrictors, such as angiotensin and norepinephrine, which are critical regulators
of systemic and primary pulmonary hypertension (212, 213) . Thus, alterations in the
serotonergic system can play a pathological role in multiple cardiovascular diseases. In
addition, serotonin’s role in cardiac valvular function was first noted after patients
prescribed fenfluramine, an appetite suppressant that acts by increasing serotonin,
developed valvulopathy and fibrosis (213).
Respiratory System. Early work by Reid and Rand described the role of 5-HT in
breathing control mediated by the serotonergic system in the brainstem and pre and
postsynaptic 5-HT receptors (214). In a feline model, they observed apnea following
intravenous injections of 5-HT (214). Subsequent studies revealed serotonin as a
neuromodulator of breathing, facilitator of respiratory rhythm and regulator of CO2/pH
homeostasis (215, 216). Additionally, adverse changes in serotonin levels and signaling
have been correlated with severe breathing disorders.
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Gastrointestinal Tract. Perhaps the most prominent role of serotonin in the periphery is
its role in regulating digestion. In fact, 5-HT is involved in the digestion of food on many
levels, from stimulation of taste-bud cells to the induction of intestinal motility and to the
secretion of digestive enzymes (pancreatic enzymes) (203, 217, 218). Considering
serotonin’s involved role in the gastrointestinal activities, it is no surprise that
abnormalities in serotonin signaling has been implicated in bowel disorders, such as
irritable bowel syndrome (219).
In summary, the serotonergic system is complex with a wide range of modulatory activity
of biologic responses. The overwhelming involvement of serotonin is governed by a
large class of serotonin receptors that are expressed in both the CNS and PNS.
Experimental evidence has linked a number of specific serotonin receptors to a given
process, allowing for the opportunity to pharmacologically target these receptors in
various disease states. The next section will discuss the various serotonin receptor
classes.
Serotonin Receptor Structure and Signaling
Serotonin exerts its effects through the interaction with as many as 13 distinct
heptahelical, G-protein coupled receptors (GPCR) and ligand-gated ion channels (220).
Serotonergic Ligand-Gated Ion Channels. The 5-HT3 receptor family are the only
serotonin receptors that are cation-selective (Na+ or K+) channels. Upon interaction with
5-HT, rapid neuronal depolarization occurs and the cation channels open in response,
creating an excitatory response (221). 5-HT3 receptors are expressed in both the CNS
and PNS, modulating excitatory synaptic transmission and neurotransmitter release
(222, 223).
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Serotonergic G-Protein Coupled Receptors. There are six families of class A (rhodopsinlike) GPCR that are modulated by serotonin (5-HT1,2,4-7). The 5-HT families are further
divided into subclasses based on their distribution, function and structure (220). The 5HT1,5 receptors are coupled to Gαi/Gαo, the 5-HT4,6,7 receptors are coupled to Gαs and
the 5-HT2 receptors are coupled to Gαq/Gα11 (220). Briefly, when serotonin or a 5-HT
receptor agonists interacts with any of the GPCR mentioned above, a conformational
change of the GPCR occurs (224, 225). The now activated Gα protein exchanges GDP
for GTP, in turn, triggering the dissociation of Gα subunit from the Gβγ heterodimer from
the receptor. The dissociated Gα and Gβγ heterodimer goes on to interact with a variety
of intracellular proteins to induced signal transduction cascades (226). Figure 1.11 is a
visual representation of this process.
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Figure 1.11: GPCR Cycle. Basal conformation of GPCR associated with Gαβγ heterotrimer (Top Left). Ligand binding activates and induces conformational change
of the GPCR allowing exchange of GDP for GTP on the Gα subunit (Top Right). The GαGTP and Gβγ subunits dissociate into their active state (Middle Right). Activated
subunits can then interact with downstream effectors, for example Gα can interact with
an effector (E) (Bottom Right). Gα and Gβγ interaction with an effector leads to the
activation of second messengers (Bottom Left). The GTP in Gα is hydrolyzed to GDP,
leading to the inactivation of Gα and Gβγ subunits and the reassociation of the Gα-Gβγ
heterodimer complex on the GPCR. Once the GPCR is inactive, GRKs and β-arrestin
associate with the GPCR to promote internalization of the receptor (Middle Left).GPCR:
G-protein coupled receptor, GEF: guanine nucleotide exchange factor (GEF), GDP:
guanine diphosphate, GTP: guanine triphosphate, GRK: G protein-coupled receptor
kinases, PM: plasma membrane. Adapted from (226).
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Intracellular signaling is dependent upon the Gα subunit coupled to the GPCR.
Specifically, Gαq/11 heterodimer activates phospholipase C (PLC) cleavage of
phosphoinositol 4,5-biphosphate (PIP2) to diacyl glycerol (DAG) and inositol
triphosphate (IP3) for the consequent release of intracellular calcium from the
endoplasmic reticulum(220, 227). Gαs and Gαi both modulate cyclic adenosine
monophosphate (cAMP) production via activating or inhibiting adenylate cyclase activity,
respectively. cAMP is considered a second messenger as one of its primary functions is
regulating the activity of the serine/threonine PKA family (208, 220).
It is extremely crucial to mention the signaling role of Gβγ heterodimer upon its
dissociation from Gα. While Gβγ heterodimer signaling is vastly understudied, Gβγ
heterodimer is known for activating distinct signaling pathways via regulation of ion
channels such as N-type calcium channels and direct protein-protein interactions with a
variety of different effectors such as PI3K (228, 229). Another important observation is
that the activation of Gαi-coupled GPCR releases a great amount of Gβγ to achieve
significant effector signaling (228). However, it is important to note that these pathways
are both tissue-and context-dependent.
Serotonin in the Kidney
Serotonin is actively synthesized by the proximal tubules in the renal cortex. Renal
serotonin has been reported to be involved in renal metabolism and vascular tone and
speculated to play a role in inflammatory and fibrotic responses following renal injury
(230). Xu et al. characterized the intrarenal serotonergic system, which includes
receptors belonging to the 5-HT1,2 family as well as the serotonin transporter (SERT),
particularly in the proximal tubule epithelial cells (231). This study also revealed
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serotonin stimulated the expression of two mediators of extracellular matrix
accumulation and vascular endothelial growth factor (VEGF), indicating the possible role
of renal 5-HT in fibrosis, however, the full extent of 5-HT signaling in the kidney has yet
to be reported (231). The high presence of renal serotonin and its receptors not only
suggests a prominent role of serotonin in the kidney but also supports the use of renal 5HT receptors as therapeutic targets.
Functional Role of Serotonin Receptors in Mitochondria Homeostasis and
Biogenesis
The role of serotonin receptors in regulating mitochondrial homeostasis is of particular
interest to our laboratory because a phenotypic screening assay revealed agonists of 5HT1,2 receptors induced MB in RPTC. Specifically, DOI enhanced mitochondrial function
(cellular

respiration,

ATP

production,

mitochondrial

membrane

potential)

and

mitochondrial mass (respiratory chain proteins and mtDNA copy number) in RPTC (197).
These positive effects on mitochondrial function and content were determined to be
dependent on PGC-1α and was blocked when RPTC were treated with a pan-5-HT
receptor antagonist (AM-193). Furthermore, DOI restored mitochondrial function (cellular
respiration) following oxidant injury in RPTC (197). This work was further extended to
reveal that 5-HT2C agonist and antagonist promoted MB in RPTC in a 5-HT2A receptordependent manner (232). These studies indicate that targeting serotonin receptors for
the induction of MB is a potential therapeutic strategy to promote the recovery of
mitochondrial and renal function in the presence of injury.
In addition to our findings, other groups linked the 5-HT receptors to mitochondria.
Nebigil et al. extensively characterized the role of the 5-HT2B as a vital regulator of
survival signals in cardiomyocytes (233). Interestingly, his worked revealed that the
depletion and overexpression of the 5-HT2B receptor altered mitochondrial function and
integrity. Specifically, 5-HT2B receptor knockout mice exhibited reduced mitochondrial
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enzyme activities (cytochrome oxidase and succinate dehydrogenase), mitochondrial
number and swollen cristae. These mitochondrial abnormalities were associated with
myocardial cell death (234). Transgenic mice overexpressing the 5-HT2B receptor
exhibited hypertrophic cardiomyopathy and dilated cardiomyopathy as a result of
increased mitochondrial proliferation and cell size. These mice also displayed increased
succinate dehydrogenase and cytochrome c oxidase activities (235). Interestingly, the
overexpression of the 5-HT2B receptor yielded a similar phenotype observed in mice that
overexpressed cardiac PGC-1α (236).
The 5-HT3 and 5-HT4 receptors have also been associated with cardiac mitochondria.
Both receptors are functionally located on the mitochondrial membrane and exhibit
distinct effects on mitochondrial function (237).

Cardiac 5-HT3 and 5-HT4 receptors

influence mitochondrial calcium uptake, mitochondrial respiration and ATP production as
well as modulation of the mitochondrial permeability transition pore. These alterations in
mitochondria homeostasis and function were also associated with impaired cardiac
behaviors as measured by cardiac rhythm (237). Taken together, these studies suggest
that both types of serotonin receptors, ion channel and GPCR, influence mitochondrial
function and ultimately essential cellular functions.
Based on the aforementioned findings, our laboratory continued to probe for 5-HT
receptor ligands that promote the induction of renal MB with the hopes of identifying a
novel target for the recovery of renal function in the setting of AKI.

48

5-HT1F RECEPTOR
5-HT1F Receptor Structure and Distribution
The 5-HT1F receptor was cloned and sequenced in 1992 and shares the greatest
sequence homology with the 5-HT1E receptor (238). The 5-HT1F receptor is a GPCR
containing 366 amino acids that inserts into cellular plasma membrane forming four
extracellular, seven transmembrane and four cytoplasmic domains (238).
The brain distribution of the 5-HT1F receptor was elucidated using selective 5-HT1F
radioligand, [3H]LY344370, revealing 5-HT1F receptor localization in layers IV-V of
cortical regions, striatum,olfactory bulb, CA3 hippocampal region, nucleus accumbens
and thalamus (239). Peripheral expression of the 5-HT1F receptor has been reported in
reproductive, cardiac, hepatic, retinal, renal and intestinal tissues, as well as peripheral
blood lymphocytes (238-242). While the 5-HT1F receptor is arguably the most
understudied serotonin receptor, its expression has been identified in numerous tissue
types, shedding light on the importance of the 5-HT1F receptor in the modulation of
physiological and potentially pathological cellular processes.
5-HT1F Receptor Signaling Physiological Roles
The 5-HT1F receptor exerts its cellular effects via forskolin (FSK)-stimulated inhibition of
adenylate cyclase activity and the subsequent reduction of cAMP accumulation, a
common signaling transduction pathway of 5-HT1 receptors (243). NIH-3T3 and LM(tk-)
cells (cultured mouse fibroblasts) were transfected with 1.7 and 4.4 pmol/mg protein 5HT1F receptor density, respectively, to explore the functional coupling of the 5-HT1F
receptor. Interesting, only 10% receptor occupancy was required to mediate halfmaximal response of cAMP inhibition in these cells, illustrating the potent ability of the 5HT1F receptor in promoting Gαi/o signaling (243). This study also revealed alternative
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signal transduction pathways downstream of the 5-HT1F receptor, which appears to be
cell or context specific. LM(tk-) cells transfected with 5-HT1F receptor were exposed to
relatively small concentrations of serotonin, inducing IP3 stimulation and the consequent
increase in intracellular calcium concentration (243). However, IP3 activation and calcium
release were absent in the NIH-3T3 cells, even at serotonin concentrations as high as
100μM (243). These data suggest that cells possessing high 5-HT1F receptor density
have the ability to interact with multiple cellular effectors beyond those of the canonical
signaling pathway.
The 5-HT1F receptor has been described as a neuronal receptor of the CNS that
mediates pain without vasoaconstrictive effects (244). Experimental studies dedicated to
the 5-HT1F receptor has focused on the development of 5-HT1F receptor agonists for the
treatment of migraines (244). The trigeminal system is responsible for carrying pain
impulses from the face, neck, teeth and ears to the central nervous system, thus, it is a
primary target for the treatment of migraines (245). The 5-HT1F receptor is highly
expressed in the blood vessels and nerve endings of the trigeminal system, therefore,
targeting the 5-HT1F receptor has proven to be an effective strategy in the augmentation
of migraine pain (244, 246, 247).
5-HT1F Receptor Agonists. There are two major classes of 5-HT1F receptor agonists,
triptans and flurobenzamides. Triptans are specific and selective 5-HT1 receptor agonists
that exhibit affinity for 5-HT1B, 5-HT1D and 5-HT1F receptors (246). Triptans were
specifically developed for the treatment of migraines. These five compounds exert their
anti-migraine effects through the vasoconstriction of cranial vessels, inhibition of dual
vasodilation by blocking the release of vasoactive neuropeptides, such as calcitonin
gene-related peptide (CGRP) and blockade of nociceptive neurotransmission (248). It is
noteworthy to mention that triptans have higher affinity for the 5-HT1B and 5-HT1D
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receptors, owing to the vasoconstrictive effects of these compounds. Systematic
vasoconstriction is a major limitation in the utilization of triptans as a therapeutic
strategy, especially in the case of chronic treatment. Thus, specific 5-HT1F receptor
agonists were developed to augment migraine pain independent of vasoconstriction.
To this end, 4-fluoro-N-[3-(1-methyl-4-piperidinyl)-1H-indol-5-yl]benzamide (LY334370)
and

N-[(3R)-3-(dimethylamino)-2,3,4,9-tetrahydro-1H-carbazol-6-yl]-4-fluorobenzamide

(LY344864) were developed and both of these compounds failed to induce vasoactive
changes in the vasculature of human, bovine, rodent and rabbit (244, 249, 250).
LY334370 and LY344864 are selective and efficacious agonists of the 5-HT1F receptor
with a reported pKd of 8.7and 8.2, respectively (251, 252). It is important to mention that
LY334370 also has affinity for the 5-HT1A receptor with a pKd of 7.8, while LY344864
binds with 100 fold greater affinity for the 5-HT1F receptor than other 5-HT receptors
(251, 252). Selective 5-HT1F receptor stimulation is proposed to augment migraine pain
by blocking migraine nociceptive transmission and preventing the release of glutamate,
which is thought to play a role in migraine development (244, 246). In addition to these
compounds, lasmiditan, the most recently developed selective 5-HT1F receptor agonist,
is currently in the final stage of clinical trials for migraine treatment, eliciting its effects
through mechanisms similar to those of LY334370 and LY344864 (253, 254).
5-HT1F Receptor in MB
Given the aforementioned role of serotonin receptors in modulating mitochondrial
homeostasis, it is unsurprising that the 5-HT1F selective agonists, LY334370 and
LY344864 yielded positive results in our phenotypic screening for MB. Specifically, both
compounds (1-100 nM) significantly increased FCCP-uncoupled oxygen consumption
rates by 30-40% in RPTC at 24 hr (192). Comparatively, the non-selective serotonin
receptor agonist, αm5-HT increased FCCP-uncoupled oxygen consumption rates by 2051

30% in RPTC (192), suggesting that both compounds are exhibiting FCCP-uncoupled
oxygen consumption rates at the maximal potential for serotonin agonists.
To confirm that the observed increase in FCCP-uncoupled oxygen consumption rates
were indeed a consequence of MB, gene expression of PGC-1α and respiratory chain
components (COX1, ND6, NDUFB8), in addition to mtDNA copy number,

were

measured in RPTC treated with LY3344370 and LY344864. Interestingly, LY344864
increased gene expression of all endpoints, however, LY334370 only enhanced the
gene expression of PGC-1α, COX1 and ND6 at 24 hr. In addition, LY334370 and
LY344864 both increased protein expression of ATP Synthase β, COX1 and NDUFB8 in
RPTC at 24 hr (192). These observed effects on MB were prevented by siRNA
knockdown of the 5-HT1F receptor, confirming that the mechanism by which LY334370
and LY344864 induce MB is 5-HT1F receptor dependent (192). It is important to note that
LY344864 was used to further characterize the role of the 5-HT1F receptor as LY334370
was proven to be less efficacious for the induction of MB and demonstrated toxicity in
larger animal species.
To determine whether MB was altered in the renal cortex because of LY344864
treatment, we assessed mRNA expression of renal cortical PGC-1α, COX1 and
NDUFB8 in time course and dose dependent studies. A single dose of LY344864 (2
mg/kg) rapidly increased transcript levels of PGC-1α and COX1 (1 hr) followed by
elevated NDUFB8 mRNA expression (8 hr) and mtDNA copy number (24 hr) in the renal
cortex of mice (192). Taken together, these findings confirm the hypothesis that 5-HT1F
receptor stimulation induces MB in both primary RPTC and murine kidneys.
To assess the role of the 5-HT1F receptor in MB and renal function under pathological
conditions, mice subjected to bilateral renal ischemia were treated daily with saline
vehicle or LY344864 over the course of 144 hr following surgery. I/R mice treated with
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LY344864 showed accelerated recovery of renal function by decreased BUN levels from
the initiation of treatment to near-control levels at the completion of treatment (192).
Tubular injury was measured using renal cortical KIM-1 in both groups of I/R mice. As
expected, KIM-1 protein expression was significantly reduced in LY344864-treated mice
compared to mice that did not receive LY344864 (192). Treatment with LY344864 also
promoted the recovery of renal cortical mtDNA copy number. Together, these findings
demonstrate that the stimulation of 5-HT1F receptor is a viable strategy to accelerate the
recovery of renal function and tubular repair in the setting of AKI, and the 5-HT1F
receptor-dependent renal recovery is correlated with restoration of mtDNA copy number.
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PROJECT GOALS
As discussed above, AKI is a severe disease characterized by a rapid loss in renal
function that leads to substantial morbidity and mortality (7). The treatment options for
AKI are currently limited to supportive measures and dialysis, indicating a tremendous
need for the identification of novel targets for the development of effective therapeutics
(69). Following renal I/R injury, persistent mitochondrial dysfunction and depletion of
mitochondrial proteins correlate with sustained renal tubular injury and renal dysfunction
(191). It has been further demonstrated that I/R injury is attenuated following the
generation of new, functional mitochondria through the stimulation of MB (192, 193,
199). However, few pharmacological agents are known to induce MB. To this end, our
laboratory has recently demonstrated that the 5-HT1F receptor agonist LY344864
stimulated MB in vitro in RPTC and in vivo in healthy mouse kidneys. Additionally,
LY344864 administration increased mtDNA copy number and improved renal function in
mice subjected to I/R-induced AKI.
To our knowledge, these are the first evidence linking the 5-HT1F receptor to
mitochondria. Therefore, the first goal of this study was to identify the early signal
transduction mechanisms by which LY344864 induces MB in primary RPTC. In order to
address this objective, we utilized pharmacological inhibitors of known cellular mediators
of MB. This aim focused on the eNOS/cGMP/PKG pathway, which has been implicated
as a mitochondrial biogenic pathway. We also explored ERK1/2 as a potential negative
regulator of LY344864-induced MB. Additionally, based on the classification of the 5HT1F receptor as a Gαi/o-coupled GPCR, We examined the role of the Gβγ heterodimer
signaling in LY344864-induced MB.
Another goal of this study was to determine the physiological role of the 5-HT1F receptor
in mitochondrial homeostasis and renal function. In order to address this aim, we
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established a breeding colony of 5-HT1F receptor wild-type (WT), heterozygous (HET)
and homozygous (KO) mice. We hypothesized that renal cortical mitochondrial
homeostasis is disrupted in the absence of the 5-HT1F receptor and that this disruption
impairs renal function. Additionally, mitochondrial homeostasis endpoints were explored
in cardiac left ventricle as stimulation of the 5-HT1F receptor has been shown to induce
cardiac MB and the heart is a well-documented contributor and target of I/R-induced
AKI. Since mitochondria are critical regulators of age-related pathologies, We also
focused on mitochondrial homeostasis with respect to age in the 5-HT1F receptor KO
mouse, with an expectation of worsened outcomes over time.
The final aim of this study was to examine the role of 5-HT1F receptor signaling on PGC1α, mitochondrial homeostasis and function in I/R-induced AKI and the recovery of renal
function thereafter. Based on considerable evidence demonstrating the renal protective
effects induced by 5-HT1F receptor stimulation I expected 5-HT1F receptor KO mice to
have worsened mitochondrial homeostasis and function and subsequently diminished
recovery of renal function following I/R-induced AKI compared to WT controls. We
hypothesized this aim would identify 5-HT1F receptor dependent MB as an essential
regulator of mitochondrial homeostasis and function for the proper recovery of renal
function in the setting of I/R-induced AKI.
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CHAPTER TWO:
Identification of Dual Mechanisms Mediating 5-hydroxytryptamine Receptor 1F
Induced MB
ABSTRACT
Our laboratory recently made the novel observation that 5-hydroxytryptamine 1F (5HT1F) receptor activation induces MB, the production of new, functional mitochondria, in
vitro and vivo. We sought to determine the mechanism linking the 5-HT1F receptor to MB
in renal proximal tubule cells. Using LY344864, a selective 5-HT1F receptor agonist, we
determined that the 5-HT1F receptor is coupled to Gαi/o and induces MB through Gβγ
dependent activation of Akt, endothelial nitric oxide (eNOS), cyclic guanosinemonophosphate (cGMP), protein kinase G (PKG) and peroxisome proliferator-activated
receptor gamma coactivator-1α (PGC-1α). We also report that the 5-HT1F receptor
signals through a second, Gβγ dependent pathway that is linked by Akt phosphorylation
of Raf. In contrast to the activated Akt pathway, Raf phosphorylation reduced ERK1/2
and FOXO3a phosphorylation, suppressing an inhibitory MB pathway. These results
demonstrate that the 5-HT1F receptor regulates MB through Gβγ dependent dual
mechanisms that activate a stimulatory MB pathway, Akt/eNOS/cGMP/PKG/PGC-1α,
while simultaneously repressing an inhibitory MB pathway, Raf/MEK/ERK/FOXO3a.
Novel mechanisms of MB provide the foundation for new chemicals that induce MB to
treat acute and chronic organ injuries.
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INTRODUCTION
In addition to its roles as a hormone and neurotransmitter in the central nervous system,
5-HT (serotonin, 5-hydroxytryptamine) mediates vascular contraction and relaxation,
gastrointestinal motility, apoptosis and platelet aggregation through peripheral receptors
(1-6). The biological roles of 5-HT are mediated by a family of G protein-coupled
receptors (GPCR).Recently, our group revealed a novel role for 5-HT receptors in MB
(MB), or generation of new, functional mitochondria (7-9).
MB is an attractive target for pharmacological intervention following acute organ injuries
such as ischemia reperfusion (IR) injury (10, 11). Rapid and persistent loss of
mitochondrial homeostasis is a major contributor to the pathology of IR-induced renal
injury and IR suppresses peroxisome proliferator-activated receptor gamma coactivator1α (PGC-1α), the master regulator of MB, and its downstream targets (10, 11).
Increasing PGC-1α promotes the transcription of genes necessary for mitochondrial
function during repair and restoration following oxidant injury in renal proximal tubule
cells (RPTC) and IR-induced acute kidney injury (AKI) (12-15).
Despite the promise of MB as a therapeutic target, few nontoxic pharmacological agents
stimulate PGC-1α expression and activity. Our laboratory developed a phenotypic assay
to measure MB and identified several pharmacological targets that activate PGC-1α and
induce MB, including the 5-HT1F receptor (7, 16). The selective 5-HT1F receptor agonist
LY344864 is a potent and efficacious inducer of MB in vitro and in vivo as demonstrated
by increased electron transport chain gene and protein levels (7). LY344864 exhibits
high affinity for the 5-HT1F receptor with a reported pKd of 8.2 and is ~100 times more
selective for the 5-HT1F receptor compared to 5- HT1A,

1B, 1D, 1E

(17). Additionally,

LY344864-induced 5-HT1F receptor activation in a mouse model of IR- AKI restored
mitochondrial DNA (mtDNA) copy number and accelerated recovery of renal function (7),
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providing evidence that the 5-HT1F receptor is a good therapeutic target to stimulate MB
and promote recovery from acute organ failure. While we have identified a novel role for
this receptor, however, the signaling mechanism of 5-HT1F receptor-induced MB remains
unknown. In this paper we identify the signaling pathways responsible for MB by 5-HT1F
receptor activation.

74

METHODS
Reagents
LY344864, pertussis toxin, gallein, LY294002, LNAME, ODQ, and KT5823 were
purchased from Tocris (Ellisville, MO). GDC0068 was purchased from Selleckcem.
(Houston, TX).
Isolation and Culture of Renal Proximal Tubule Cells and Oxygen Consumption
Female White New Zealand Rabbits (1.5-2.0 kg) were purchased from Charles River
Laboratories (Wilmington, MA). RPTC were isolated using the iron perfusion method
previously described (18). RPTC were plated and cultured in 96-well respiratory plates
or 35-mm dishes in media previously described (7). Experiments were performed on the
third or sixth day after plating when cells had formed a confluent monolayer. Oxygen
consumption rate (OCR) of RPTC was measured using the Seahorse Bioscience XF-96
Extracellular Flux Analyzer as previously described (16). Each 96-well assay plate was
treated with vehicle (DMSO, < 0.5%) or the experimental compounds. Basal OCR was
measured before injection of carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone
(FCCP, 0.5μM) to measure the uncoupled OCR (FCCP-OCR), a marker of MB (16). All
studies conducted were approved by the Institutional Animal Care and Use Committee
at the Medical University and University of Arizona.
Analysis of Mitochondrial DNA Content
Mitochondrial DNA content was determined by quantitative real-time PCR analysis.
Total DNA was isolated from RPTC using the DNeasy Blood and Tissue Kit (Qiagen,
Valencia, CA) as described in the manufacturer’s protocol. Extracted DNA was
quantified and 5 ng was used for PCR. Relative mitochondrial DNA content was
assessed by the mitochondrial encoded NADH Dehydrogenase 1 (ND1) and was
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normalized to nuclear- encoded β- Actin. Primer sequences for ND1 and β- Actin were:
5’-TAGAACGCAAAATCTTAGGG-

3’;

ND1

antisense:

5’-

TGCTAGTGTGAGTGATAGGG-3’; β-Actin sense: 5’- GGGATGTTTGCTCCAACCAA-3’;
and β-Actin antisense: 5’- GCGCTTTTGACTCAGGATTTAA-3’.
Protein Isolation, Immunoblot Analysis and Immunoprecipitation
Protein isolation and immunoblot analysis were performed as previously described (7).
For immunoprecipitation experiments, protein (500 μg) were pre- cleared by incubating
with Pierce Protein A/G Plus Agarose beads for 30 min, then centrifuged at 14, 000 x g
for 10 min at 4°C. The supernatant was collected and incubated with an anti-PGC-1α
antibody (3 μg) overnight at 4°C. Pierce Protein A/G Plus Agarose beads were washed
and incubated with PGC-1α-protein lysates for 2 hr at 4°C. Lysates were then washed in
immunoprecipitation buffer (25 mM Tris, 150 mM NaCl, pH 7.4) followed by
centrifugation at 2,000 x g for 1 min. Laemmli buffer and β-mercaptoethanol (1:50) was
added to collected supernatant and incubated at 95 °C for 5 min. Following a brief
centrifugation, the supernatant was collected and analyzed by immunoblotting using
antibodies against phosphoserine/threonine (1:1000) from Abcam (Cambridge, MA) and
PGC-1α (1:1000) from EMD Millipore (Billerica, MA). Primary antibodies p-AKT Ser473
(1:000), total AKT (1:1000), p-eNOS Ser1177 (1:500), p-VASP Ser239 (1:1000), total
VASP (1:1000), p-ERK p44/42 (1:1000), total ERK (1:1000), p-FOXO3a Ser294, and
total FOXO3a were purchased from Cell Signaling Technologies (Danvers, MA), total
eNOS (1:1000) was purchased from Abcam and GAPDH (1:10,000) from Fitzgerald
(Acton, MA). Secondary antibodies include horseradish peroxidase- labeled anti rabbit
and mouse from Abcam (Cambridge, MA).
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cAMP and cGMP Enzyme-Linked Immunosorbent Assay
RPTC in 35-mm dishes were treated with DMSO or LY for 1 hr. RPTC were then
harvested according to the manufacturer’s protocol and cAMP or cGMP levels were
measured using an ELISA kit (Cayman Chemical, Ann Arbor, MI). cAMP and cGMP
values (pmol) were normalized to protein (mg) as quantified by a bicinchoninic acid
assay followed by normalization to vehicle control for each biological replicate.
Statistical Analysis
Data are presented as the mean ± S.E.M. Single comparisons were performed using
the Student’s t test. Multiple comparisons were subjected to one-way analysis of
variance followed by the Tukey’s post hoc test, with p< 0.05 considered to be a
statistically significant difference between means. Different subscripts indicate
statistically differences. RPTC isolated from a single rabbit represented an individual
experiment (n =1) and were repeated until n =4-5 was obtained.
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RESULTS
5-HT1F receptor agonism decreases cAMP formation and induces FCCP-uncoupled
OCR and mtDNA Copy Number in a Gβγ-Akt-NOS-PKG dependent manner
Because the 5-HT1F receptor has been reported to be negatively coupled to adenylyl
cyclase via Gαi/o (19), we first sought to explore the roles of the Gαi/o and Gβγ in RPTC
(20). To verify that the renal 5-HT1F receptor is a Gαi-coupled GPCR, we measured
cAMP in LY treated RPTC in the presence and absence of pertussis toxin (PT). PT
catalyzes the ADP-ribosylation of the Gαi/o subunits locking the α subunits into an
inactive state and inhibiting adenylate cyclase activity, leading to increased cellular
cAMP (21). RPTC were pretreated with 100ng/ml PT or DMSO for 24 hr, followed by a
20 min exposure to 10 nM LY344864 or DMSO. A 10 nM concentration of LY344864
was previously determined to induce MB in RPTC (7). Treatment with PTX alone
increased cAMP levels (Fig.1A). LY344864 reduced cAMP formation by 70% and this
reduction was blocked by PT pretreatment (Fig. 2.1A), verifying that LY344864-induced
5-HT1F receptor signaling in RPTC is mediated by Gαi/o, PT-sensitive G proteins.
Our laboratory developed a high-throughput screening assay to assess MB by
measuring FCCP-induced uncoupled oxygen consumption rates (FCCP-OCR) in RPTC,
a marker of MB (16). Previous studies demonstrated that LY-induced FCCP-OCR
resulted from increased mtDNA number and electron transport chain proteins at 24 hr
(7). To understand the signaling pathways leading to increased FCCP-OCR, inhibitors of
Gβγ and other pathways were analyzed for their ability to block LY344864-induced
FCCP-OCR. RPTC were pretreated for 30 min with DMSO or gallein (Gal), GDC0068
(GDC), LNAME, ODQ, and KT5823 (KT), inhibitors of Gβγ, Akt, nitric oxide synthase
(NOS), soluble guanylyl cyclase and protein kinase G (PKG), respectively (22-25), and
then exposed to DMSO or LY344864 for 24 hr. Pretreatment with these inhibitors
prevented LY-induced FCCP-OCR (Fig. 2.1B). In addition, pretreatment with gallein,
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GDC, LNAME, ODQ and KT prevented LY344864-induced mtDNA copy number (Fig.
2.1C), suggesting that Gβγ, Akt, NOS, cGMP, and PKG are key regulators of 5-HT1F
receptor induced MB pathway.
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Figure 2.1: 5-HT1F receptor agonism decreases cAMP formation and induces
FCCP-uncoupled OCR and mtDNA Copy Number in a Gβγ-Akt-NOS-PKG
dependent manner. cAMP levels were measured by ELISA after a 20 min treatment
with <0.5% DMSO, 10 nM LY344864 or a 24 hr pretreatment of pertussis toxin
(100ng/mL) followed by DMSO or LY (A). RTPC were pretreated with DMSO or
pharmacological inhibitors, gallein (Gal,100 nM), GDC0068 (GDC,100 nM), LNAME (10
µM), ODQ (100 nM), or KT5823 (KT, 100 nM) for 30 min. DMSO or LY344864 were then
added and FCCP-OCR uncoupled mitochondrial respiration was measured using
Seahorse XF 96 analyzer 24 hr later (B). RTPC were pretreated with DMSO or
pharmacological inhibitors, Gal, GDC, LNAME, ODQ or KT for 30 min followed by 24 hr
exposure of DMSO or LY and mtDNA copy number was assessed (C). Data are
reported as mean ± SEM, n =4-5. Bar with different superscripts are significantly
different from one another (p < 0.05).
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LY344864 induced Akt and eNOS phosphorylation is blocked by inhibitors of Gβγ,
PI3K and Akt
To examine Akt phosphorylation following LY344864 treatment, RPTC were treated with
LY344864 or DMSO for 15 min, 30 min, 1, 2, and 3 hr. Immunoblot analyses revealed a
2-fold increase in p-Akt at Ser473 at 15 min and a 1.5-fold increase at 30 min (Fig. 2.2A,
B). RPTC were pretreated with gallein (100 nM, 30 min) and exposed to LY344864 for
15 min.

Immunoblot analyses revealed that gallein inhibited LY344864-induced Akt

phosphorylation (Fig. 2.2C, D). Because Akt is a substrate of PI3K, RPTC were
pretreated with the PI3K inhibitor LY294002 (10 μM, 30 min) and then treated with
LY344864. Blockade of PI3K inhibited Akt phosphorylation after treatment (Fig. 2.2E, F).
Next, we examined eNOS phosphorylation at Ser1177, a direct phosphorylation target of
Akt. RPTC were treated with DMSO or LY344864 for 1, 2, 3, and 4 hr. eNOS
phosphorylation was elevated 2.5- and 3-fold at 1 and 2 hr, respectively (Fig. 2.2G, H).
To confirm that Gβγ and Akt are upstream of eNOS phosphorylation, RPTC were
pretreated with gallein and GDC (100 nM, 30 min), then exposed to LY344864 for 1 hr
(Fig. 2.2I, L). Inhibiting Gβγ and Akt also prevented LY344864-induced eNOS
phosphorylation. These data demonstrate that LY344864 activates the Gβγ-PI3K-AkteNOS pathway.
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Figure 2.2: LY344864 induced Akt and eNOS phosphorylation is blocked by
inhibitors of Gβγ, PI3K and Akt. Phosphorylated Akt (Ser473) was measured by
immunoblot analysis 15 min, 30 min, 1 hr, or 3 hr after treatment with DMSO or
LY344864 (A, B), after 30 min pretreatment with DMSO or gallein (Gal, 100 nM) followed
by exposure to DMSO or LY344864 for 15 min (C, D), and after 30 min pretreatment
with DMSO or LY29004 (LY29, 10 µM) followed by exposure to DMSO or LY344864 for
15 min (E, F). Phosphorylated eNOS (Ser1177) was measured by immunoblot analysis
after 1, 2, 3, or 4 hr treatment with DMSO or LY344864 (G, H), after 30 min treatment
with DMSO or Gal (100 nM) followed by exposure to DMSO or LY for 1 hr (I, J), and
after 30 min pretreatment with DMSO or GDC0068 (GDC, 100nM) followed by exposure
to DMSO or LY344864 for 1 hr (K, L). Data are reported as mean ± SEM, n≥5. Bars with
different superscripts are significantly different from one another (p < 0.05).
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LY344864 increases cGMP formation and cGMP- and PKG-dependent VASP
phosphorylation
Numerous reports demonstrate that increased PGC-1α expression and other markers of
MB in tissues, including the kidney, are elevated through an increase in cGMP
production (26-28). To determine if cGMP is involved in LY344864-induced MB, we
measured cGMP following LY344864 treatment. RPTC were treated with the
phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX, 100 μM), and DMSO or
LY344864. LY344864 elicited a transient 1.6-fold increase in cGMP at 1 hr that returned
to baseline levels at 2 hr (Fig. 2.3A). The formation of cGMP induces a conformational
change in cGMP-dependent protein kinase (PKG) allowing activation of this
serine/threonine protein kinase and the phosphorylation of substrate proteins (29).
Vasodilator-stimulated phosphoprotein (VASP), a marker of PKG activation, was
assessed to determine the role of PKG in LY344864-induced MB signaling (30). RPTC
expressed the PKG splice variant PKGI which preferentially phosphorylates VASP at
Ser239 (31). LY344864 increased VASP phosphorylation 1.8- and 2-fold at 1and 2 hr,
respectively (Fig. 2.3B, C). To determine if cGMP production and PKG activation are
responsible for increased VASP phosphorylation, RPTC were pretreated with ODQ (100
nM, 30 min) or KT (100 nM, 30 min) and then exposed to LY344864 for 1 hr. LY344864induced p-VASP upregulation was inhibited by blockade of cGMP production (ODQ) and
PKG activation (KT) (Fig. 2.3D, G). Taken together these findings reveal agonist
stimulation of the 5-HT1F receptor mediates Gβγ-PI3K-AKT-eNOS-cGMP-PKG-VASP
signaling.
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Figure 2.3: LY344864 increases cGMP formation and cGMP- and PKG- dependent
VASP phosphorylation. cGMP levels were measured by ELISA after 1 hr treatment
with DMSO or LY344864 in the presence of 3-isobutyl-1-methylxanthine (IBMX, 100 µM,
A). Phosphorylated VASP (Ser239) was measured by immunoblot analysis 1 or 2 hr
after treatment with DMSO or LY344864 (B, C), after 30 min treatment with DMSO or
ODQ (100 nM) followed by exposure to DMSO or LY344864 for 1 hr (D, E), and after 30
min treatment with DMSO or KT5923 (KT, 100 nM) followed by exposure to DMSO or
LY344864 for 1 hr (F, G). Data are reported as mean ± SEM, n ≥ 5. Bars with different
superscripts are significantly different from one another (p < 0.05).
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LY344864 increases phosphorylated serine/threonine residues on PGC-1α
PGC-1α

is

regulated

by

numerous

posttranslational

modifications

such

as

phosphorylation, methylation, and acetylation (10, 32-34). Since we elucidated a number
of activated kinases in the 5-HT1F receptor signaling pathway, we examined the
phosphorylation of PGC-1α in RPTC exposed to LY344864 or DMSO for 2 hr. PGC-1α
was immunoprecipitated from RPTC and subjected to immunoblot analysis with
antibodies against phosphoserine/threonine residues and PGC-1α. The ratio of
phosphorylated serine/threonine to total PGC-1α was elevated 2.8-fold and this increase
was attenuated following Akt and PKG inhibition (Fig. 2.4A, B), suggesting
posttranslational activation during 5-HT1F receptor signaling in RPTC is dependent upon
Akt and PKG activity.
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Figure 3.4: LY344864 increases phosphorylated serine/threonine residues on
PGC-1α. Phosphorylated serine/threonine residues were measured following
immunoprecipitation of PGC-1α by immunoblot analysis after 30 min treatment with
DMSO, KT (100nM) or GDC (100nM) followed by exposure to DMSO or LY344864 for 2
hr treatment (A, B). Total PGC-1α expression was measured to verify presence of PGC1α protein following immunoprecipitation and equal protein input. Twenty percent of total
protein lysate was used to verify immunoprecipitation of PGC-1α was successful. Data
are reported as mean ± SEM, n=5. Bars with different superscripts are significantly
different from one another (p < 0.05).
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LY344864 reduces ERK phosphorylation and inhibitors of Gβγ and Akt prevent the
reduction in ERK phosphorylation
ERK1/2 signaling has been implicated as a negative regulator of MB (35). We analyzed
the phosphorylation of ERK1/2 in RPTC at 1, 2, and 3 hr after LY treatment. ERK1/2
phosphorylation decreased 50% at 1 hr (Fig. 2.5A, B). We hypothesized that this
reduction was also mediated by Gβγ signaling. RPTC were pretreated with DMSO and
gallein (100 nM, 30 min), followed by 1 hr exposure of DMSO or LY344864. Blockade of
Gβγ prevented LY344864-mediated decrease in ERK1/2 phosphorylation elevating
ERK1/2 phosphorylation above vehicle levels (Fig. 2.5C, D).
To investigate cross-talk between LY344864-mediated Akt and ERK signaling, RPTC
were pretreated with GDC (100nM, 30 min) and then DMSO or LY. Akt inhibition
prevented decreased LY344864-mediated ERK1/2 phosphorylation and increased
ERK1/2 phosphorylation compared to vehicle (Fig. 2.5E, F). RPTC were also pretreated
with LNAME (10 µM, 30 min), prior to 1 hr treatment with LY344864 to determine if NOS
is involved in modulating p-ERK1/2. ERK1/2 phosphorylation was unchanged compared
to LY344864-treated RPTC, indicating that NOS was not responsible for reduced
ERK1/2 phosphorylation (Fig. 2.5G, H). It is important to note that gallein and GDC
alone increased ERK1/2 phosphorylation by 2.5- and 2-fold in RPTC, respectively,
suggesting that inhibition of Gβγ-AKT modulates ERK1/2 under physiological conditions,
strengthening the premise that the AKT and ERK1/2 pathways collaborate to maintain
cellular processes in RPTC. Collectively, these data reveal that Gβγ and Akt activation is
upstream of the suppression of ERK1/2 phosphorylation following LY344864 treatment
in RPTC.
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Figure 2.5: LY344864 reduces ERK phosphorylation and inhibitors of Gβγ and Akt
prevent the reduction in ERK phosphorylation. Phosphorylated ERK (p44/42) was
measured by immunoblot analysis 1, 2, or 3 hr after treatment with DMSO or LY344864
(A, B), after 1 hr treatment with DMSO or gallein (Gal,100 nM) followed by exposure to
DMSO or LY344864 for 1 hr (C, D), after 1 hr treatment with DMSO or GDC0068
(GDC,100 nM) followed by exposure to DMSO or LY344864 for 1 hr (E, F), and after 1
hr pretreatment with DMSO or LNAME (10 µM) followed by exposure to DMSO or
LY344864 for 1 hr (G, H). Data are reported as mean ± SEM, n ≥ 5. Bars with different
superscripts are significantly different from one another (p < 0.05).
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LY344864 induced c-raf phosphorylation at site Ser259 and is Akt-dependent
c-Raf is known to regulate the activity of the ERK1/2 signaling cascade. Typically, c-raf
phosphorylation of Ser338 activates the MEK-ERK1/2 pathway, while phosphorylation of
site Ser259 is inhibitory (36, 37). c-Raf Ser259 is a target of active Akt and there is
evidence that Raf-MEK-ERK and PI3K-Akt pathways cross-talk at the level of raf and Akt
(37, 38). We detected phosphorylation of both Ser259 and Ser338 in DMSO and
LY344864-treated RPTC for 15 and 30 min. Ser259 phosphorylation was elevated 1.5fold at 30 min in the presence of LY344864, while Ser338 phosphorylation remained at
control levels (Fig. 2.6A-C). Additionally, GDC (100 nM, 30 min) pretreatment, followed
by 30 min LY344864 exposure inhibited Ser259 phosphorylation (Fig. 2.6D, E). In
summary, LY344864 exposure resulted in Akt-dependent c-raf inhibition, further
evidence that ERK1/2 inhibition is regulated by Akt.
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Figure 2.6: LY344864 induced c-raf phosphorylation at site Ser259 and is Aktdependent. Phosphorylated c-raf was measured by immunoblot analysis 15 or 30 min
after treatment with DMSO or LY344864 (A). Densitometry analysis of Ser259 (B) and
Ser338 (C) phosphorylation. Phosphorylated c-raf (Ser259) was measured by
immunoblot analysis after 30 min treatment with DMSO or GDC0068 (GDC,100 nM)
followed by exposure to DMSO or LY for 15 min (D, E). Data are reported as mean ±
SEM, n ≥ 5. Bars with different superscripts are significantly different from one another
(p < 0.05).
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LY344864 reduces FOXO3a phosphorylation
We recently reported that ERK1/2 inhibition reduces phosphorylation of FOXO3a,
allowing for increased nuclear FOXO3a to activate transcription of genes including PGC1α (35). We observed that FOXO3a phosphorylation at Ser294 was reduced 40% by
LY344864 at 2 hr (Fig. 2.7), suggesting that suppressed ERK1/2 phosphorylation up
regulates PGC-1α through FOXO3a.
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Figure 2.7: LY344864 reduces FOXO3a phosphorylation. Phosphorylated FOXO3a
(Ser294) was measured by immunoblot analysis 1 or 2 hr after treatment with DMSO or
LY344864. Data are reported as mean ± SEM, n ≥ 5.Bars with different superscripts are
significantly different from one another (p < 0.05).
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DISCUSSION
Classically, the 5-HT1F receptor has been characterized as a mediator of pain without
vasoconstriction, which led to the development of 5HT1F agonists such as LY344864 for
the treatment of migraines. However, the biological roles of peripherally expressed 5HT1F receptors have been understudied. We recently observed that LY344864 induces
MB and accelerates recovery of renal function following IR-AKI in mice (7). The goal of
this study was to elucidate the signaling mechanism connecting the 5-HT1F receptor to
MB. Utilizing a high-throughput MB screening assay and immunoblot analyses, we
determined that Gβγ, Akt, NOS, cGMP, and PKG are crucial components in MB
following 5-HT1F receptor stimulation. In addition, a second, parallel pathway was
identified that negatively regulates PGC-1α and MB through ERK and FOXO3a
phosphorylation. This is the first study to report that Gβγ initiates MB through dual
mechanisms,

increasing

Akt/eNOS/cGMP/PKG/PGC-1α

Raf/MEK/ERK/FOXO3a pathways (Fig.2.8).
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and

decreasing

Figure 2.8: Proposed 5-HT1F receptor mediated MB pathway proceeds through
dual mechanisms dependent upon Gβγ in RPTC. Gβγ initiates Akt phosphorylation
and the subsequent phosphorylation of eNOS, both in a PI3K dependent manner.
LY344864 increases cGMP production, induces PKG activation and PGC-1α
phosphorylation in RPTC. Simultaneously, Raf phosphorylation reduces ERK1/2 and
FOXO3a phosphorylation, also a Gβγ dependent process. Reduced FOXO3a
phosphorylation promotes nuclear translocation of FOXO3a for transcription of genes
such as PGC-1α. Orange phosphorylation sites indicates activation of downstream
effectors. Red phosphorylation sites indicate reduction of downstream effectors. PI3K:
phosphoinositide-3-kinase, Akt: protein kinase B, eNOS: endothelial nitric oxide
synthase, cGMP: cyclic guanosine monophosphate, PKG: protein kinase G, PGC-1α:
peroxisome proliferator- activated receptor gamma coactivaor-1α, Raf: rapidly
accelerated fibrosarcoma, ERK: extracellular signal- regulated kinase, FOXO3a:
forkhead box O3, MB: MB
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Following ligand binding to the Gαi-coupled GPCR, the Gαi and Gβγ disassociate and
activate downstream signaling. Gβγ has been shown to activate a variety of signal
transduction pathways (39-42). Through the use of gallein, we demonstrated that Gβγ
activates the PI3K-Akt pathway in RPTC following 5-HT1F receptor stimulation. By
recruiting the PI3K regulatory subunits p101 to the membrane, Gβγ is reported to be a
direct activator of GPCR-induced PI3K activity. Gβγ has also been previously linked to
Akt phosphorylation through PI3K stimulation (43).
This study not only elucidated the signaling mechanism of 5-HT1F receptor-induced MB
in RPTC, but also the duration of this signaling, which is crucial in the roles of Akt and
NO. Specifically, chronic activation of Akt and NO has been linked to defective
mitochondrial function and mitophagy (44-46). We demonstrate that Akt and eNOS are
sequentially and transiently activated to produce MB as opposed to the oxidative stress
that can occur due to prolonged NO production (47). NO is a key molecule in PGC-1α
regulation predominantly through induction of soluble guanylate cyclase and cGMP (15).
Downstream effectors of cGMP, such as PKG have also been linked to PGC-1α
expression and activity (48, 49). Though the role of PKG in 5-HT1F receptor induced MB
remains unclear, we demonstrated that PKG is upstream of LY- induced PGC-1α
phosphorylation. Further studies will elucidate the direct link between PKG and PGC-1α
phosphorylation. One possibility is that the PKG substrate, p38 MAPK, is directly
phosphorylating PGC-1α and increasing its activity. Several studies have reported p38
MAPK to phosphorylate and activate PGC-1α, specifically by disrupting the interaction
between PGC-1α and the co-repressor p160MBP as observed in myoblasts (32, 49, 50).
PGC-1α is also a substrate for a number of other kinases that regulates its activity. AMPactivated protein kinase (AMPK) phosphorylates and activates PGC-1α as well as
increases its transcription (51), however, we did not observe any changes in AMPK
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phosphorylation following acute or chronic 5-HT1F receptor stimulation (data not shown).
Furthermore, Akt substrates such as GSK3β and mTOR regulate PGC-1α activity (5153), but the phosphorylation of these substrates were unchanged directly following Akt
activation

(data

not

shown).

Collectively,

these

findings

implicate

the

Akt/eNOS/cGMP/PKG signaling axis as a critical mechanism for LY- induced MB.
Interestingly, parallel to the activated Akt/eNOS/cGMP/PKG pathway, we observed
decreased ERK/FOXO3a signaling. Collier et al. recently demonstrated that reduced
FOXO3a phosphorylation leads to increased nuclear FOXO3a expression that ultimately
increased PGC-1α (35). We determined that both Gβγ and Akt mediate LY344864
reduction of p-ERK1/2 and p-FOXO3a. Inhibition of Gβγ and Akt resulted in increased
ERK1/2 phosphorylation, while activation of Gβγ and Akt following LY344864 treatment
reduced ERK1/2 phosphorylation. These exciting results support the hypothesis that
there is cross-talk between Raf/MEK/ERK and PI3K/Akt pathways in MB. Cross-talk
between Raf/MEK/ERK and PI3K/Akt pathways has been reported in numerous cell
types including renal cells (37, 54-56). Consistent with other findings, we determined the
inhibitory 14-3-3 binding site on c-raf (Serine259) is directly phosphorylated by Akt,
leading to reduced ERK1/2 signaling in RPTC treated with LY344864 (37).
Our group and others have demonstrated persistent disruption of mitochondrial
homeostasis and inhibition of MB in myocardial infarction, spinal cord injury, stroke,
drug- induced toxicities, and AKI (57-61). Restoration of mitochondrial number and
function are necessary for normal cell and tissue function, and is critical in ATPdependent repair processes for the recovery of organ function. Despite strong evidence
supporting mitochondria as a therapeutic target, there are very few drugs available to
promote mitochondrial function or MB. Many of these available agents lack specificity,
potency, or have toxic effects.
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Our laboratory has identified potent inducers of MB that act on different targets. For
example, the 5-HT2A receptor agonist, NBOH-2C-CN and the β2-adrenergic receptor
agonist formoterol, are potent inducers of PGC-1α and MB in vitro and in vivo (8, 9, 14).
Additionally, specific inhibition of phosphodiesterases 3 and 5 increased cGMP to induce
MB and accelerate the recovery of renal function following AKI (28). These studies
provide evidence that induction of MB to stimulate repair and recovery of organ
dysfunction is an effective approach to treat a variety of acute and chronic disease.
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CHAPTER THREE:
The 5-hydroxytryptamine Receptor 1F Regulates Mitochondrial Homeostasis in
Kidney and Heart

ABSTRACT
Our laboratory previously reported that agonists of the 5-hydoxytryptamine 1F (5-HT1F)
receptor induces renal and cardiac MB (MB). In addition, we reported that stimulation of
the 5-HT1F receptor following ischemia/reperfusion (I/R)-induced acute kidney injury
(AKI) accelerated the recovery of renal function in mice. The goal of this study was to
examine the contribution of the 5-HT1F receptor in the regulation of renal and cardiac
mitochondrial homeostasis and renal function in naïve and injured mice. While 5-HT1F
receptor knockout (KO) mice were healthy and fertile and did not exhibit renal
dysfunction, renal MB and mitochondrial fission gene expression increased and heart
MB and mitochondrial fission gene expression decreased at 10 weeks of age. Finally, 5HT1F receptor KO mice exhibited greater proximal tubular injury and diminished renal
recovery after I/R-induced AKI compared to wild-type mice. These findings were also
associated with the persistent suppression of renal cortical MB, and elevated oxidative
stress markers. In summary, the 5-HT1F receptor is a component of physiological MB
regulation in renal and cardiac tissues, its absence potentiates renal injury and recovery,
and it remains a promising target of MB and renal injury.
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INTRODUCTION
Mitochondrial dysfunction is a hallmark pathophysiological mediator of many acute and
chronic diseases. As such, loss of ATP-dependent cellular functions and increased
reactive oxygen species propagate injury and subsequent tissue and organ dysfunction
(1, 2). Specifically, our laboratory demonstrated that persistent mitochondrial dysfunction
and suppression of MB corresponds to worsened renal function after I/R-induced AKI
and folic acid-induced AKI (3-5).
MB has received increasing attention as a therapeutic target to promote restoration of
normal cellular and organ function, and several studies have reported pharmacological
induction of MB as a treatment for acute organ injury and cardiovascular disease (6-9).
MB is defined as the dynamic process of generating new, functional mitochondria and is
a highly regulated process controlled by the central mediator and transcriptional coactivator peroxisome proliferator-activated receptor α coactivator-1α (PGC-1α) (10).
Several groups have developed strategies designed to increase the expression and
activity of PGC-1α for the subsequent induction of MB, as evidenced by increased
mitochondrial number and function (2, 11, 12). For example, we reported that a 5hydroxytryptamine 1F (5-HT1F) receptor agonist LY344864 induced MB in vitro and in
vivo, restored MB, and accelerated the recovery of renal function following I/R-induced
AKI in mice. (5). Furthermore, knockdown of the 5-HT1F receptor in renal proximal
tubular cells resulted in decreased mitochondrial proteins, suggesting that the 5-HT1F
receptor may be regulating MB under basal conditions. In addition to the renal MB
findings, 5-HT1F receptor stimulation also induced cardiac gene expression of nuclear
and mitochondrial encoded electron transport chain (ETC) proteins and mitochondrial
DNA (mtDNA) content in mice (5). These findings implicate the 5-HT1F receptor as a
potential regulator of MB in kidney and heart.
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Based on these findings, we utilized a recently developed 5-HT1F receptor knockout (KO)
mouse to further understand the contribution of the 5-HT1F receptor in the regulation of
renal and cardiac mitochondrial homeostasis in young and aged mice. In addition, we
tested the hypothesis that the absence of the 5-HT1F receptor potentiates AKI in mice.
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METHODS
I/R-induced AKI Model
Male and female 5-HT1F receptor KO mice (B6N(Cg)-Htr1ftm1.1(KOMP)Vlcg/J, stock
no. 024269) were age-matched wild-type female and male C57BL/6NJ (WT, stock no.
005304) purchased from the Jackson Laboratory (Bar Harbor, ME). A 5-HT1F receptor
KO breeding colony was generated from heterozygous mutants and were housed in
temperature-controlled conditions under a light/dark photocycle with unrestricted food
and water supplied ad libitum. Male and female mice were weighed periodically. Ten and
26 week old mice were chosen to evaluate age-related changes in 5-HT1F receptor KO
mice.
Ten-week old male WT and KO mice underwent I/R surgery using bilateral renal pedicle
clamping for 18 min as described previously (13). Briefly, the renal artery and vein were
isolated and blood flow was occluded with a vascular clamp for 18 min while body
temperature was maintained at 36-37oC. Sham mice were treated the same as I/R mice
without clamping of the renal pedicles. Mice were euthanized 24 hr after surgery, and
blood and kidneys (flash frozen in liquid nitrogen) were collected for analysis. Studies
were carried out in strict accordance with the recommendations in the Guide for the Care
and Use of Laboratory Animals of the National Institutes of Health. All protocols were
approved by the Institutional Animal Care and Use Committee at the Medical University
of South Carolina and the University of Arizona, and all efforts were made to minimize
animal suffering.
Agarose Gel Electrophoresis
Genomic DNA was isolated from mice tail clippings using Viagen Direct PCR DNA Lysis
Reagent (Los Angeles, CA) containing 0.4 mg/ml Proteinase K. PCR amplification was
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performed using Promega PCR Master Mix (Madison, WI). PCR products were
separated on a 2% agarose gel in 1x TBE (89 mM Tris, 89 mM boric acid, 2 mM EDTA)
and 0.5 µg/mL ethidium bromide. Gels were visualized using the GE ImageQuant
LAS4000 (GE Life Sciences, Pittsburgh, PA). Primer pairs annealing with the WT allele
and the mutant allele were obtained from Jackson Laboratory and are listed in Table 3.1.
Complete Blood Count, Blood Urea Nitrogen (BUN) and Serum Creatinine
Evaluation
Following euthanasia by isoflurane inhalation, peripheral blood was collected via cardiac
puncture using EDTA as an anticoagulant and complete blood counts (CBC) were
obtained using a HEMAVET Multispecies Hematology Analyzer. Blood was collected via
retro-orbital bleed following isoflurane inhalation. BUN was determined using the
QuantiChrom Urea Assay kit (BioAssay Systems, Hayward, CA) and serum creatinine
was determined using the Creatinine Enzymatic Reagent Kit (Pointe Scientific, Canton,
MI) based on the manufacturer’s directions.
Protein Isolation and Immunoblot Analysis
Mouse kidney cortex and left ventricular cardiac tissue was homogenized in protein lysis
buffer (1% Triton X 100, 150 mM NaCl, 10 mM Tris-HCl, pH 7.4; 1 mM EDTA; 1 mM
EGTA; 2 mM sodium orthovanadate; 0.2 mM phenylmethylsulfonylfluoride; 1 mM
HEPES pH 7.6; 1 µg/ml leupeptin; and 1 µg/ml aprotinin) using a polytron homogenizer.
The homogenate was stored on ice for 10 min and then centrifuged at 7,500 g for 5 min
at 4°C. The supernatant was collected and protein determined using a bicinchoninic acid
kit (Sigma Chemical Co, St. Louis, MO) with bovine serum albumin as the standard.
Proteins (50 µg) were separated on 4–20% gradient sodium dodecyl sulfate
polyacrylamide gels and transferred to nitrocellulose membranes. Membranes were
blocked in 5% dried milk in TBST (0.1% Tween 20 in 1× TBS) for 1 hr and incubated
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with antibodies for kidney injury molecule-1 (KIM-1) (1:1000; R&D systems, Minneapolis,
MN), neutrophil gelatinase-associated lipocalin (NGAL), PGC-1α, TFAM, COX1,
NDUFS1, 4-HNE and SOD2 (1:1000, Abcam, Cambridge, MA), overnight at 4°C. After
incubation for 2 h at room temperature with donkey anti-goat secondary antibody
(1∶2000; Santa Cruz, Dallas, TX),goat anti-rabbit (1: 20000; Abcam) or rabbit anti-mouse
(1:20000, Abcam) conjugated with horseradish peroxidase before visualization using
enhanced chemiluminescence (Thermo Scientific, Waltham, MA) and the GE
ImageQuant LAS4000 (GE Life Sciences, Pittsburgh, PA).Optical density was
determined using the National Institutes of Health ImageJ software (version 1.46).Each
target protein was normalized to β-Actin loading control.
Quantitative Real-Time Polymerase Chain Reaction Analysis of mRNA Expression
Total RNA was isolated from renal cortical and left ventricle cardiac tissue with TRIzol
reagent (Life Technologies, Grand Island, NY). The iScript Advanced cDNA Synthesis
Kit for quantitative real-time polymerase chain reaction qRT-PCR (Bio-Rad Laboratories,
Hercules, CA) was used to produce a cDNA library from 1 μg total RNA according to the
manufacturer’s protocol. For human experiments, we obtained human renal cDNA from
Takara Bio USA, Mountain View, CA. Human cardiac samples were obtained from
BioChain Institute, Inc. We performed qRT-PCR with the generated cDNA using the
SsoAdvanced Universal SYBR Green Supermix reagent (Bio-Rad Laboratories). The
relative mRNA expression of all genes was determined by the 2−ΔΔCt method, and β-actin
was used as a reference gene for normalization. Primer pairs used for PCR are listed in
Table 3.1.
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Analysis of Mitochondrial DNA Content
Total DNA was isolated from the renal cortex and left ventricle cardiac tissue using the
DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA) as described by manufacturer’s
protocol. Extracted DNA was quantified and 5 ng was used for qRT-PCR. Relative DNA
content was assessed by the mitochondrial-encoded NADH dehydrogenase subunit 1
(ND1) and was normalized to nuclear-encoded β-actin. Primer sequences are listed in
Table 3.1.
Determination of ATP Content
Renal cortical ATP was measured using the ATP Assay Kit (Abcam). Briefly, mouse
renal cortex was homogenized in ice-cold 2M perchloric acid using a polytron
homogenizer. Homogenate was stored on ice for 45 min and then centrifuged at 13,000
x g for 2 min at 4°C. The supernatant was collected and diluted in the ATP Assay buffer.
For each sample, pH was measured and adjusted to equal 6.5-8 using 0.1M KOH or
PCA. Samples were then centrifuged at 13,000 x g for 15 min at 4°C and supernatant
was collected. ATP was measured using the Tecan Spark 10M plate reader. ATP
concentration (nmol/uL) was normalized to protein.
Histology
Kidney sections approximately 5 microns from WT and 5-HT1F receptor mice 24 and 144
hr subjected to sham or I/R surgery were stained with Periodic Acid Schiff staining. Each
section was scored based on morphologic changes in a blinded fashion by a renal
pathologist (J.M.). The following measures were chosen as an indication of morphologic
damage to the kidney: proximal tubule dilation, brush-border damage, proteinaceous
casts, interstitial widening and necrosis. These measures were evaluated on a scale
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from 0 to 4, which ranged from not present (0), mild (1), moderate (2), severe (3) and
very severe (4).
Statistical Analysis
Data are expressed as means ± SEM for all the experiments. Multiple comparisons of
normally distributed data were analyzed using one-way analysis of variance (ANOVA)
with an appropriate post-hoc test, group means were compared using Holm-Sidak’s
post-test. Single comparisons were analyzed by Student’s t-test where appropriate. The
criterion for statistical differences was p≤0.05 for all comparisons.
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Table 3.1: Primer sequences used for RT-qPCR.
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RESULTS
Renal and cardiac 5-HT1F receptor gene absence in 5-HT1F receptor knockout mice

Genomic DNA was isolated from the tails of pups derived from a cross of two
heterozygous mice followed by agarose gel electrophoresis to verify loss of the
5-HT1F receptor gene. WT mice only expressed the wild type 5-HT1F receptor
PCR product (163 bp), KO mice only expressed mutant PCR product specific to
the sequence targeted to disrupt the 5-HT1F receptor gene (509 bp), and HET
mice expressed both the wild type and mutant PCR product (Fig. 3.1A). In
addition, HET x HET matings yielded Mendelian ratios of 1:2:1 of WT, HET, and
KO. KO x KO matings also yielded viable mice. To verify that the presence of
the mutant gene caused a decrease in the 5-HT1F receptor, we measured 5-HT1F
receptor mRNA. Renal and cardiac 5-HT1F mRNA was decreased 50% in HET
mice and absent in KO mice (Fig. 3.1B, C). These findings confirm the successful
breeding of 5-HT1F receptor KO mice.
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Figure 3.1: Renal and cardiac 5-HT1F receptor gene absent in 5-HT1F receptor
knockout mice. Genotyping of 5-HT1F receptor using PCR and subjected to 2.5%
agarose gel electrophoresis. Wild-type 5-HT1F receptor PCR product is 163 bp and
mutated 5-HT1F receptor PCR product is 509 bp. 100bp DNA ladder is shown in the far
left lane. Mice expressing only the wild- type 5-HT1F receptor PCR product is WT, mice
expression only the mutated 5-HT1F receptor PCR product is KO, and mice expressing
both the wild- type and mutated 5-HT1F receptor PCR product is HET (A). Expression of
renal 5-HT1F receptor was measured at the mRNA level in WT, HET, and KO mice (B).
Expression of cardiac 5-HT1F receptor was measured at the mRNA level in WT, HET,
and KO mice (C). Data are reported as mean ± SEM, n = 6. *p<0.05 versus WT controls
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The lack of 5-HT1F receptor does not affect body weight, blood counts or serum
chemistries
We compared WT to KO mice with respect to weight gain, serum chemistry and
complete blood count at 10 weeks of age. Male and female WT and KO mice were
weighed weekly for 3-10 weeks. There were no differences in weight gain with age
between WT and KO mice (male or female) (Fig. 3.2A). There were also no differences
in white blood cells, red blood cells or in any serum chemistries between WT and KO
mice (Fig. 3.2B). Thus, the loss of the 5-HT1F receptor did not alter body weight,
electrolyte, metabolic, or blood cell composition at early ages.
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Figure 3.2: The lack of 5-HT1F receptor does not affect body weight, blood counts
or serum chemistries. Body weight of 5-HT1F receptor WT and KO male and female
mice from 3 to 10 weeks of age (A). Complete blood count and serum chemistries of 5HT1F WT and KO mice at 10 weeks of age (B).Data are reported as mean ± SEM, n = 56.
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The lack of the 5-HT1F receptor does not induce renal injury
We evaluated BUN in WT and KO mice. There was no difference in BUN levels at 10 or
26 weeks of age (10 week WT: 26 ± 3 mg/dL, 10 week KO: 25 ± 2 mg/dL; 26 week WT:
21 ± 1 mg/dL, 26 week KO: 30 ± 1 mg/dL). To further assess if the absence of the 5HT1F receptor induced renal tubular injury, kidney injury molecule-1 (KIM-1) and
neutrophil gelatinase-associated lipocalin (NGAL) were evaluated in the renal cortex of
WT and KO mice. At 10 and 26 weeks, KIM-1 was not detected and NGAL was
unchanged in KO mice compared to WT mice (Fig. 3.3A, B). Taken together, these data
suggest that the KO of the 5-HT1F receptor alone does not cause renal injury at ages up
to 26 weeks.
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Figure 3.3: The lack of the 5-HT1F receptor does not induce renal injury.
Immunoblot analysis of renal cortical KIM-1 and NGAL expression was used to assess
tubular injury in 10 week (A) and 26 week (B) old male 5-HT1F receptor WT and KO
mice.
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Altered renal mitochondrial homeostasis in young and aged 5-HT1F KO mice
Our laboratory demonstrated that stimulation of the 5-HT1F receptor results in increased
MB as measured by increased expression of mitochondrial proteins and mtDNA copy
number (5). Furthermore, knockdown of the 5-HT1F receptor in renal proximal tubular
cells resulted in a decrease in mitochondrial proteins (5). Thus, we hypothesized that the
absence of the 5-HT1F receptor would lead to a reduction in mitochondrial markers in the
renal cortex. We assessed mRNA expression of MB proteins and components of the
ETC, including PGC-1α, nuclear respiratory factor-1 (Nrf-1), nuclear respiratory factor-2
(Nrf-2), mitochondrial transcription factor A (TFAM), and nuclear-encoded NADH
dehydrogenase (ubiquinone) FE-S protein 1 (NDUFS1), ATP synthase β (ATPSβ), and
mitochondrial-encoded

cytochrome

c

oxidase

subunit

1

(COX1)

and

NADH

dehydrogenase 1 (ND1). Transcript levels of Nrf-2, TFAM, NDUFS1, ATPSβ, and COX1
were increased (1.4-,1.4-, 1.7-, 1.3-, and 1.6-fold, respectively) at 10 weeks and these
increases corresponded with elevated mtDNA copy number (Fig. 3.4A). At 26 weeks,
mRNA expression of PGC-1α and COX1 were elevated 1.5- and 1.8-fold, respectively,
compared to WT levels and these changes were also accompanied by a 1.7-fold
increase in mtDNA copy number, whereas NDUFS1, ATPSβ, and ND1 transcript levels
returned to WT levels (Fig. 3.4C). These results reveal the loss of the 5-HT1F receptor
leads to increased MB genes in the kidney.
Mitochondrial fission and mitophagy are critical processes in maintaining mitochondrial
homeostasis.(14, 15) As such, we measured markers of mitochondrial fission, dynaminrelated protein 1 (Drp1) and mitophagy, mitochondrial PTEN-induced putative kinase 1
(PINK1). At 10 weeks, Drp1 and PINK1 were elevated 1.7- and 1.6-fold, respectively
(Fig. 3.4B). In contrast, at 26 weeks, PINK1 was decreased 40%, yet Drp1 was
maintained at a 1.6-fold increase compared to WT mice (Fig. 3.4D). These results reveal
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that mitochondrial fission and mitophagy may be increased in response to the loss of the
5-HT1F receptor.
Finally, we assessed superoxide dismutase 2 (SOD2) and uncoupled protein 2 (UCP2),
markers of oxidative stress and mitochondrial uncoupling (16, 17). UCP2 mRNA, but not
SOD2 was elevated 1.4-fold at 10 weeks; however, both UCP2 and SOD2 transcript
levels were unchanged compared to WT mice at 26 weeks (Fig. 3.4B,D). These findings
reveal that renal UCP2 is transiently altered in 5-HT1F receptor KO mice.
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Figure 3.4: Altered renal mitochondrial homeostasis in young and aged 5- HT1F KO
mice. Total RNA was harvested from renal cortical tissue of 5-HT1F receptor WT and
KO mice. Gene expression of key regulators of MB, fission, oxidative stress were
measured on the mRNA level at 10 weeks ( A, C) and 26 weeks (B,D) of age.. Relative
mitochondrial DNA content in the renal cortex was determined by qRT-PCR analysis at
10 weeks (A) and 26 weeks (B) of age. Data are reported as mean ± SEM, n = 6.
*p<0.05 versus WT controls.
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Altered cardiac mitochondria homeostasis in young and aged 5-HT1F KO mice
Because stimulation of the 5-HT1F receptor induced cardiac MB in mice, we
hypothesized that the absence of the 5-HT1F receptor would also lead to disruption of
mitochondrial homeostasis in the heart. In contrast to the changes observed in renal
cortical tissue, cardiac mRNA of PGC-1α, Nrf-1, Nrf-2, TFAM, ATPSβ, COX1, ND1, and
mtDNA copy number were decreased (40, 35, 40, 35, 40, 55, 40, and 30%, respectively)
at 10 weeks of age (Fig. 3.5A). All genes returned to WT levels except PGC-1α and
TFAM, which were both increased 1.8-fold compared to WT levels at 26 weeks of age
(Fig. 3.5C). These results reveal that the loss of the 5-HT1F receptor leads to decreased
MB genes at 10 weeks of age and mostly return to WT levels at 26 weeks of age in the
heart.
Cardiac gene expression of Drp1, PINK1 and SOD2 were reduced (45, 40, 35%,
respectively) in KO mice at 10 weeks of age (Fig. 3.5B). However, PINK1, and UCP2
transcript levels were elevated 1.6- and 1.5-fold, respectively, in KO mice at 26 weeks of
age (Fig. 3.5D).
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Figure 3.5: Altered cardiac mitochondrial homeostasis in young and aged 5- HT1F
KO mice. Total RNA was harvested from left ventricle cardiac tissue of 5-HT1F receptor
WT and KO mice. Gene expression of key regulators of MB, fission, oxidative stress
were measured on the mRNA level at 10 weeks ( A, C) and 26 weeks (B,D) of age..
Relative mitochondrial DNA content in left ventricle was determined by qRT-PCR
analysis at 10 weeks (A) and 26 weeks (B) of age. Data are reported as mean ± SEM, n
= 6. *p<0.05 versus WT controls.
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Altered renal 5-HT receptor gene expression in 5-HT1F KO mice
We explored the possibility that the lack of the 5-HT1F receptor results in altered gene
expression of other 5-HT receptors. Absence of the 5-HT1F receptor decreased renal
mRNA of 5-HT1B, 5-HT1D, and 5-HT2A, receptors (~30, 35, 45%) at 10 weeks, while 5HT2B receptor mRNA increased ~2.6-fold and 5-HT2C receptor mRNA did not change
compared to WT (Fig. 3.6A). By 26 weeks of age the transcripts of 5-HT1D, 5-HT2A and
5-HT2C receptors were elevated by ~2.3-, 1.6-, and 1.7-fold, respectively, whereas 5HT1B and 5-HT2B receptor mRNA returned to WT levels (Fig. 3.6B). Thus, altered renal
5-HT receptor gene expression may be a compensatory mechanism in response to the
absence of the 5-HT1F gene.
We also measured cardiac 5-HT receptor gene expression in response to 5-HT1F
receptor absence. Cardiac 5-HT1D and 5-HT2B receptor mRNA expression were both
decreased by ~40% at 10 weeks, while 5-HT2A receptor mRNA increased 1.6-fold
compared to WT levels (Fig. 3.6C). At 26 weeks, 5-HT1B, 5-HT1D, 5-HT2A, and 5-HT2C
receptor mRNA were elevated ~1.2-, 1.6-, 2.7-, and 1.7- fold, respectively, in KO mice
(Fig. 3.6D). These results reveal that compensatory mechanisms may be tissue-specific,
producing differences in mitochondrial gene expression in the kidney and heart.
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Figure 3.6: Altered renal and cardiac 5-HT receptor gene expression in KO mice.
Total RNA was harvested from renal cortical and left ventricle cardiac tissue of 5-HT1F
receptor WT and KO mice. Expression of 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B and 5-HT2C
were measured on the mRNA level at 10 weeks (A, C) and 26 weeks (B,D) of age. Data
are reported as mean ± SEM, n = 6. *p<0.05 versus WT controls.
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The absence of the 5-HT1F receptor potentiates I/R-induced AKI at 24 hr
While the absence of the 5-HT1F receptor did not cause renal injury, it is possible that
under stress the absence of the 5-HT1F receptor could potentiate renal injury. To test this
hypothesis, we subjected 10-week-old WT and KO mice to renal I/R injury. Renal
function was assessed 24 hr after I/R-induced AKI and an increase in serum creatinine
and BUN in WT and KO AKI mice was observed compared to sham controls. However,
there was no statistical difference in serum creatinine or BUN between genotypes (Fig.
3.7A,B). To assess renal cortical injury in this model, we measured two markers of renal
injury, KIM-1 and NGAL protein in the renal cortex at 24 hr. KIM-1 and NGAL increased
3- and 2-fold, respectively, in 5-HT1F receptor KO mice subjected to I/R injury compared
to WT mice subjected to IR injury (Fig. 3.7C-E). It is also important to note 5-HT1F
receptor mRNA decreased by ~50% in WT mice subjected to I/R (Fig. 3.7F).
Renal histopathology was assessed using periodic acid-Schiff (PAS) staining. Kidneys
from both WT and 5-HT1F receptor KO mice subjected to I/R injury exhibited proximal
tubule necrosis and brush border damage. However, the absence of the 5-HT1F receptor
did not potentiate tubular necrosis or brush border damage at 24 hr (Fig. 3.8). Despite
the renal histology findings, these data indicate that I/R-induced AKI results in depletion
of the 5-HT1F receptor mRNA and that the loss of this receptor potentiates renal injury
and suggests that the 5-HT1F receptor is renal protective under stress.
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Figure 3.7: The absence of the 5-HT1F receptor potentiates I/R- induced AKI at 24
hr. Serum creatinine (A) and BUN (B) was assessed 24 hr after renal I/R injury in WT
and 5-HT1F receptor KO mice. Immunoblot analysis of renal cortical KIM-1 and NGAL
expression was used to asses tubular injury in WT and 5-HT1F receptor KO mice
following I/R- induced AKI (C). Densitometry analysis of KIM-1 (D) and NGAL (E)
following I/R injury. Total RNA was harvested from renal cortical of WT and 5-HT1F
receptor KO mice following I/R- induced AKI. Expression of 5-HT1F receptor mRNA was
measured (E).Data are reported as mean ± SEM, n = 4-6. Different superscripts indicate
statistically significant differences (p<0.05).
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Figure 3.8: Absence of the 5-HT1F receptor has no effect on renal cortical histology
at 24 hr. Renal cortical sections of WT and 5-HT1F receptor KO mice subjected to
sham or I/R-induced AKI were stained with Periodic acid-Schiff (PAS). PAS stain of
representative slides of renal cortical tissues at 24 hr (magnification, x100x) (A). Tubular
necrosis scoring (B). Loss of brush border scoring(C).Data are reported as mean ± SEM,
n = 5-6.
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The absence of the 5-HT1F receptor reduces the recovery of renal function
A previous study demonstrated that the stimulation of MB though the activation of the 5HT1F receptor accelerates the recovery of renal function and tubular injury after AKI.
Thus, we postulated that the absence of the 5-HT1F receptor would reduce recovery of
renal function following injury (5). Renal function and tubular injury were assessed at 24
hr and 144 hr following I/R-induced AKI in WT and KO mice. All I/R mice had equal initial
injury with an overall average serum creatinine of 0.7 ± 0.2 mg/dL and BUN of 67 ± 23
mg/dL. However, 5-HT1F receptor KO and WT mice failed to recover renal function as
demonstrated by persistent overall elevated serum creatinine and BUN levels of 0.5 ±
0.2 mg/dL and 52 ± 23 mg/dL, respectively at 144 hr (Fig.3.9 A, C). It is noteworthy to
mention that tubular necrosis and brush border damage remained elevated at 144 hr
following I/R injury, however, renal histology scoring revealed that all mice exhibited the
same degree of tubular necrosis and loss of brush border (Fig.3.10).
To further explore renal recovery in 5-HT1F receptor KO mice, renal function
improvement was calculated as change in serum creatinine and BUN (delta serum
creatinine and BUN) at 144 hr compared to 24 hr following AKI in each mouse. Using
this analysis serum creatinine decreased ~0.25 mg/dL in AKI WT mice compared to no
decrease in serum creatinine in AKI KO mice (Fig. 3.9 B). Similar results were observed
in BUN which decreased ~35 mg/dL in AKI WT mice compared to no decrease in AKI
KO mice (Fig. 3.9D).
To assess renal tubular injury, renal cortical KIM-1 and NGAL levels were measured by
immunoblot analysis. KIM-1 and NGAL were upregulated by 2- and 3- fold, respectively,
in 5-HT1F receptor KO mice subjected to I/R injury compared to WT mice (Fig.3.9E-G).
Taken together, these findings provide strong evidence that the loss of the 5-HT1F
receptor potentiates AKI and is key to facilitate renal recovery.
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Figure 3.9. The absence of the 5-HT1F receptor reduces the recovery of renal
function. Serum creatinine(A), delta serum creatinine (B), BUN (C) and delta BUN (D)
were assessed 144 hr after renal I/R injury in WT and 5-HT1F receptor KO mice.
Immunoblot analysis of renal cortical KIM-1 and NGAL expression was used to asses
tubular injury in WT and 5-HT1F receptor KO mice following I/R- induced AKI (E).
Densitometry analysis of KIM-1 (F) and NGAL (G) following I/R injury. Data are reported
as mean ± SEM, n = 4-6. Different superscripts indicate statistically significant
differences (p<0.05).
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Figure 3.10: Absence of the 5-HT1F receptor has no effect on renal cortical
histology at 144 hr. Renal cortical sections of WT and 5-HT1F receptor KO mice
subjected to sham or I/R-induced AKI were stained with Periodic acid-Schiff (PAS). PAS
stain of representative slides of renal cortical tissues at 144 hr (magnification, x100x)
(A). Tubular necrosis scoring (B). Loss of brush border scoring(C).Data are reported as
mean ± SEM, n = 5-6.
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The absence of the 5-HT1F receptor suppresses MB during I/R- induced AKI
To determine whether greater tubular injury in the 5-HT1F receptor KO mice was
associated with suppressed MB, we assessed renal cortical PGC-1α, NDUFS1, COX1
and TFAM protein at 24 and 144 hr in mice subjected to I/R. PGC-1α and TFAM protein
were reduced ~50-60% in KO mice after I/R-induced AKI compared to WT and KO sham
mice at 24 hr (Fig. 3.11A, C, F). No difference in PGC-1α and TFAM protein was
detected in I/R injured WT mice (Fig. 3.11A, C, F). We assessed the same endpoints at
144 hr following I/R injury. Renal cortical PGC-1α, NDUFS1 and COX1 protein were
reduced by ~50, 75, 50%, respectively, in 5-HT1F receptor KO mice compared to sham
animals of both genotypes at 144 hr (Fig.3.11 B, G, H). It is important to note that
NDUFS1 protein was reduced at 144 hr in WT mice following injury and to a further
extent in 5-HT1F receptor KO mice subjected with I/R (Fig. 3.11 B,H). Similar findings
were observed following mRNA analysis of these endpoints (Fig. 3.12). These findings
suggest that MB is persistently suppressed following AKI and to a greater magnitude in
the absence of the 5-HT1F receptor.
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Figure 3.11: The absence of the 5-HT1F receptor suppresses MB during I/Rinduced AKI. Total protein was harvested from the renal cortex of WT and 5-HT1F
receptor KO mice following I/R- induced AKI. Immunoblot analysis of renal cortical PGC1α , NDUFS1, COX1 and TFAM protein expression was used to assess MB in WT and
5-HT1F receptor KO mice following I/R- induced AKI at 24 hr (A) and 144 hr (B).
Densitometry analysis of 24 hr PGC-1α (C), NDUFS1 (D), COX1 (E) and TFAM (F) and
144 hr PGC-1α (G), NDUFS1 (H), COX1 (I) and TFAM (J) following I/R injury. Data are
reported as mean ± SEM, n = 4-6. Different superscripts indicate statistically significant
differences (p<0.05).

132

Figure 3.12: The absence of the 5-HT1F receptor disrupts gene expression of
mitochondrial homeostasis following I/R-induced AKI. Total RNA was extracted
from renal cortical tissue. Gene expression of 24 hr PGC-1α (A), NDUFS1 (B), COX1
(C), TFAM (D) and 144 hr PGC-1α (E), NDUFS1 (F), COX1 (G), TFAM (H) were
measured to assess mitochondrial homeostasis following I/R- induced renal injury. Data
are reported as mean ± SEM, n = 4-6. Different superscripts indicate statistically
significant differences (p<0.05).
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5-HT1F receptor KO mice exhibit persistent decrease in ATP levels following I/Rinduced renal injury
To assess whether the absence of the 5-HT1F receptor alters mitochondrial function
following I/R-induced AKI, cortical ATP levels were measured. ATP was reduced by
~50% following I/R injury in both genotypes at 24 hr (Fig. 3.13A). However, WT mice
exhibited partial recovery in ATP content by 144 hr, which was absent in the 5-HT1F
receptor KO mice (Fig. 3.13B).
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Figure 3.13: 5-HT1F receptor KO mice exhibit persistent decrease in ATP levels
following I/R- induced renal injury. Renal cortical ATP concentration (nmol/uL) was
measured in WT and 5-HT1F receptor KO mice 24 hr (A) and 144 hr (B) following renal
I/R injury and then normalized to wet weight of protein (mg). Data are reported as mean
± SEM, n = 4-6. Different superscripts indicate statistically significant differences
(p<0.05).
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The absence of the 5-HT1F receptor increases oxidative stress at 144 hr following
I/R- induced AKI
Previous studies reported that renal I/R results in oxidative stress. (18) Thus, we
measured 4 hydroxy-2-nonenal (4-HNE) protein modifications as a marker of oxidative
stress in renal cortical proteins at 24 and 144 hr in WT and 5-HT1F receptor KO mice
subjected to I/R. At 24 hr no differences were detected in any group (Fig. 3.14). In the
absence of the 5-HT1F receptor 4-HNE protein modifications increased by 1.5- fold
compared to WT mice following I/R injury, suggesting increased oxidative stress in KO
mice.
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Figure 3.14: The absence of the 5-HT1F receptor induces oxidative stress at 144 hr
following I/R- induced AKI. Total protein was harvested from the renal cortex of WT
and 5-HT1F receptor KO mice following I/R- induced AKI. Immunoblot analysis of renal
cortical 4-HNE protein expression was used to assess oxidative stress in WT and 5-HT1F
receptor KO mice following I/R- induced AKI at 24 hr (A) and 144 hr (B). Densitometry
analysis of 24 hr 4-HNE (C) and 144 hr 4-HNE (D) following I/R injury. Data are reported
as mean ± SEM, n = 4-6. Different superscripts indicate statistically significant
differences (p<0.05) versus WT controls
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5-HT1 and 5-HT2 receptors are expressed in human kidney and heart
To determine the translatability of this model to human disease, we measured gene
expression of 5-HT1 and 5-HT2 receptors in renal and cardiac human samples. 5-HT1B,
5-HT1D, 5-HT1F, 5-HT2A, 5-HT2B, and 5-HT2C receptor gene expression were all detected
in both renal and cardiac human samples (Fig. 3.15A, B).
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Figure 3.15: 5-HT1 and 5-HT2 Receptors are Expressed in Human Kidney and
Heart. Total RNA was extracted from human and mouse renal and cardiac tissue.
Expression of renal and left ventricle 5-HT1B, 5-HT1D, 5-HT1F, 5-HT2A, 5-HT2B and 5-HT2C
receptors were measured on the mRNA level in human and mouse (A, B). Data reported
as delta Cq values.

139

DISCUSSION
Mice homozygous for the mutated 5-HT1F receptor gene were viable and physically
similar to WT mice. While the 5-HT1F receptor KO mice did not have gross morphological
alterations, nor changes in blood counts and serum chemistries, our data provide clear
evidence that mitochondrial homeostasis in renal and cardiac tissue is disrupted.
Assimilating various mitochondrial markers revealed that the loss of the 5-HT1F receptor
gene resulted in MB and increased mtDNA copy number in the kidney. Associated with
increased markers of MB was an increase in the mitochondrial fission protein Drp1 and
mitophagy marker, PINK1. One explanation for these results is that the loss of the 5HT1F receptor and its associated basal control over MB results in a compensatory
response to increase MB. Consequently, we hypothesize that mitochondrial fission and
mitophagy are increased to maintain a given level of healthy mitochondria.
It is also possible that another 5-HT receptor may compensate for the loss of the 5-HT1F
receptor. This hypothesis is supported by a body of evidence indicating functional cross
talk as well as direct interaction between different 5-HT receptors. For example, the
functional cross talk between 5-HT2A and 5-HT2C receptors, between 5-HT1B and 5-HT2C
receptors and the 5-HT1A and 5-HT7 receptors (19-21). In this study, examination of
other 5-HT receptors revealed altered gene expression in response to the absence of
the 5-HT1F receptor. Only the 5-HT2B receptor was upregulated at 10 weeks in the kidney
of the 5-HT1F KO mouse. Interestingly, the 5-HT2B receptor is associated with
mitochondrial function in the heart (22, 23). At 26 weeks of age the 5-HT1D,

2A, 2C

receptors were upregulated in the 5-HT1F receptor KO mouse. While the 5-HT1D receptor
has not been linked to mitochondria, 5-HT2A,2C receptors have been linked to
mitochondrial function in the kidney (24). In fact, 5-HT2A receptor agonists induce MB in
renal proximal tubular cells (24). Other possibilities exist and future studies are needed
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to identify the mechanism by which MB is induced in the absence of the 5-HT1F receptor
and the potential role of the other 5-HT receptors.
In marked contrast to the kidney, cardiac mtDNA content and markers involved in MB,
fission, and autophagy were diminished in young 5-HT1F receptor KO mice. These
findings suggest that compensatory pathways in the young 5-HT1F receptor KO heart are
different and not sufficient to maintain mitochondrial homeostasis, leading to suppressed
MB, fission and mitophagy. Down regulation of genes involved in fission and autophagy
may indicate a mitochondrial preservation pathway that occurs in the absence of a MB
signal.

In the aged 5-HT1F receptor KO heart, an unknown compensatory pathway

develops, as PGC-1α and TFAM mRNA are increased, while other mitochondrial
markers have returned to levels found in WT mice.
Examination of other 5-HT receptors in the heart of 5-HT1F receptor KO mice revealed a
different pattern of induction compared to the kidney. 5-HT2B receptor gene expression
was downregulated and 5-HT2A receptor gene expression was upregulated in the heart
at 10 weeks. Absence of the 5-HT2B receptor has been linked to marked reductions in
ventricular mitochondrial enzyme activities, mitochondrial number and increased
myocardial cell death (22). It is possible that the cardiac 5-HT2B receptor plays a role in
modulating MB in the absence of the 5-HT1F receptor. Furthermore, it is also possible
that the tissue-specific differences in gene expression of MB, fission, and autophagy
markers in the kidney and heart are in response to tissue-specific expression of other 5HT1 and 5-HT2 receptors at 10 weeks. At 26 weeks of age, 5-HT1D, 5-HT2A, and 5-HT2C
receptor transcripts were upregulated in both the kidney and heart. This similar pattern in
5-HT receptor gene expression corresponds to elevated PGC-1α gene expression in
both the kidney and heart at 26 weeks. Future studies will need to investigate the tissue-
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dependent roles of 5-HT receptor signaling in MB in response to the absence of the 5HT1F receptor.
Having demonstrated that 5-HT1F receptor-deficient mice are healthy, we investigated
the effects of I/R- induced AKI on renal function and MB in 5-HT1F receptor KO mice.
The rationale for these experiments was supported by our previous findings that
demonstrated stimulation of the 5-HT1F receptor accelerated renal recovery following I/Rinduced AKI and rescued mtDNA copy number in mice (5). An important role for the 5HT1F receptor in the onset and recovery of renal injury following AKI was demonstrated
by sustained renal tubular injury and worsened tubular injury as measured by KIM-1 and
NGAL protein expression in KO mice. These data are corroborated by the reduction in 5HT1F receptor gene expression following AKI in WT mice at 24 hr. However, there were
no differences in renal cortical histology between injured WT and 5-HT1F receptor KO
mice. A possible explanation for similar proximal tubule necrosis and brush border loss
is that both genotypes reached maximal histological injury at 24 hr.
The observation that renal injury was worsened in 5-HT1F receptor KO mice was also
associated with persistent suppression of MB. Our findings are supported by published
results from our laboratory and other groups that have demonstrated that PGC-1α and
MB are protective following I/R-induced AKI (25-27). We propose that loss of 5-HT1F
receptor dependent MB is the mechanism responsible for diminished PGC-1α and ETC
protein expression observed in the 5-HT1F receptor KO mice. Given that the generation
of ATP primarily takes place at the ETC, it is unsurprising that the 5-HT1F receptor KO
mice exhibit renal cortical ATP depletion. It is also important to mention that 5-HT1F
receptor mice displayed elevated oxidative protein damage following I/R-induced AKI.
Further studies are needed to fully understand the mechanisms by which the 5-HT1F
receptor is mediating oxidative stress however, we hypothesize that MB governed by the
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5-HT1F receptor is essential for the maintenance of proper mitochondrial homeostasis
and the depletion of this receptor is sufficient to disrupt normal mitochondrial quality
control mechanisms that mediate renal organ recovery.
This study provides insight for the role of 5-HT1F receptor in modulating MB and
mitochondrial homeostasis. Mitochondrial dysfunction is a critical pathophysiological
mediator in various disease states, including, acute organ injury and cardiovascular
disease (2, 28-31). The induction of MB to restore mitochondria number and function
increases the energy supply needed for tissue repair. Thus, MB is a promising
therapeutic strategy for many human pathologies. However, there are only a few,
nontoxic compounds that selectively induce MB (2). This presents an opportunity to
target 5-HT receptors for the treatment of human acute organ injuries and cardiovascular
diseases. We have provided evidence that 5-HT1F, and other 5-HT1 and 5-HT2 receptors
are present in human renal and cardiac tissue. While classical functional roles of 5-HT1
and 5-HT2 receptors in the cardiovascular system include renal vascular dilation,
vasoconstriction, and platelet aggregation (32). Future studies will be needed to
understand the involvement of 5-HT receptors in MB and the pathogenesis of human
acute organ injuries and cardiovascular disease.
In summary, these results provide the first evidence that the 5-HT1F receptor regulates
mitochondria in renal and cardiac tissue under physiological conditions. Our data also
demonstrates that the 5-HT1F receptor plays a protective role in I/R- induced AKI and this
protection is mediated, through mitochondrial homeostasis and biogenesis.
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CHAPTER FOUR:
Summary, Contributions and Future Directions
SUMMARY OF CURRENT LITERATURE
Disruption of MB in AKI
Mitochondrial dysfunction, particularly within the renal tubular epithelium, has been
implicated as a major contributor to the development and progression of AKI (1). Based
on experimental and clinical studies of ischemic, septic and nephrotoxic AKI, disruption
in mitochondrial homeostasis creates a pathogenic environment (increased ROS,
apoptosis, calcium influx, ATP depletion), ultimately, preventing renal repair (2-4).
The main focus of our laboratory has been dedicated to understanding the role of MB
following AKI as a potential mechanism and therapeutic target. MB is a multifactorial
process, including transcription and translation of nuclear-and mitochondrial encoded
proteins involved in oxidative phosphorylation and mitochondrial dynamics, to generate
new, functional mitochondria (5). Our laboratory demonstrated suppression of MB in
multiple models of AKI. In particular, Funk et al. observed reduced gene and protein
expression of PGC-1α, as well as reduced activity as measured by increased acetylation
in the renal cortex of mice subjected to I/R-induced AKI (6). As the master regulator of
MB, reduced PGC-1α was associated with persistent decreased renal cortical
expression of several respiratory proteins, nuclear-encoded NDUFB8 and ATP synthase
β, and mitochondrial-encoded COXI and COXIV (6). These findings indicate persistent
suppression of MB after renal ischemic injury and similar changes were observed in
mouse models of glycerol-induced rhabdomyolysis, folic acid nephropathy and septicinduced AKI (6-8). These studies were further extended to demonstrate the link between
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MB and mitochondrial dynamics and function. Disruptions in MB were also accompanied
by up-regulation of mitochondrial fission regulator, Drp1 and caspase 3 cleavage,
indicating mitochondrial fragmentation and apoptotic induction in I/R and glycerolinduced AKI (6). Further studies revealed the loss of in tubular FCCP-uncoupled oxygen
consumption and ADP-stimulated respiration in isolated mitochondria of mice subjected
to I/R-induced AKI, supporting the importance of MB in the setting of AKI (9).
It is important to note that changes in mitochondrial homeostasis have been documented
in human AKI patients. Skeletal muscle biopsies from septic patients admitted to the
intensive care unit exhibited decreased ATP content, reduced complex I activity,
glutathione depletion and elevated markers of oxidative stress. In addition, mitochondrial
swelling was observed in biopsy samples from patients that suffered I/R-induced AKI
(10). In a recent study by Whitaker, et al. urinary mtDNA copy number was associated
with increased risk of worsening of AKI progression in patients that developed AKI postcardiac surgery (11). Taken together, these findings indicate that mitochondrial
dysfunction and loss of mitochondrial number is a common entity in both the
experimental and clinical setting. Thus, pharmacological targeting of MB represents a
viable strategy to prevent both mitochondrial and renal dysfunction following AKI.
Our laboratory has explored the molecular mechanisms that are responsible for
alterations in MB in cellular and animal models of renal oxidant and ischemic injury.
These studies revealed that stimulation of the β2-adrenergic receptor, a Gαs-coupled
GPCR, by formoterol restores respiratory protein expression, mitochondrial and renal
function after I/R injury in mice (9). In addition, treatment with sildenafil, a cGMPselective phosphodiesterase 5 inhibitor promotes increased MB and function following
folic acid-induced AKI (7). These findings indicate that GPCRs and cGMP are potential
mediators of MB signaling. One goal of the work discussed here was to further
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characterize signaling events leading to the induction of PGC-1α and MB. We
hypothesize that this work will increase the understanding of mechanisms underlying
mitochondrial dysfunction and identify better therapeutic approaches for the treatment of
renal injury.
Role of Serotonin in Mitochondrial Homeostasis and Biogenesis
Despite promising results in the identification of mitochondrial biogenic compounds,
these studies only yield partial recovery of mitochondrial and renal function, so our
laboratory further characterized pathways leading to MB. To this end, serotonin receptor
activation was identified as an efficacious inducer of MB in cellular and animal models.
Rasbach et al. identified the 5-HT2 family of receptors as a regulator of MB (12). RPTC
treated with the 5-HT2 pan-agonist DOI increased FCCP-uncoupled respiration,
respiratory protein expression, ATP generation and mitochondrial mass/number,
indicating biogenesis of new, functional mitochondria in response to 5-HT2 receptor
activation (12). Additionally, DOI accelerated the recovery of mitochondrial function
following oxidant injury in primary RPTC, further indicating the therapeutic potential of
the 5-HT2 receptor class (12). This study also revealed that the induction of MB in renal
proximal cells is indeed dependent on PGC-1α, strengthening the need for the
elucidation of pathways upstream of PGC-1α activation.
Additional work was performed to determine the specific 5-HT2 receptor responsible for
the observed biogenic effects of DOI. The 5-HT2 receptor family is coupled to Gαs and
comprised of three receptors, 5-HT2A,B,C. Using a Seahorse Extracellular Flux assay, a
phenotypic screen used for the identification of mitochondrial biogenic agents, our
laboratory identified the 5-HT2C receptor agonist CP-809,101 and 5-HT2C receptor
antagonist SC-242,084 as potent inducers of MB based on increased FCCP-uncoupled
oxygen consumption (13). Both compounds increased PGC-1α mRNA and gene
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expression of nuclear-and mitochondrial-encoded respiratory chain components in
primary RPTC and similar changes were observed in mice (13).
It is intriguing that both an agonist and antagonist for the same receptor elicit the same
mitochondrial biogenic response. To determine if CP-809,101 and SB-242,084 are
acting through the 5-HT2C receptor, both compounds were administered to mice lacking
the 5-HT2C receptor (13). In the absence of the 5-HT2C receptor, NDUFB8 and ND1 were
further elevated compared to wild-type control mice treated with each compound,
indicating that the 5-HT2C receptor is not responsible for the mitochondrial biogenic effect
observed in the presence of CP-809,101 and SB-242,084. However, the 5-HT2C receptor
does seem to be involved in the maintenance of mitochondrial homeostasis in the renal
cortex as the absence of the 5-HT2C receptor reduced PGC-1α mRNA expression under
physiological conditions (13). Further examination of this phenomenon, revealed that
these compounds exert their effects through the 5-HT2A receptor (13). These findings
were confirmed utilizing RPTC that lacked expression of the 5-HT2A receptor and no
change in PGC-1α mRNA was noted with either drug (13). These results indicate that
the 5-HT2A receptor is responsible for the induction of MB in the renal cortex.
Although the pharmacological potential of 5-HT2A receptor agonists and antagonists was
disappointing, our laboratory continued to screen other 5-HT receptor agents for their
ability to induce MB. This screening revealed that the LY334370 and LY344864,
agonists of the Gαi-coupled, 5-HT1F receptor induced FCCP-uncoupled oxygen
consumption rates in RPTC at nanomolar concentrations (14). Garrett. et al. also
determined that both 5-HT1F receptor agonists increased protein expression of NDUFB8,
ATP Synthase β and COX1 and these changes were blocked in RPTC transfected with
siRNA against the 5-HT1F receptor, demonstrating that both agonists are indeed
signaling through the 5-HT1F receptor (14). It is important to note that knock down of the
150

5-HT1F receptor resulted in decreased mitochondrial proteins, suggesting that the 5-HT1F
receptor is required for proper mitochondrial homeostasis under physiological levels
(14). In mice, LY344864 increased renal cortical mRNA expression of PGC-1α, COX1
and NDUFB8, as well as mtDNA copy number. Of note, 5-HT1F receptor was identified
in a number of tissues, including cardiac and hepatic, and MB was also observed in
these tissues following LY344864 treatment (14). The most intriguing aspect of this
study is LY344864 accelerated the recovery of renal function following I/R-induced AKI.
The LY344864 induced-restoration in renal function was associated with the recovery of
renal mtDNA copy number (14). Interpretation of these data reveal the 5-HT1F receptor
should be considered a promising regulator of MB and a key target for treating renal
injury.
When discussing the role of 5-HT receptors in modulating mitochondrial homeostasis, it
is important to discuss the historical findings by Nebigil et al. detailing the significant role
of the 5-HT2B receptor in cardiac mitochondrial function and structural integrity (15).
Specifically, their laboratory demonstrated that the ablation and overexpression of the 5HT2B receptor both lead to alterations in mitochondria. Overexpression of cardiac 5-HT2B
receptor lead to increased ventricular mitochondrial enzyme activities and increased
mitochondrial proliferation lead to increased cardiac hypertrophy (16). In contrast,
specific knockout of cardiac 5-HT2B receptor lead to reduction in succinate
dehydrogenase cytochrome oxidase activity and mitochondrial number as well as altered
mitochondrial structure. In addition, these mice exhibited increased myocardial cell death
(17). These studies further illustrate the role of 5-HT receptors in regulating cellular
functions under both physiological and pathological conditions.
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Pharmacological Induction of MB for the Treatment of Acute Organ Injury
Acute organ injuries in multiple organ systems share common pathophysiological
features, including vascular disturbances, inflammation and mitochondrial dysfunction.
Experimental strategies have targeted each of these pathological events with hopes to
gain a better understanding of the major contributors of acute organ dysfunction and to
identify better treatment strategies to restore organ function following insult. Of these
studies, modulation of mitochondrial function and number has proven to be one of the
most promising approaches. This section will discuss the variety of potential drug targets
of MB and the consequent improvement in mitochondrial homeostasis in multiple tissues
to demonstrate the true effectiveness of inducing MB in acute organ injury.
AMPK: AMPK is a ubiquitously expressed heterotrimeric kinase that acts as a highly
conserved energy sensor and participates in the regulation of energy-generating and
consumption pathways. AMPK triggers increases in glucose uptake, oxidative
phosphorylation, autophagy, and MB. AMPK has been reported to directly phosphorylate
PGC-1α at two sites, activating its transcription (18). An alternative mechanism by which
AMPK may activate PGC-1α function is via deacetylation catalyzed by the nicotinamide
adenine dinucleotide (NAD)-dependent deacetylase sirtuin (SIRT) 1(19). Stimulation of
AMPK following ATP depletion in rats enhanced NRF-1 binding activity and
subsequently restored mitochondrial density. Pharmacological activation of AMPK has
been observed with multiple compounds, including 5-aminoimidazole-4-carboxamide
ribonucleotide (AICAR) (20, 21). AICAR is an adenosine analog AMPK activator, which
has shown positive effects following cardiac and renal I/R injury through enhanced
glucose uptake and SIRT1 expression, respectively (22, 23). AICAR has also been
successful in chronic disease models, such as type II diabetes, by preventing insulin
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resistance in multiple tissues, as well as in AD through decreases in amyloid-β protein
levels (24-26).
ERK1/2: MAPKs are serine-threonine kinases that mediate intracellular signaling
associated with a variety of cellular activities, including cell proliferation, differentiation,
survival, death, and transformation. As discussed above, ERK1/2, a member of the
MAPK family, has been implicated as a negative regulator of MB (27) as ERK1/2
reduces PGC-1α and its downstream targets in a number of disease models. For
example, ERK1/2 activation impaired mitochondrial function, as evidenced by altered
mitochondrial dynamic processes and reduced mitochondrial membrane potential in an
animal model of Alzheimer’s disease (28). Additionally, ERK1/2 activation preceded the
initial decrease in renal PGC-1α mRNA and loss of renal function in a mouse model of
I/R-induced AKI (27).
ERK1/2 is thought to be the only substrate for mitogen-activated protein kinase kinase
(MEK1/2) phosphorylation; therefore, pharmacological inhibition of ERK1/2 can be
accomplished using MEK1/2 inhibitors. Treatment with the MEK1/2 inhibitor U0126 was
found to rescue hippocampal PGC-1α, TFAM, and NRF-1 protein levels following
amyloid-β injections in rats (29). Additionally, our laboratory has reported that inhibition
of ERK1/2 using trametinib not only attenuates the early decrease in PGC-1α, but also
prevents decreased renal function following I/R-AKI (27). These studies provide
evidence that targeting negative regulators of MB is an effective strategy to induce MB
and restore organ function following injury.
cAMP/PKA/CREB Pathway: PDE inhibitors tightly regulate levels of cAMP, thus, these
compounds are often used to activate the cAMP/PKA/CREB pathway. Rolipram and
cilostazol are cAMP-selective PDE inhibitors that have been found to induce PGC-1α
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and mitochondrial activity in multiple cellular and animal models. For example, rolipram
increased PGC-1α deacetylation, PGC-1α mRNA expression and mtDNA content in
skeletal muscle isolated from mice (30). Similar changes were observed in cultured
endothelial cells treated with cilostazol (31). In addition, rolipram and cilostazol
demonstrated protection in preclinical models of neurodegenerative disease (32, 33).
Sirtuins: The SIRTs are a family of proteins that act predominately as NAD-dependent
deacetylases. As mentioned above, PGC-1α is activated through deacetylation, which
primarily occurs via its interaction with SIRT1. SIRT1 also controls the acetylation of
forkhead box O (FOXO) transcription factors, acetylation status of FOXO directs it to
certain targets, such as the PGC-1α promoter (34, 35). Studies revealing SIRT1-induced
activation of PGC-1α led to the interest in nutraceutical and pharmacological activators
of SIRT1.
Resveratrol and other natural products, such as the isoflavones found in soybeans, the
flavonoids such as quercetin and green tea polyphenols found in fruits and cocoa,
respectively, have been shown to increase SIRT1-mediated MB and metabolic functions
(36-39). Interestingly, quercetin has been shown to increase PGC-1α expression and
mtDNA copy number in various brain regions of rats exposed to aluminum, a widely
distributed element linked to several neurological diseases including Alzheimer’s and
Parkinson’s disease.(40, 41). PGC-1α activation using green tea polyphenols rescued
reductions in respiratory chain proteins and mtDNA content in a rat model of
cyclosporine A-induced nephrotoxicity, and consequently, attenuating kidney injury and
improving renal function. These data implicate natural products as a promising
therapeutic strategy for toxicant-induced mitochondrial suppression to promote tissue
repair and regeneration (42). Identification of natural SIRT1 activators encouraged the
search for pharmacological inducers of SIRT1. As a result, a number of SIRT1 activators
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were developed, including SRT1720, SRT1460, and SRT2104. Specifically, SRT1720
demonstrated protective effects across a variety of disease states in mice, including
renal ischemic injury and MI, through activation of SIRT1/PGC-1α (43, 44).
In summary, preclinical and human studies indicate that the induction of MB via various
pathways promote functional recovery in a number of disease states, including metabolic
disorders, I/R injuries, neurodegenerative and cardiovascular pathologies. Unfortunately,
relatively few drugs have been identified for the induction of MB, and such drugs are
often functionally promiscuous. Therefore, a significant amount of work is still needed to
identify safe and efficacious compounds. The above list, including mitochondrial biogenic
agents identified by our laboratory provide researchers and clinicians with valuable tools
for developing mitochondrial biogenic based strategies for therapeutic intervention for
both acute and chronic diseases.
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CONTRIBUTIONS TO THE FIELD
Mechanisms Underlying the Induction of MB
Although our laboratory and others have identified a number of mitochondrial biogenic
targets, there has been very few studies aimed at determining the molecular mechanism
mediating this effect. Specifically, we explored the signal transduction mechanism linking
the 5-HT1F receptor to MB. As mentioned earlier, the 5-HT1F receptor is a Gαi-coupled
receptor. As the Gβγ heterodimer mediates much of Gαi/o signaling (45), its role was an
important aspect to consider when investigating the 5-HT1F receptor-mediated MB
pathway. Additionally, there was some evidence indicating that the eNOS/cGMP/PKG
pathway is involved in regulating PGC-1α and MB (7, 46, 47).
To explore this possibility, we utilized the Seahorse Extracellular Flux Assay to
determine the key regulatory components mediating LY344864-induced cellular
respiration as a marker for MB. As stated earlier LY344864 is a potent and specific
agonist of the 5-HT1F receptor. LY344864 increased FCCP-uncoupled oxygen
consumption in RPTC, which was prevented when RPTC were pretreated with inhibitors
of Gβγ heterodimer, Akt, NOS, sGC and PKG. To confirm that the changes observed in
FCCP-uncoupled oxygen consumption were indicative of changes in MB, mtDNA copy
number was assessed and similar findings were observed. These findings indicate that
Gβγ heterodimer, Akt, NOS, sGC (cGMP) and PKG are key components of the 5-HT1F
receptor induced MB pathway.
Since we identified potential mediators of 5-HT1F receptor-induced MB, we then
elucidated the sequence of events within this pathway that result in MB following 5-HT1F
receptor stimulation. The sequence of events identified were agonist stimulation of 5HT1F receptor leading to Gβγ dependent activation of Akt/eNOS/PKG/PGC-1α.
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To investigate the potential for additional signaling events downstream of 5-HT1F
receptor that stimulate MB, we focused on the MAPK pathway since ERK1/2 has been
implicated as a negative regulator of PGC-1α and MB (27). Interestingly, LY344864
decreased ERK1/2 phosphorylation in RPTC. Next, we examined the upstream signaling
events that lead to diminished ERK1/2 phosphorylation, especially since the canonical
MAPK pathway is independent of the PI3K/Akt/eNOS signaling axis. We determined Gβγ
heterodimer and Akt activation are responsible for the suppression of ERK1/2
phosphorylation,

through

the

direct

inhibition

of

c-raf-MEK1/2

and

ERK1/2

phosphorylation.
Overall, this study demonstrated that 5-HT1F receptor-mediated MB occurs through dual
mechanisms dependent upon Gβγ heterodimer activation. Specifically, Gβγ heterodimer
dependent signaling is activating a known mitochondrial biogenic stimulatory pathway,
Akt/eNOS/cGMP/PKG/PGC-1α,

while

simultaneously

suppressing

an

inhibitory

mitochondrial biogenic pathway, c-raf/MEK/ERK/FOXO3a. We hypothesize that the dual
mechanisms are responsible for the efficacy of LY344864 induction of MB, thus,
providing an explanation for the robust mitochondrial biogenic effects exerted by
LY344864 under physiological and pathological conditions. To our knowledge, this is the
first study to elucidate a 5-HT1F receptor-mediated MB pathway. This novel mechanism
of MB provides a better understanding of the cellular events leading to increased
mitochondrial number and identifies additional therapeutic targets for diseases
characterized by mitochondrial dysfunction.
5-HT1F receptor as an in vivo regulator of MB
Given the beneficial effects of 5-HT1F receptor stimulation described by Garrett et al., we
were interested in understanding the role of the 5-HT1F receptor in the regulation of
mitochondrial and renal biogenesis and function under physiological and pathological
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conditions. To explore this relationship, we utilized 5-HT1F receptor KO mice. Since a
significant increase in renal cortical MB markers was observed in naïve mice following
LY344864 administration, we postulated that the absence of the 5-HT1F receptor would
lead to the suppression of PGC-1α and its downstream targets. However, a significant
increase in renal cortical genes that encode for nuclear-and mitochondrial-encoded
respiratory chain proteins, as well as mtDNA copy number was observed. In addition, we
detected increased mRNA expression in Drp1 and Pink1 in the renal cortex of 5-HT1F
receptor KO mice. It is important to note that these observations were made in young
(10-week old) WT and 5-HT1F receptor KO mice. Based on the established role of
mitochondria in age-related pathological processes, we assessed the same parameters
for mitochondrial homeostasis in aged (26-week old) WT and 5-HT1F receptor KO mice,
and, surprisingly, PGC-1α mRNA expression and mtDNA copy number remained
elevated in the renal cortex as 5-HT1F receptor KO mice aged. In summary, 5-HT1F
receptor KO mice exhibited increased expression of genes involved in the proper
maintenance of mitochondrial homeostasis, suggesting that renal cortical signaling
mechanism(s) have the ability to initiate an adaptive response to limit deleterious effects
in the absence of the 5-HT1F receptor under physiological conditions.
We also assessed the gene expression of mitochondrial homeostasis markers in left
ventricle tissue since the 5-HT1F receptor has been shown to stimulate cardiac MB and it
is an important contributor to and target of renal dysfunction. In contrast to changes
observed in the renal cortex of 5-HT1F receptor mice, we observed decreased mRNA
expression of respiratory chain components, fission and autophagy markers in the left
ventricles of young 5-HT1F receptor KO mice. In addition, the majority of these markers
returned to WT levels as the 5-HT1F receptor mice aged. It is noteworthy to mention that
cardiac PGC-1α mRNA was elevated in the aged 5-HT1F receptor mouse, indicating that
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PGC-1α is involved in the rescue of mitochondrial homeostasis markers in aged 5-HT1F
receptor KO mice.

Taken together, these findings revealed distinct patterns of

mitochondrial gene expression in a tissue-specific manner in the absence of the 5-HT1F
receptor. Specifically, these results strongly support the idea that activation of
compensatory mechanisms occurs in the renal cortex but that, this response seems to
be absent or insufficient in the left ventricle of 5-HT1F receptor KO mice.
After determining 5-HT1F receptor-mediated tissue-specific differences in mitochondrial
homeostasis markers, we focused on elucidating the mechanisms responsible for this
observation. To this end, we assessed mRNA expression of other 5HT1 and 5-HT2
receptors in naïve WT and 5-HT1F receptor KO mice. Interesting, we observed distinct
renal cortical and left ventricle mRNA expression patterns of 5-HT2A and 5-HT2B
receptors, which have both been implicated as regulators of MB and/or function.
Specifically, 5-HT2A receptor gene expression is reduced and 5-HT2B receptor gene
expression is elevated in the renal cortex of young 5-HT1F receptor KO mice. In contrast
to these findings, increased 5-HT2A receptor gene expression and decreased 5-HT2B
receptor gene expression was observed in aged 5-HT1F receptor KO mice. We
hypothesize that the differences in 5-HT2A and 5-HT2B receptor expression represents
alterations in the signaling pathways downstream of these receptors and are involved,
at least in part, in the differential changes in renal cortical and left ventricle mitochondrial
homeostasis markers in 5-HT1F receptor KO mice. It is noteworthy to mention that the
expression of 5-HT1 and 5-HT2 receptors has been detected in human renal and cardiac
tissue, highlighting the therapeutic potential for pharmacological intervention following
renal and cardiac organ injuries. Further studies are warranted to confirm the
physiological significance of tissue-specific 5-HT receptor signaling in the absence of the
5-HT1F receptor.
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We next focused on the role of the 5-HT1F receptor in renal and mitochondrial
homeostasis following I/R-induced AKI. While 5-HT1F receptor KO mice are completely
healthy under physiological conditions, we hypothesized that depletion of the 5-HT1F
receptor would lead to worsened outcomes under stress. While renal function, as
measured by serum creatinine and BUN, of the 5-HT1F receptor KO mice was no
different of that of the WT mice 24 hr following I/R injury, the more sensitive markers
renal tubular injury (KIM-1, NGAL) revealed that renal damage was greater in the 5-HT1F
receptor mice, suggesting that the 5-HT1F receptor is involved in the initiation of tubular
injury and, in turn, is likely to elicit renal protective effects under stress.
Earlier studies from our laboratory demonstrated that 5-HT1F receptor stimulation
accelerated the recovery of renal function and MB in the setting of I/R-induced AKI.
Thus, we sought to determine if the absence of the 5-HT1F receptor would prevent renal
recovery. As expected, 5-HT1F receptor KO mice failed to recover renal function by 144
hr following the renal I/R insult, compared to the partial recovery of renal function
observed in WT mice. In fact, renal recovery in WT mice was approximately 50% greater
compared to 5-HT1F receptor KO mice. In addition, failed renal recovery was associated
with elevated tubular injury in 5-HT1F receptor KO mice post-I/R injury. Taken together,
these findings support the notion that the 5-HT1F receptor has a meaningful role in
facilitating repair and/or regenerative mechanisms necessary for renal function recovery.
As discussed earlier, renal recovery following AKI depends on adequate mitochondrial
homeostasis and function. Therefore, impaired renal recovery in the absence of the 5HT1F receptor may thus be linked to disruption in MB. Renal cortical PGC-1α and its
downstream targets, nuclear-and-mitochondrial proteins of the respiratory chain were
persistently suppressed in 5-HT1F receptor KO mice compared to WT mice subjected to
renal I/R injury. These findings were also associated with persistent depletion of renal
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cortical ATP production in 5-HT1F receptor KO mice. Interpretation of these findings
suggest that disrupted MB, and subsequent impairment of mitochondrial function are
together a potential explanation for worsened tubular injury and renal function in the 5HT1F receptor mice. These findings are consistent with previous reports from our
laboratory demonstrating that disruption of MB is closely associated with worsened
tubular injury and renal function following I/R-induced AKI.
Because PGC-1α is also involved in the regulation of additional mitochondrial processes,
such as ROS-detoxifying mechanisms, we measured SOD2 protein expression as it
participates in reducing ROS in the mitochondria. We detected a significant reduction in
SOD2 protein in 5-HT1F receptor KO mice and this was associated with increased
oxidative protein damage in the renal cortex of 5-HT1F receptor mice following I/Rinduced AKI. These observed changes were absent in WT mice. Further studies are
needed to identify the mechanism by which the 5-HT1F receptor modulates oxidative
stress following renal I/R injury. However, we hypothesize that reduced PGC-1α
expression and signaling in the absence of the 5-HT1F receptor ultimately impairs the
ability for MB pathways to induce expression of proteins required for both oxidative
phosphorylation and ROS scavenging programs. Overall, these findings reveal that the
5-HT1F receptor exerts renal protective effects by modulating MB and function in the
setting of I/R-induced AKI.
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FUTURE DIRECTIONS
5-HT1F Receptor Mediated MB Signaling
While the pathway of 5-HT1F receptor mediated MB was elucidated in the scope of this
project, there are additional questions that remain unanswered. We were surprised to
observe tissue-specific differences in the expression of mitochondrial homeostasis
markers in the absence of the 5-HT1F receptor. We hypothesized that signaling of other
5-HT receptors is involved in mediating this differential effect. However, we did not
further pursue the physiological relevance of 5-HT receptor signaling in mitochondrial
homeostasis. Additional experiments should investigate the role of 5-HT receptors in
mediating mitochondrial homeostasis in the absence of the 5-HT1F receptor as this may
lead to identification of novel therapeutic targets. One of the most intriguing future
experiments that should be performed is exploring the downstream signaling events
contributing to the adaptive response in the kidney and to determine why this is not
present or sufficient in the heart. To this end, we measured renal cortical ERK1/2 and
Akt phosphorylation in WT and 5-HT1F receptor KO mice. ERK1/2 and Akt
phosphorylation was elevated in the absence of the 5-HT1F receptor (Fig. 4.2). It would
be interesting to conduct additional studies to investigate if the change in Akt and
ERK1/2 phosphorylation status is contributing to the observed increase in mitochondrial
homeostasis markers and to compare levels Akt and ERK1/2 phosphorylation in the left
ventricle. We predict that the pattern of expression will differ from that of the renal cortex,
potentially explaining the difference between renal cortical and left ventricular
mitochondrial homeostasis in the absence of the 5-HT1F receptor. Together, these
results could provide additional information on the mechanisms regulating MB.
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Figure 4.1: Renal cortical Akt and ERK phosphorylation is increased in the
absence of the 5-HT1F receptor at 10 weeks. Total protein was harvested from the
renal cortex of WT and 5-HT1F receptor KO mice. Immunoblot analysis of renal cortical
Akt and ERK phosphorylation (A) was assessed and normalized to total Akt and ERK,
respectively. Densitometry analysis of Akt (B) and ERK(C) phosphorylation. Data are
reported as mean ± SEM, n = 4. * indicate statistically significant differences compared
to WT controls (p<0.05).
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The Role of the 5-HT1F Receptor in Mitochondrial Homeostasis
The above findings present a number of exciting questions that deserve attention to fully
understand the role of the 5-HT1F receptor not only in MB, but also in mitochondrial
homeostasis. In an I/R-induced model of AKI, we identified 5-HT1F receptor-dependent
activation of MB as an essential mechanism for renal recovery. We have been
particularly interested in whether this pathway might involve the regulation of
mitochondrial dynamics and mitophagy, that is, selective mitochondrial autophagy. While
the generation of new, functional mitochondria is imperative to drive energy-dependent
repair and renal processes in the face of injury, perhaps prompting the clearance of
damaged and dysfunctional mitochondria is also important to prevent deleterious events,
such as excessive ROS generation. Additionally, numerous reports have demonstrated
that the balance of MB and mitophagy is required for proper energy metabolism under
both physiological and pathological conditions.
To determine, if mitophagy is being modulated in response to LY344864-mediated MB in
RPTC, we assessed a number of proteins that comprise the autophagy/mitophagy signal
transduction pathway. At 24 hr, an increase in Akt/mTOR/ULK1 (S757) signaling
pathway was observed by measuring the phosphorylation status of these proteins (Fig.
4.2 A-D). This pathway has been shown to inhibit autophagy/mitophagy. Next, we
assessed components of the autophagic (LC3BII and p62) and mitophagic (Pink1)
machinery following LY344864 treatment, however, no change in protein expression was
observed in any of these markers at 24 hr (Fig. 4.2E-F). It is noteworthy to mention that
at this same time point, 24 hr, LY344864 increases MB (cellular respiration and
respiratory complex proteins). Given these results in naïve RPTC, we postulate that
mitophagy signaling is not needed in uninjured RPTC and that suppression of mitophagy
may further promote increased mitochondrial content. Further work using both genetic

164

and pharmacological approaches are warranted to determine the signaling mechanism
contributing to 5-HT1F receptor-mediated mitophagy signaling.
While we have elucidated the signaling mechanism responsible for 5-HT1F receptormediated MB in RPTC, the mechanism mediating the degradation of mitochondrial
proteins following LY344864-induced MB stimulation is still unknown. To address this, a
series of wash-out experiments were performed in the presence and absence of the
lysosomal inhibitor, chloroquine. Following a single dose of LY344864, nuclear-and
mitochondrial-encoded proteins are increased at 24 hr and returned to control levels by
48 hr in RPTC. We demonstrate lysosomal inhibition prevents the degradation of
mitochondrial proteins following LY344864-induced MB as evidenced by the persistent
and potentiated increase in NDUFB8 and COX1 protein expression at 48 hr (Fig. 4.3A,
B). According to these preliminary results, lysosomal degradation may responsible for
mitochondrial protein degradation following MB. Further work is necessary to fully
understand the mechanisms involved in mitochondrial protein degradation following MB.
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Figure 4.2: LY344864 suppresses autophagy/mitophagy signaling in naïve RPTC.
Total protein was harvested from RPTC. To assess autophagy/mitophagy signaling,
immunoblot analysis of Akt (A), ERK (A), AMPKα (A), mTOR (C) and ULK1 (Ser757) (C)
phosphorylation were measured and normalized to total Akt, ERK, AMPKα, mTOR,
ULK1, respectively. Densitometry analysis of Akt, ERK and AMPKα (B). Densitometry
analysis of mTOR and ULK1 (D). Proteins involved in autophagy/mitophagy, Pink1,
LC3BII and p62 were also assessed using immunoblot analysis. Densitometry of Pink1,
LC3BII and p62 (F). Date reported as mean ± SEM, n = 4.* indicate statistically
significant differences compared to vehicle treated controls(p<0.05).
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Figure 4.3: 5-HT1F receptor stimulation is required for sustained MB and
degradation following MB is lysosomal-dependent. RPTC were pretreated with
chloroquine or vehicle control, a lysosomal inhibitor, and then exposed to LY344864 or
vehicle control for 24 or 48 hr. Total protein was harvested from RPTC and was
subjected to immunoblot analysis. NDUFB8 and COX1 protein expression was assessed
(A). Densitometry analysis of NDUFB8 and COX1 (B, C). Data reported as mean ± SEM,
n = 4. Different superscripts indicate statistically significant differences (p<0.05).
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Studies conducted in both cellular and animal models of renal injury have documented
that the induction of autophagy is renal protective (48, 49). In fact, inhibition of
autophagy has proven to worsen renal and mitochondrial outcomes following I/Rinduced AKI (50). Our laboratory reported significant mitophagy, selective mitochondrial
autophagy, as evidenced by colocalization of mitochondria and lysosomes following
exposure to the oxidant TBHP in RPTC (51). These studies also revealed that PGC-1α
protein expression was up-regulated for up to 3 days following TBHP exposure, and this
was accompanied by elevated basal and uncoupled oxygen consumption rates (51).
Rasbach et al. concluded that elevation of PGC-1α was responsible for the restoration of
mitochondrial function by the generation of new mitochondria to compensate for the
mitochondrial damage induced by TBHP.
To test the hypothesis that LY344864 is also a modulator of mitochondrial dynamics, I
performed this same experimental setup with TBHP treated RPTC in the presence and
absence of LY344864. It should be noted that I did not detect any changes in
mitochondrial dynamic markers in naïve RPTC treated with LY344864 (data not shown).
As expected PGC-1α protein was elevated following TBHP treatment of RPTC, however,
mitochondrial fusion protein, Mfn2 and phosphorylation of Drp1 at Serine 637 was
reduced (Fig. 4.4A-D), indicating enhanced mitochondrial fission. RPTC treated with
LY344864 following TBHP treatment exhibited further increase in PGC-1α protein
expression and enhanced Mfn2 expression and Drp1 Serine 637 phosphorylation. In
addition, mtDNA copy number was also markedly increased in LY344864 treated RPTC
following TBHP exposure compared to RPTC treated with TBHP alone. Taken together
these findings provide strong evidence that 5-HT1F receptor stimulation not only
increases mitochondrial content but may also drive the formation of mitochondrial
networks, both of which are considered beneficial for cellular survival (52). Based on
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these findings and discovery of LY344864 suppressing autophagy/mitophagy signaling
in naïve RPTC, future experiments are warranted to determine if and how LY344864 is
modulating mitochondrial dynamics and mitophagy following injury.
To set the foundation for this aim,

a preliminary experiment was performed with a

similar experimental design as above and observed that, in LY344864 treated RPTC
compared to RPTC treated with TBHP alone, there was a marked increased in
phosphorylation of AMPKα and ULK1 (Serine 555) (Fig. 4.5A-C), which are key signaling
events in autophagy signaling. In addition, greater expression of LC3BII and p62 was
observed in RPTC treated with LY344964 following TBHP exposure (Fig. 4.6 A-C).
These data reveal that LY344864 is indeed increasing autophagic flux, in turn,
mitophagy may also be enhanced. Additionally, an autophagic flux assay utilizing
chloriquine, a lysosomal inhibitor, was performed to confirm that LY344864-induced
increase in autophagic markers following TBHP exposure were indeed due to increased
autophagy (Fig. 4.6 D, E). Further examination of mitophagy markers such as Pink1 will
resolve if 5-HT1F receptor has a role in regulating mitophagy under stress conditions. It
should be noted that immunoblot analysis of autophagy and mitophagy markers may not
be the best approach in assessing these processes. Alternative approaches such as
imaging should be employed in future experiments to accurately elucidate LY344864mediated effects on autophagy/mitophagy under pathological conditions. It would be
interesting to utilize the 5-HT1F receptor KO mice subjected to renal I/R injury to further
elucidate the role of 5-HT1F receptor in mitochondrial homeostasis.
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Figure 4.4: LY344864 increases PGC-1α protein expression and rescues markers
of mitochondrial dynamics following oxidant injury in RPTC. RPTC were pretreated
with TBHP or vehicle control for 45 min, then exposed to LY344864 or vehicle control for
24 hr. Total protein was isolated from RPTC and subjected to immunoblot analysis.
PGC-1a, Mfn2 and DRP1 phosphorylation (A) were assessed. Densitometry analysis of
PGC-1a, Mfn2 and Drp1 phosphorylation (normalized to total Drp1) (B-D). Data reported
as mean ± SEM, n = 3. Different superscripts indicate statistically significant differences
(p<0.05).
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Figure
4.5:
5-HT1F
receptor
stimulation
activates
a
stimulatory
autophagy/mitophagy pathway following oxidant injury in RPTC. RPTC were
pretreated with TBHP or vehicle control for 45 min, then exposed to LY344864 or vehicle
control for 24 hr. Total protein was isolated from RPTC and subjected to immunoblot
analysis. AMPKα and ULK1 (Ser555) phosphorylation (A) were assessed. Densitometry
analysis of AMPKα and ULK1 phosphorylation, normalized to total AMPKα and ULK1,
respectively (B, C). Data reported as mean ± SEM, n = 3. Different superscripts indicate
statistically significant differences (p<0.05).
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Figure 4.6: 5-HT1F receptor stimulation increases autophagic flux following oxidant
injury in RPTC.RPTC were pretreated with TBHP or vehicle control for 45 min, then
exposed to LY344864 or vehicle control for 24 hr. Total protein was isolated from RPTC
and subjected to immunoblot analysis. LC3BII and p62 (A) were assessed. Densitometry
analysis of LC3BII and p62 (B,C) TBHP and LY344864 treated RPTC were pretreated
with chloroquine to assess autophagic flux. Protein isolated from these RPTC were
subjected to immunoblot analysis and p62 was assessed (D). Densitometry analysis of
p62 (E). Data reported as mean ± SEM, n = 3-4. Different superscripts indicate
statistically significant differences (p<0.05).
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The Role of the 5-HT1F Receptor in Endothelial Homeostasis
Recent studies have documented the role of the renal vasculature in the progression
from AKI to chronic kidney disease. The endothelial cells have been identified as a
target of injury, as AKI results in a marked reduction in microvasculature. Renal injury
may directly damage the renal vasculature and alter its activity; such as alter vascular
responsiveness, barrier function, coagulation cascades, and inflammatory processes
(53-55). Unfortunately, there are many unanswered questions about the mechanisms of
renal endothelial repair and regeneration. Particularly, there are very few studies on the
role of angiogenesis, or new vessel formation, which is required for oxygen and nutrient
delivery during tissue repair, after AKI, and how modulation of angiogenesis may lead to
accelerated renal repair.
Based on our previous findings that MB is renal protective as it accelerates the recovery
of renal function and tubular injury, our laboratory has recently begun to document the
role of MB in modulating angiogenic responses in endothelial cells. Our preliminary
findings revealed that MB and homeostasis are required for angiogenic responses.
Thus, additional experiments should test the hypothesis that MB in the renal
endothelium will increase kidney function after injury. Our preliminary data demonstrates
that targeting the 5-HT1F receptor is a promising strategy which is unsurprising as the 5HT receptors are well-documented in modulating vascular functions. Specifically, our
findings indicate the expression of the 5-HT1F receptor in the endothelial cell and in the
absence of the 5-HT1F receptor the renal vasculature is significantly reduced.
Additionally, stimulation of the 5-HT1F receptor increases MB in endothelial cells and this
was associated with enhances angiogenesis in vitro and in vivo. Endothelial 5-HT1F
receptor stimulation under hypoxic conditions also increased cellular proliferation and
repair. Overall our preliminary findings suggest that 5-HT1F receptor stimulation of MB
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and the subsequent activation of angiogenesis is protective in endothelial cells under
stress conditions. Future studies using our recently developed 5-HT1F receptor KO mice
are required to fully understand the role of the 5-HT1F receptor and its downstream
signaling events in regulating endothelial cell function physiological and pathological
conditions. Additionally, future studies are needed to explore the role of 5-HT1F receptor
agonists in promoting renal vascular recovery and function after I/R injury in mice. It is
noteworthy to mention that our laboratory is in the process of developing proximal tubule
and endothelial specific 5-HT1F receptor KO mice, which will aid in the experimental
design of all future studies discussed in this section.
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APPENDIX
Disrupted Mitochondrial Homeostasis and Inflammation in Peri-infarct Cortex and
Striatum Following Stroke: A Window for Therapeutic Intervention

ABSTRACT
The goal of these studies is to establish the relationship between acute mitochondrial
dysfunction, inflammation and behavioral outcomes following a unilateral ischemic
stroke. Rats received unilateral stroke and were tested on sensitive behavioral tasks.
Animals were then sacrificed at 24h, 48h and 144 h to determine expression of key
mitochondria factors and indicators of inflammation, apoptosis and regenerative
processes in ipsilesion cortex and striatum. Rats with stroke induced-behavioral deficits
had sustained, 144 h post-lesion, decreases in mitochondrial-encoded electron transport
chain proteins NADH dehydrogenase subunit-1 and cytochrome c oxidase subunit-1
(mRNA and protein) and mitochondrial DNA content in the remaining perilesion cortex.
Uncoupling-protein-2 gene expression, but not superoxide dismutase-2, remained
elevated in cortex and striatum at this time. Cortical inflammatory cytokine, interleukin-6,
was increased early and followed by increased macrophage marker F4/80 after stroke.
Cleaved caspase-3 activation, a marker of apoptosis, was elevated in cortex and growth
associated protein -43 was elevated in the cortex and striatum six days post-lesion. We
found a relationship between three disrupted pathways, identified as (1) sustained loss
of mitochondrial proteins and mitochondrial DNA copy number in the cortex linked to
decreased mitochondrial gene transcription; (2) early inflammatory response mediated
by interleukin- 6 followed by macrophages; (3) apoptosis in conjunction with the
activation of regenerative pathways. The stroke-induced spatial and temporal profiles lay
the foundation to target neuroprotecitve and behavioral therapeutics.
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INTRODUCTION
Stroke is currently the fourth leading cause of death and the leading cause of
long-term disability in the United States (1). Annually, stroke is responsible for 130,000
deaths with an estimated cost of 34 billion dollars for medications, health care, and
disability services (2, 3). Ischemic strokes make up 87% of all strokes [2] and treatment
for ischemic stroke patients is limited to TPA, which has a small window of effectiveness
(<4hr post-stroke) and several severe side effects. Therefore, there is a need to improve
treatment options to decrease the morbidity and mortality associated with cerebral
ischemia.
Within minutes to hours after injury, apoptosis starts to occur, normally due to
calcium influx and mitochondria dysfunction (4). Degeneration of distal axons, also
known as Wallerian degeneration occurs days to weeks following injury due to onset of
deleterious metabolic pathways which leads to expansion of infarct size and worsening
of clinical outcome. The area undergoing secondary injury that surrounds the core of the
ischemic lesion is termed the penumbra and is clinically attractive due to the delayed
onset of pathogenic mechanisms, which provides a window of opportunity to salvage the
penumbra via therapeutic intervention (5).
Neurons are energetically demanding yet have little energy reserves; therefore
neurons rely heavily on properly functioning mitochondria for normal neuronal
communication and activity. In addition to synthesizing ATP, the mitochondrion is also
important in cell metabolism, calcium homeostasis, free radical production, and
apoptosis (6-8). During the secondary phase of ischemic injury, these mitochondriadependent pathways are disrupted leading to increased reactive oxygen species,
intracellular calcium and induction of pro-apoptotic cascades (4, 9, 10). Thus, the
development of pharmacological agents to promote recovery of mitochondria and ATP180

dependent cellular functions may limit secondary neuronal damage following cerebral
ischemia.
Our laboratory previously demonstrated that decreases in the master regulator of
MB, peroxisome proliferator-activated-receptor γ coactivator-1α (PGC-1α) is associated
with decreased ability to maintain adequate mitochondria number in response to injury
(11, 12). Mitochondria abundance and the integrity of mitochondrial DNA (mtDNA) is
crucial for recovery of cellular function following ischemic injury. Therefore, the aim of
this study was to examine the components of the PGC-1α signaling pathway including
genes that encode for respiratory chain subunits and antioxidant genes, to understand
the underlying mechanism that leads to alterations in mitochondrial homeostasis in an
endothelin-1 (ET-1) induced experimental model of ischemic stroke to the caudal
forelimb area of the sensorimotor cortex (SMC) (13). Furthermore, we examined two
markers of inflammation in this model and related changes in these markers to the
mitochondrial changes.
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MATERIALS AND METHODS
Animals
Long Evans male rats (n=86, 3-4 months old) received food and water ad libitum and
were kept on a 12:12hr light:dark cycle. Rats were randomly assigned to one of six
groups that received either a sham or stroke procedure and were euthanized at one of
three time points: 24hr (sham=10; stroke=10), 72hr (sham=14; stroke=22), or 144hr
(sham=10; stroke=20). All animal protocols followed the National Institutes of Health
(NIH )Guide for the Care and Use of Laboratory Animals, and were approved by the
Medical University of South Carolina Animal Care and Use Committee.
Surgical Procedures
Rats were anesthetized with ketamine (1.1mg/kg I.P.) and Xylazine (0.7mg/kg I.P.).
Unilateral ischemic lesions were induced via ET-1 (American Peptide, Inc) into a
randomly assigned hemisphere in the forelimb area of the SMC (Fl-SMC). A craniotomy
was performed at 1.0 mm posterior and 2.0 mm anterior to bregma and 3.0–5.0 mm
lateral to midline and dura was gently retracted. ET-1 was applied on the brain surface
at approximately 1ul/min, with a 2 min wait between applications using a total of 4ul.
After the final 1ul of ET-1, the brain was left undisturbed for 5 min and then the
craniotomy was covered with gel film (Invotec International) and dental acrylic. Sham
animals had all procedures up to craniotomy. All animals received buprenorphine
(0.5mg/kg S.C.) prior to incision for pain.
Ladder Task
To assess ischemia-induced impairments of forelimb function and compare these to
mitochondria homeostasis markers, all animals were tested on the ladder task on days
0, 1, 3, and 6. The ladder task was used to assess coordinated forelimb use, stepping
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accuracy, and limb placement and is sensitive to motor cortex damage (14).The ladder
apparatus is made of two plexiglass walls, with 3mm diameter pegs spaced 1cm apart
from each other. The ladder is raised ~20cm off the ground with a neutral start cage and
the animal’s home cage at the end. Through slow-motion video replay, all forelimb
placements were qualitatively scored on a 0-6 rating scale over three trials (three
traverses across the ladder). A perfectly placed limb received a score of 6. Errors were
scored as follows: 0 = limb missed the ladder rung and the limb fell through the rungs; 1
= the limb was placed the limb but when weight bearing either fell (score of 1) or slipped
(score of 2) (14). Percent errors was calculated as: sum of errors (0+1+2)/(total steps)
per test day.
Tissue Collection
Animals were deeply anesthetized with Euthasol (0.1mg/kg) and brains were removed to
obtain fresh tissue punches from the ipsilesional remaining sensory and motor cortex
and the striatum. Samples were taken medial and anterior to the injury based on specific
lesions and anatomical observation. Tissue was placed on dry ice to preserve mRNA
and protein levels. Samples remained in a -80 freezer until RNA isolation or western blot
analysis was performed.
RNA Isolation and Real-Time PCR
Total RNA was extracted from cortex and striatum using TRIzol reagent (Invitrogen)
according to the manufacturer’s protocol. Reverse transcription was performed using the
RevertAid First Strand cDNA kit (Thermo Fisher Scientific) with 0.5-1 ug of RNA. 5 uL of
cDNA template was used to amplify PCR products using 2x Maxima SYBR green qPCR
master mix (Thermo Fisher Scientific). The primer sequences used in the qPCR protocol
are listed in Table 5.1. Fold changes in mRNA expression were normalized to tubulin
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were calculated using the ΔΔ- Ct analysis method detailed previously by Wills et. al.
(15).
Mitochondrial DNA Content
Relative mtDNA content in rat cortex and striatum samples was measured using
real-time PCR. DNA was isolated from tissues using the DNEasy Blood and Tissue Kit
(Qiagen), 5 ng of cellular DNA was used to perform qPCR. Relative quantity of mtDNA
was assessed by expression of NADH dehydrogenase 1 (ND1), a mitochondrial gene,
and normalized to nuclear-encoded β-actin. Primer sequences for ND1 and β-actin were
ND1

sense:

5’-TGAATCCGAGCATCCTACC-3′;

ND1

antisense:

5’-

ATTCCTGCTAGGAAAATTGG-3’; β-actin sense: 5’-TAAGGAACAACCCAGCATCC-3’;
and β-actin antisense: 5’-CAGTGAGGCCAGGATAGAGC-3′. The ΔΔ-Ct analysis
method was used to calculate fold changes in expression (15).
Immunoblot Analysis
Rat cortex and striatum tissue was homogenized in 150 μL of protein lysis buffer
and protease inhibitors (1% Triton X-100, 150 mM NaCl, 10 mM Tris-HCl, pH 7.4; 1 mM
EDTA; 1 mM EGTA; 2 mM sodium orthovanadate; 0.2 mM phenylmethylsulfonyl fluoride;
1 mM HEPES, pH 7.6; 1 μg/ml leupeptin; and 1 μg/ml aprotinin) using a Polytron
homogenizer. Then the samples were sonicated and centrifuged at 14,000 g for 15 min
at 4°C. The supernatant was collected and protein quantified using a bicinchoninic acid
kit (Sigma). Proteins (30 μg) were separated on 4 to 20% gradient SDS-polyacrylamide
gels and transferred to nitrocellulose membranes. Membranes were blocked in 5% BSA
or milk in TBST (0.1% Tween 20 in 1× Tris-buffered saline) and incubated with primary
antibodies overnight at 4°C. Primary antibodies used in this study included: COX1
(1:2000 Abcam); ND1 (1:2000, Abcam); NDUFS1 (1:2000, Abcam); cleaved caspase 3
(1:1000, Cell Signaling, Danvers); Caspase 3 (1:1000, Santa Cruz); GAP-43 (1:1000,
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Cell Signaling) and GAPDH (1:10000, Fitzgerald). After incubation for 1hr at room
temperature with secondary rabbit (1:2000) or mouse (1:20000) antibodies conjugated
with horseradish peroxidase, membranes were detected by chemiluminescence.
Densitometric analysis was performed using ImageJ (16).
Statistical Analysis
All data are reported as group means with ±S.E.M. Repeated analysis of
variance (rANOVA) was used to test for behavioral differences with post-hoc
comparisons for each post-operative day. Single comparison of molecular data was
performed using the Student t-test, whereas data found to not have a normal distribution
were subjected to a Mann-Whitney U-test. Sample size was determine based on a
power analysis for AVOVA with effect size equal to 0.25, α= 0.05, β= 0.8 and previous
behavioral studies. Data were considered statistically significantly different at p ≤ 0.05.
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Table 5.1: Primer sequences used for RT-qPCR
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RESULTS
Stroke-induced Motor Impairment
As demonstrated previously, unilateral ET-1 lesions to the (Fl-SMC) result in lasting
impairments in the forelimb opposite the lesion (14). Animals exhibited more limb
placement errors while walking across a horizontal ladder with their impaired limb at 24,
72, and 144hr post-injury compared to sham animals (Fig. 5.1A). There were no
differences seen with the non-impaired forelimb compared to sham animals or pre-stroke
number of errors (Fig. 5.1B).
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Figure 5.1: Stroke-induced motor impairment. Following injury, animals made
significantly more errors with their impaired limb compared to sham controls (A). There
was no difference in errors made with the non-impaired forelimb between stroke and
sham animals (B). Data are reported as mean ± SEM, n = 6. *p<0.05 versus Sham
animals.
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Decreased PGC-1α and respiratory chain gene expression and mtDNA content in
ipsilesional motor and sensory cortex
Mitochondrial dysfunction is a major contributor to neuronal death following ischemic
stroke (7). Therefore, we assessed mRNA expression of PGC-1α, and components of
the electron transport chain, nuclear-encoded NADH dehydrogenase (ubiquinone) Fe-S
protein 1 (NDUFS1), and mitochondrial-encoded cytochrome c oxidase subunit 1
(COX1) and ND1. We observed a non-significant downward trend (p= 0.056) in PGC-1α
mRNA expression 24hr post-stroke (Fig. 5.2A). NDUFS1 mRNA expression was
decreased by 25% at 24hr and did not return to sham levels until 144hr post-stroke (Fig.
5.2B). Additionally, there was a robust reduction of COX1 and ND1 transcript levels at
72hr and remained suppressed by 50% at 144hr following injury (Fig.5.2C, D).
Mitochondrial DNA copy number was assessed as a marker of mitochondrial content.
There was a persistent suppression of mtDNA copy number to 74%, 71%, and 64% (24,
72, 144hr post-stroke, respectively) (Fig. 5.2E). Taken together, these findings reveal
disruption in transcriptional regulation of mitochondrial proteins involved in oxidative
phosphorylation and mitochondrial content following ET-1 induction of cerebral ischemia.
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Figure 5.2: Decreased respiratory chain gene expression and mitochondrial DNA
in ipsilateral cortex. Rats were subjected to either sham or ET-1 treatment. PGC-1α
(A), NDUFS1 (B), COX1(C) and ND1 (D) mRNA expression was determined by RT-PCR
using tubulin as a control gene. mtDNA copy number (E) was determined by qPCR,
using ND1 for the mtDNA gene and actin for the nuclear control gene. These markers
were measured in the ipsilateral cortex 24, 72, and 144 hr. Data are reported as mean ±
SEM, n = 6. *p<0.05 versus Sham animals.
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Transitory changes of mitochondrial encoded transcripts in ipsilesional striatum
We screened for mitochondria damage in the ipsilesional striatum following ET-1
ischemic damage due to secondary injury in this area (17). There were no changes in
PGC-1α and NDUFS1 mRNA expression during the 24-144hr injury phase (Fig. 5.3A,
B). However, we did observe a transitory decrease in COX1 and ND1 mRNA expression
at 72hr post-stroke (70% and 53%, respectively). By 144hr, COX1 and ND1 mRNA
levels recovered back to sham levels (Fig. 5.3 C, D). At 24hr, we detected a 25%
reduction of mitochondrial DNA copy number in the ipsilesional striatum which returned
to sham levels at 72hr (Fig. 5.3E). These results reveal that ET-1 induced SMC lesions
have transitory damaging effects on the striatum, indicating that the striatum is
susceptible to disruptions in mitochondrial homeostasis and function.

191

Figure 5.3: Altered regulation of mitochondrial- encoded transcripts in ipsilateral
striatum. Rats were subjected to either sham or ET-1 treatment. PGC-1α (A), NDUFS1
(B), COX1(C) and ND1 (D) mRNA expression was determined by RT-PCR using tubulin
as a control gene. mtDNA copy number (E) was determined by qPCR, using ND1 for the
mtDNA gene and actin for the nuclear control gene. These markers were measured in
the ipsilateral striatum 24, 72, and 144 hr. Data are reported as mean ± SEM, n = 6.
*p<0.05 versus Sham animals.
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Reduced mitochondrial encoded protein expression in the ipsilesional cortex and
striatum
To assess if ET-1 disrupts the translation of mitochondrial genes we measured protein
levels of COX1, ND1, and NDUFS1. Immunoblot analysis revealed that at 144hr, COX1
and ND1 were depressed to 67% and 76% compared to sham levels in the ipsilesional
cortex (Fig. 5.4A). COX1 and ND1 protein expression were also decreased in the
ipsilesional striatum to 80% and 77% (Fig. 5.4B). NDUFS1 remained at sham control
levels at this 144hr time point. These data reveal that in our model of cerebral ischemia
mitochondrial-encoded genes

are

more

disruption than nuclear-encoded genes.

193

sensitive

to

transcriptional/translational

Figure 5.4: Altered respiratory chain protein expression in ipsilateral cortex and
striatum. Rats were subjected to either sham or ET-1 treatment. COX1, ND1, and
NDUFS1 protein expression was determined by immunoblot analysis. These markers
were measured in protein isolated from ipsilateral cortex (A) and striatum (B) 144 hr
following ET-1 exposure. These markers were measured in the ipsilateral striatum 24,
72, and 144 hr. Data are reported as mean ± SEM, n = 6. *p<0.05 versus Sham animals.
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UCP2 activation in the ipsilesional cortex and striatum
Excessive reactive oxygen species (ROS) generation can induce the up regulation of
mitochondrial ROS detoxifying enzymes, manganese superoxide dismutase 2 (SOD2)
and the uncoupling protein 2 (UCP2) to neutralize the detrimental effects initiated by
oxidative stress. Along with its uncoupling role to mitigate ROS production, UCP2 has
been implicated in neuroprotection by suppressing pro- inflammatory cytokines and
elevating anti- apoptotic mediator, Bcl2 (18). Therefore, we measured SOD2 and UCP2
in ipsilesional cortex and striatum. Interestingly, we only observed a modest 17%
decrease of SOD2 transcript at 72hr in the cortex and SOD2 mRNA levels remained
unchanged in the striatum (Fig. 5.5A, C). In contrast, cortical UCP2 transcript levels
increased by ~1.5-fold within 24hr and further increased to ~3-fold by 72hr which
persisted to 144hr (Fig. 5.5B).In the ipsilesional striatum, UCP2 increased 1.5-fold over
sham control at 72hr and remained elevated at 144hr (Fig. 5.5D). These data reveal that
ET-1 mediates sustained increases in UCP2 in cortex and striatum.
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Figure 5.5: Activated antioxidant gene expression in ipsilateral cortex and
striatum. Rats were subjected to either sham or ET-1 treatment. Cortical (A, B) and
striatal (C, D) SOD2 and UCP2 mRNA expression was determined by RT-PCR using
tubulin as a control gene. These markers were measured 24, 72, and 144 hr following
ET-1 exposure. Data are reported as mean ± SEM, n = 6. *p<0.05 versus Sham
animals.
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Gene expression of inflammatory mediators and macrophages in the ipsilesional
cortex and striatum
Since macrophages are known to be involved in innate immune response following
ischemic injury (19), we examined the transcriptional expression of F4/80, a surface
marker for mature macrophages. We observed a 5-fold increase in cortical F4/80 mRNA
expression over sham animals at 72 and 144hr (Fig. 5.6A). Additionally, we observed
significant 3-, 2- and 1.5-fold increases in cortical interleukin-6 (IL-6) transcripts at 24,
72, and 144hr, respectively (Fig. 5.6B). We detected a transitory 1.5-fold increase in
F4/80 at 72hr that returned to sham levels by 144hr in the striatum (Fig. 5.6C). IL-6
induced a 2.5-fold increase at 24hr and reduced to 1.5-fold increase 72hr in the striatum
(Fig. 5.6D). Our data provides evidence and a partial time-course for a pro-inflammatory
environment in both the cortex and striatum following ischemic stroke.
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Figure 5.6: Induced gene expression of inflammatory mediators in ipsilateral
cortex and striatum. Rats were subjected to either sham or ET-1 treatment. Cortical
(A, B) and striatal (C, D) F4/80 and IL6 mRNA expression was determined by RT-PCR
using tubulin as a control gene. These markers were measured 24, 72, and 144 hr
following ET-1 exposure. Data are reported as mean ± SEM, n = 6. *p<0.05 versus
Sham animals.
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Caspase 3 cleavage and GAP43 expression in ipsilateral cortex and striatum
Rodent models of neurodegenerative diseases implicate caspase dependent apoptosis
as an important contributor to neuronal and tissue damage (20-23) Immunoblot analysis
was used to assess the level of caspase 3 activation by measuring the cleaved form of
caspase 3 following ET-1 induced stroke. Cleaved caspase 3 was detected in the
ipsilateral cortex, but not in the ipsilateral striatum 144hr following stroke (Fig.5.7A, B).
To determine growth factor expression in our ET-1 model of ischemic stroke we
measured GAP-43, a growth factor known to increase during periods of axonal sprouting
within the first week post- stroke in areas surrounding the primary site of injury (24, 25).
In line with previous reports, we observed a 3-fold increase in GAP-43 protein
expression in the ipsilesional cortex at 144hr (Fig. 5.7C). We also detected a 4-fold
increase in the striatum at 144hr post–stroke (Fig. 5.7D).

These data reveal that

sufficient cell injury occurs in the early stages post-stroke to activate regenerative
processes.
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Figure 5.7: Caspase 3 cleavage and GAP43 expression in ipsilateral cortex and
striatum. Rats were subjected to either sham or ET-1 surgeries. Cleaved caspase 3,
procaspase 3, and GAP-43 protein expression was determined by immunoblot analysis.
Protein was isolated from ipsilesional cortex (A) and striatum (B) 144hr post- injury.
Cortical (C) and striatal (D). GAP-43 protein expression were quantified. GAPDH is used
as loading control. Data are reported as mean ± SEM, n = 6. *p<0.05 versus Sham
animals.
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DISCUSSION
Several studies have demonstrated mitochondrial dysfunction as a common
consequence of cerebral ischemia including mitochondrial induced-oxidative stress (9,
26, 27). ROS signals for both beneficial and detrimental pathways following injury.
Beneficial ROS signaling initiates neuroprotective pathways such as ROS-scavenging
mechanisms (28). However, excessive ROS causes oxidative damage to a multitude of
biomolecules such as mtDNA. Additionally, elevated ROS levels promote the release of
inflammatory cytokines and subsequent migration of inflammatory cells to the ischemic
and penumbra zones promoting an inflammatory environment that can mitigate injury
progression or boost the progression of neuronal damage (19, 29).
Using an ET-1-induced rat stroke model, we identified mitochondrial disruption and
activation of inflammatory responses in the SMC and striatum during the first week postinjury. In the cortex, we observed decreased expression of nuclear and mitochondrial
encoded subunits of complex I and IV, and depletion of mitochondrial DNA number.
Specifically, NDUFS1, complex I gene expression is suppressed at the early 24hr time
point and does not return to sham control levels until 144hr post- stroke. A robust
decrease in both COX1 and ND1 transcript levels, subunits of complex IV and I,
respectively, was observed at 72hr and 144hr. Importantly, we also detected significantly
reduced COX1 and ND1 protein expression at the 144hr time point. Concomitantly,
mitochondrial DNA copy number was suppressed early and persistently in the
ipsilesional cortex. We only observed reduced protein expression in mitochondrialencoded proteins which may be due to the increased sensitivity of mtDNA damage
compared to nuclear DNA. Following ischemic injury, chronic ROS production causes
extensive mtDNA damage. The inability to monitor and repair mtDNA damage is due to
the less efficient mitochondrial repair mechanisms that become overwhelmed in the
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presence of excessive oxidative stress (30).It is expected that mtDNA damage may lead
to inactive the electron transport chain thereby affecting normal mitochondrial function.
We also detected disruption of mitochondrial homeostasis in the ipsilateral striatum.
Based on the functional connectivity between the cortex and striatum, we propose that
reduction of mitochondrial DNA and mRNA expression of ND1 and COX1 may be
secondary consequences. Additionally, our experimental cerebral ischemia model
disrupted the translation of COX1 and ND1 at 144hr post-stroke. The presence of
mitochondrial suppression in the cortex and striatum depicts how pathogenic
mechanisms can affect adjacent cells, intensifying the damaging effects of ischemic
stroke. It is important to note that although we did not report a significant decrease in
PGC-1α mRNA expression in either the cortex or striatum, we do hypothesize that the
PGC-1α transcript levels are reduced abruptly following injury and recover towards
control levels to regulate compensatory mechanisms such as antioxidant mechanisms.
Under normal physiological conditions, mitochondrial respiratory complexes are a source
of ROS generation (7). When respiratory enzymes are damaged following injury, these
complexes produce an excessive amount of ROS which can lead to cytotoxicity.
Therefore, we assessed mRNA level of the mitochondrial antioxidant gene, SOD2 as a
marker of oxidative stress. We only observed a decrease in SOD2 transcript at 72hr
post-stroke in the cortex, which recovered to sham control levels by 144hr and SOD2
mRNA levels remained unchanged in the striatum. Numerous studies have reported
SOD2 is a direct downstream target of PGC-1α (31, 32); therefore, we predict that SOD2
mRNA levels transiently decreased in response to the modest suppression of PGC-1α in
the cortex at 24hr.
Recently, an increasing number of studies have focused on the various physiological
and pathological roles of UCP2 (33-36). When UCP2 detects elevated levels of
202

mitochondrial ROS, a feedback loop is activated to induce UCP2 expression in the inner
mitochondrial membrane (36). It is well documented that the primary role of UCP2 is to
dissipate the proton gradient across the inner membrane to prevent ATP synthesis and
transporting superoxide radicals across the inner mitochondrial membrane, thus
decreasing the ROS produced by the respiratory chain (34). Interestingly, UCP2 mRNA
expression was persistently increased in both the ispilesional cortex and striatum. While
cortical UCP2 induction occurred at 24hr, prior to the striatum, UCP2 expression
remained elevated in both tissues.
Additionally, UCP2 has been reported to perform other functions such as regulating
neuroinflammation and apoptosis following ischemic stroke. Haines, et al., demonstrated
that the overexpression of UCP2 alleviated ischemia-induced increase in IL-6 mRNA
which may reduce the deleterious effects of prolonged inflammation. Overexpression of
UCP2 also rescued diminished pro-survival markers such as Bcl-2, cyclin G2, and
HSP90 (18). Furthermore, UCP2 has been documented to be neuroprotective via its
involvement in neurogenesis and synaptogenesis, suggesting a role in neuronal growth
and development (36, 37). Future studies are needed to explore the potential roles of
UCP2 in our cerebral ischemic model.
The presence of neuroinflammation during the first days of experimental stroke was
confirmed by the elevated mRNA expression of macrophage marker, F4/80 and
inflammatory mediator cytokine, IL-6. We observed a 5-fold and 4-fold induction of F4/80
in the cortex at 72 and 144hr, respectively. Interestingly, cortical IL-6 transcript levels
were induced earlier with a magnitude of 3-fold and remained elevated above sham
control levels. Furthermore, the maximal expression of F4/80 and IL-6 in the cortex
corresponds to the maximal expression of both transcripts in the striatum. Taken
together, these results support the implication that ischemic injury causes detrimental
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effects in surrounding tissue days after the initial stroke; thus, the opportunity to
effectively treat per-infarct tissue extends into the post-acute recovery period.
One of the most common forms of cell death in neurodegeneration is through the
intrinsic mitochondrial apoptotic pathway. Following initiation of intrinsic pathway,
cytochrome c is released from the mitochondria and works with other apoptotic factors to
process the inactive form of procaspase 3 to the cleave, active form (38). Cleaved
caspase 3 in turn induces cellular changes including chromatin condensation, DNA
fragmentation, and formation of apoptotic bodies (39, 40). Our study revealed that
cerebral ischemia induced caspase 3 cleavage in the peri-infarct region of ipsilateral
cortex 144hr post-stroke. These data reveal that activation of cell injury and death
pathways, which produces long term effects, occur early after cerebral ischemia,
strengthening the importance for the characterization of molecular and metabolic events
that lead to ischemic cell loss as well as repair and regenerative mechanisms that can
function to preserve the function of surrounding neurons (41, 42).
Regenerative processes, such as axon sprouting and new synapse formation, following
stroke begin within days and continues for weeks after injury. GAP-43 induces formation
of new synapses, enhance axonal sprouting post injury, and may play an important role
in experience-dependent plasticity (43). Knockout of GAP-43 results in a decrease in
axon sprouting and hindered growth cone navigation (44, 45). Previous studies
demonstrate that elevated GAP-43 expression occurs between days 3 and 14
suggesting growth cone development, whereas axonal sprouting and new synapse
formation occurs between days 14 and 60 post-stroke (24, 25, 46, 47). Consistent with
the above findings, GAP-43 increased in cortex and striatum at 144hr in our ET-1 model
of ischemic stroke, demonstrating that sufficient cell injury occurs in the early stages
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post-stroke to activate regenerative processes needed to preserve and restore neuronal
function.
CONCLUSION
In conclusion, ET-1-induced focal experimental stroke to the SMC leads to mitochondrial
dysregulation, and inflammatory cell infiltration during the first week of injury which last
days following initial injury. We also observed alterations in these pathways in the
striatum, a secondary site of damage and degeneration. This suggests that the striatum
is highly susceptible to cellular injury associated with deficits in mitochondrial
homeostasis. This finding, along with the suppression of mitochondrial proteins and
sustained gene aberrations warrant further investigation to elucidate chronic changes in
these pathways related to long-term behavior outcomes. Further examination may lead
to the identification of therapeutic targets to treat ischemic stroke by reduction of
mitochondrial dysfunction, bioenergetics failure, and inflammation.
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